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SUMMARY  
Gold nanoparticles (AuNPs) are considered to have significant potential as in photothermal 
therapy, drug delivery and antibiotic activities due to their optical properties, chemical stability 
and biocompatibility. AuNP surface functionalisation plays an important role in cellular uptake 
and producing cellular responses. For this reason, novel AuNPs (5-26 nm) functionalised by a 
new family of a phosphonioalkylthiosulfate/thioacetate in this thesis, and have been shown to 
be stable for a period up to 6 months with no obvious evidence for any aggregation.  
 
Production of novel cationic phosphonium AuNPs (8-11 nm) by borohydride reduction of a 
gold (III) salt, dispersed in water or dimethylsulfoxide (DMSO) for their potential use in 
biomedical applications is outlined in Chapter 2.  
 
The environment around cancer cells is known to be mildly acidic with pH of 6.0 to 7.2, which 
is lower than in healthy cells. Based on the pH factor, AuNPs have shown abilities to induce 
cancer cell death via a photothermal therapy after aggregation. For this reason, our cationic 
phosphonium AuNPs were subjected to investigate their stability over time and at a pH range 
of 3-11. This work is described in Chapter 3. The synthesised AuNPs were primarily 
characterised using both UV-visible spectra and Dynamic light scattering (DLS). The pH study 
suggested that the optimum pH range for the AuNP colloidal samples to remain stable ( without 
aggregation) is between pH 9.2 and pH 5.1. Within this range, the diameters recorded by the 
DLS were 9.6 ± 0.9 nm, and the aggregation (instability) was noted at pH ˂ 5 and ˃ 9. The 
structural characterisations of all ligands in this thesis were confirmed by using ATR, ESI-MS 
and NMR, while the influence of the ligands on the formation and stability of AuNPs was 
investigated by DLS, TEM and UV-Vis measurements, and described in Chapter 2 to 6.  
 
Green methods used to synthesis AuNPs using ascorbic acid, as bio-reducing agent was 
important nowadays, especially within the biological cells due to its low toxicity. Well-
monodispersed AuNPs were prepared by the reduction of KAuCl4 using NaBH4 and ascorbic 
acid as reducing agents. Using different reducing agent power, obtained different results for 
AuNPs that functionalised with same conditions in Chapter 4. Small sizes with higher stability 
up to 6 months were generated when NaBH4 was used as reducing agent. Where AuNPs of 
different sizes are known to produce contradictory results sometimes in vivo and in vitro bio-
application. 
 
AuNPs functionlised by di-phosphine oxide thiol ligand are considered to be very active against 
bacteria, and have broad bio-applications. The work on AuNPs functionlised by novel related 
phosphine oxide thiols ligands is discussed in Chapter 5. 
 
Due to antibiotic drug resistance to some kinds of bacterial infection, development of new 
antibacterial agents is necessary. This thesis describes a study of the efficiencies of different 
concentrations of AuNPs (8-17 nm) on non-pathogenic bacteria including, Escherichia coli 
NCIB 8277 and Staphylococcus aureus ATCC 6538P in (Chapter 6). AuNPs exhibited 
excellent antibacterial sensitivity to both kinds of bacteria especially at high concentration (30 
µL) of AuNPs. 
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Chapter 1: Literature review 
1.1 Introduction 
The development of safe and simple methods in order to detect and cure serious diseases, 
such as cancer, is considered to be one of the biggest challenges for researchers in the 
field of biotechnology and medical research [1]. Metal nanoparticles, including Au (gold), 
Ag (silver) and Cu (copper) nanoparticles (NPs), have been widely investigated over the 
past two decades as a result to their unique optical and chemical properties such as size, 
a high surface area [2]. For a specific critical application, the modification of NP surface 
using biocompatible materials is required. For instance, there are several types of gold 
nanoparticles (AuNPs) based on shape, size and chemical composition. These include 
spherical, nanorods, nanoshells, nanocages and SERS nanoparticles (AuNPs with a 
significant surface-enhanced Raman scattering properties) (Figure 1.1). Development of 
NP synthetic methods is still ongoing and most of the different types of metal NPs can be 
manufactured with well-controlled size distribution [3].  
 
 
 
Figure 1.1. Different types of gold nanoparticles [3]. 
Nanotechnology has been applied in therapeutic treatment mostly in drug delivery in 
cancer therapy [4]. This is due to the fact that functionalised NPs have the ability to 
recognise and integrate with a biological matrix via the protecting ligands on their surface 
[5, 6]. For several years, NPs have been tested in the medical field in order to reduce side 
effects of cancer drugs by decreasing dosage of cancer drugs [4]. Some of the metal NPs 
reported in the literature have comparable sizes when compared to some biomolecules. 
Examples of these are proteins (1–20 nm), viruses (~20 nm), DNA (~diameter 2 nm), cell 
surface receptors (~10 nm), cell membrane (~6–10 nm), and haemoglobin (~5 nm) [7- 9].  
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NPs of 50 nm or less in size have shown ability to interact with DNA, proteins, enzymes 
and cell receptors extracellularly and intracellularly in human cells, which are hundred to 
thousand times bigger than these NPs [10]. For instance, smaller NPs of ≤ 20 nm in size 
have shown the ability to exit blood vessels and circulate throughout the body [10]. 
During the last decade, AuNPs were heavily tested for biomedical applications, (such as 
imaging, gene and photothermal therapies, and drug delivery) due to their unique or novel 
optical and chemical properties, as well as their stability [11-13]. 
 
The main focus of this literature review will be on the chemical and physical properties 
of biocompatible functionalised AuNPs, their synthesis, and stabilisation. Furthermore, 
their application in biomedicine will be discussed. 
1.1.1 Optical and chemical properties of gold nanoparticles (AuNPs) 
As previously mentioned, due to the unique optical, physical, chemical properties, 
stability and biocompatibility of AuNPs, they have been used in drug delivery, medical 
diagnosis and in cancer therapy [14]. AuNPs can be easily functionalised with several 
drugs or organic moieties via surface modification, which helps the uptake of such NPs 
by cell membranes [15, 16]. AuNPs are able to form stable bonds with sulfur containing 
molecules such as sulfides and thiols [17, 18].  
 
These molecules have a strong affinity for noble metals and tend to protect AuNPs via 
forming well-ordered, self-assembled monolayers (SAMs), which leads to good 
dispersion, easy characterisation, and extraordinary stability. With no protecting ligands 
and no electrostatic repulsion, bare AuNPs tend to aggregate in solution as result to their 
high surface energy [17, 19]. Thiol containing ligands protect the AuNP surface against 
oxygen adsorption, which leads to increase their stability. In addition, the binding of 
functional molecules to the surface of AuNPs is facilitated through thiol groups, leading 
to a relatively stable Au-sulfur bond [20].  
 
Moreover, 23-mercapto-3,6,9,12-tetraoxatricosan-1-ol (Figure 1.2) has been considered 
to be an excellent ligand base for biological applications and this structure can be easily 
adjusted to provide selective binding which makes AuNPs a promising platform for 
methodical biological studies [21]. Thiol and amine functionalised ligands can be used in 
order to synthesise stable AuNPs in both aqueous and organic media [22-25]. 
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Figure 1.2. Chemical structure of AuNP functionalised by ligand contains three parts including the sulfur 
atom (binding directly with Au due to its strong affinity), alkyl chain and a tetraethylene glycol spacer 
[21]. 
Amine functionalised ligands have been used to stabilise the AuNPs, and produced NP 
sizes (from 2.5 to 7 nm), depending on the conditions of the synthesis. However, it is 
worth mentioning that the covalent bonds between Au atoms in the NP surface and amine 
are weaker compared with thiol groups [26, 27]  
 
Amines, such as alkyl amines and the amino acid lysine are also used as protective ligands 
but their stability for AuNPs are moderate compared to both thiol and phosphine ligands. 
In order to get high AuNPs stability, aryl phosphines such as triphenylphosphine (TPP) 
and its’ derivatives are used due to their phenyl rings which provide stability to AuNPs 
as a result to oxidation resistance of the phosphine itself [26]. Furthermore, thiols have 
higher affinity than phosphines towards AuNP surfaces. Phosphines showed lower 
binding energy compared to thiols [20, 28, 29]. 
 
The ligand (Au55[PPh3]12Cl6) was used to protect gold nanoclusters which have good 
properties such as uniform size and high chemical stability [17]. In contrast, small 
phosphine stabilised AuNPs with chemical formula Au55[(C6H5)2P(C6H4SO3Na)]12Cl6 
have been found to be highly cytotoxic in several cell lines, due to the interaction of these 
AuNPs with the DNA [20, 26]. Diphosphines can be also used as AuNPs protecting 
ligands. For example, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl was used to stabilise 
1.7 nm AuNPs [26, 30]. 
AuNPs have different properties when they vary in size. For instance, colloidal solutions 
of spherical AuNPs are red with the SPR (surface plasmon resonance spectroscopy) band 
centred at approximately 520 nm and this band is often weakly dependent on the size of 
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the particle. However, strong changes have been noted with different shapes [31]. UV-
Vis spectroscopy was used for real-time monitoring of AuNP size as shown in Figure 1.3 
[32]. 
 
DLS and TEM have used measure the size and monodispersity of AuNPs [32]. Shape and 
size of the AuNPs can be controlled by varying experimental conditions such as reaction 
time, pH, capping agent and temperature, as well as the concentration ratio of reactants 
[2, 31]. 
 
As mentioned earlier, colloidal AuNPs, have different applications, based on their size 
and shape. With decreasing size, a lot of changes in physical and chemical reactivity were 
observed, such as an increase in the surface/volume ratio and a decrease in the melting 
temperature of AuNPs with size increased. AuNPs with size smaller than 5 nm were 
excellent for applications in catalysis. AuNPs can be formed by the deposition of a gold 
precursor, most often gold in the oxidation state Au (III) reduced to Au (0) and following 
its reduction into AuNPs due to a thermal treatment. This process is called deposition-
reduction, as result of the instability of Au (III) compounds, a thermal treatment even 
under an oxidising atmosphere, oxygen or air, generally leads to producing AuNPs [33-
35]. 
 
Particles with sizes of 10–300 nm offer strong light scattering, mostly in the visible range, 
and surface atoms are generally more active compared to closed-packed atoms inside the 
particle, as a result of their outwardly exposed dangling bonds [36].  
 
The goal from controlling of growth of shaped AuNPs is to avoid any aggregation or 
instability, which makes NPs less hazardous for biomedical applications by avoiding 
degradation processes such as partial oxidation or undesired sintering of particles [37, 
38].  
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Figure 1.3. AuNPs characterised via (A) UV-vis spectrum; size distribution of AuNPs by using both DLS 
(B) and TEM (C), the scale bar is 10 nm) [32]. 
AuNPs are chemically stable and resistant to oxidation compared to other NPs such as 
silver nanoparticles [15]. It is worth mentioning that other similar materials such as silver 
and platinum exhibit similar properties in NP form. AuNPs, however, are much less 
expensive than platinum, and much less reactive than silver, making them a much better 
candidate for use in biomedical treatments [15]. 
1.1.2 Synthesis of gold nanoparticles 
AuNPs were discovered by Faraday in 1857 [21, 39] who demonstrated the mechanism 
of formation of pure gold colloids and this synthesis was considered the bases a lot of the 
chemical routes for obtaining AuNPs with controlled shape, size and surface chemistry.  
A 
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The first structural studies of AuNPs have been produced since 1951 by Turkevich., et 
al., [39-41], via electron microscopy. This was furthered significantly by Frens [39] who 
showed the possibility to control the size of spherical AuNPs from about 16 to 150 nm. 
These studies became starting point for many of the colloidal AuNP synthetic methods 
developed and reported in the literature [39-41]. The size of AuNPs can be controlled via 
varying the ratio of gold salt, reducing agent and stabiliser as mentioned early [2, 31, 39, 
42]. 
1.1.2.1 Synthesis of AuNPs using chemical methods 
AuNPs are produced due to a reduction of HAuCl4 by a large number of reducing agents 
such as sodium citrate, borohydrides, formaldehyde, ascorbic acid, hydrazine, and 
hydroxylamine [43]. Sodium citrate has used as a reducing reagent and a protection ligand 
at the same time and AuNPs produced with variety of size / shape based on different 
concentration of citrate / HAuCl4 ratios used [43, 44]. 
 
Small size of AuNPs are produced as a result of a faster reduction causing a high 
nucleation rate and a supersaturated solution. Small sized AuNPs were resulting of using 
a strong reducing agent such as sodium borohydride compared to a weakly reducing agent 
such as sodium citrate [45-47].  
 
The aqueous reduction of AuCl4
- can be performed with an alternative reducing agent 
such as ascorbic acid (as a weak reducer). This is mentioned in Chapter 4 in the current 
study. The same protecting ligands were used in the case of NaBH4 (used as a strong 
reducing agent), resulting in creating different shapes, sizes and stability of AuNPs. Poor 
stability, with big sizes of AuNPs was noted when ascorbic acid was used as reducing 
agent [45-47]. 
 
According to Goia, D and Matijević, E., [48] iso-ascorbic acid was used as reducing agent 
for AuCl4
- in aqueous solutions to generate monodispersed spherical AuNPs with sizes 
ranging from 5 nm to 80 nm. Sizes and shapes of AuNPs strongly depend on the 
concentration of protecting ligand used as well as on concentration of the ascorbic acid 
[43, 48]. 
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1.1.2.1.1 Synthesis of gold nanoparticle in two phase solvent system and stabilisation 
by thiols 
AuNPs of small sizes (2−2.5 nm) have been synthesised by Brust−Schiffrin method 
(BSM). Different functionalised metal NPs have been synthesised for the past 20 years 
by using this method. The stability of the synthesised particles was as a result of using 
alkane thiols, which offer strong Au-S bonds to the particle surface and good passivation. 
Instead of adding different amounts of reducing agent, the produced size can be in BSM 
by using different amounts of alkane thiol in the solution [49]. Despite BSM being widely 
studied, the synthesis process is not completely understood [50].  
Another strategy used to produce cationic functionalised AuNPs is ligands exchange of 
monolayer protected AuNPs in the organic solvent as shown in Figure 1.4 [39, 51]. 
 
 
 
Figure 1.4. Brust-Schiffrin method: preparation of functionalised of AuNP by using two phases solvent 
system [39]. 
Using capping agents with strong affinity for gold is a common approach, which leads to 
the synthesis of AuNPs with good size dispersion in water. In some case, an additional 
step is required to transfer the NPs into water [31,52]. However, the phase transfer from 
aqueous to organic phase is often not easy, as result to the poor water solubility of the 
protecting ligands, which are used to stabilise the NPs. Various strategies have been used 
in order to facilitate this transfer, such as decrease the surface tension by an addition of 
acetone or a strong acid in order to neutralise charged AuNPs [39, 53].  
 
Syntheses of AuNPs in aqueous solution have some advantages as AuNPs can be 
functionalised with different biocompatible ligands and bio-molecules, such as, DNA, 
enzymes, peptide. However, there is no possibility of coating AuNPs with bio-molecules 
in organic solvents [39, 53, 54].  
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In addition, AuNPs have prepared in aqueous solution with SPR bands in the near infrared 
and this kind of AuNPs is quite useful in biological applications, allowing for AuNPs in 
biological fluids without any interference from absorption of other biological molecules 
[31]. For example, bio-molecules with both negative and positive charged end groups 
such as peptides were functionalised an AuNPs in the size range 6, 8, and 16 nm, in 
aqueous solution. Some advantages were noted when protected ligands possessed 
different end charges. This will help to overcome aggregation, and generate NPs with 
high quality and narrow dispersions. These charged NPs can be used in biomedical 
applications [39, 55]. It is well known that the cationic NPs undergo different mechanisms 
in order to entry cells, and this will be based on NPs size, charge density, shape, purity 
and stability; and also based on cellular environment [56-58]. 
1.1.2.2 Purification of gold nanoparticles 
Purification is required to obtain high-purity NPs samples; the results of NPs can be 
skewed due to small amounts of impurities. Purification methods are also important to 
develop reliable, rapid and convenient with NP produced high purity. Purification of NP 
samples can often be more challenging than the preparation itself. Filtration and solvent 
rinsing are the most used purification steps. These purification methods are normally 
sufficient to remove any impurities including residual Au salts and extra free ligands [28, 
59]. In addition, filtration was used to remove small-molecule impurities from water-
soluble NPs and for the isolation of small NPs from larger NPs in a single process. For 
example, 3-nm AuNPs functionalised by thiol-ligands was purified and separation of a 
poly-disperse sample into fractions of different core diameters. It is confirmed that, 
diafiltration generated higher degrees of purity of NPs compared with NPs purified by 
dialysis or a combination of solvent washes, ultracentrifugation, and chromatography 
[59]. 
 
In addition, there are many purification methods have been used in order to remove non-
AuNPs components and decreasing the polydispersity, such as centrifugation, solvent 
extraction, ion-exchange, dialysis and diafiltration. Centrifugation is commonly used to 
remove non-AuNP components [59]. However, it has been informed that about 1.3% of 
the citrate that used in the synthesised AuNPs solution stayed in the treated solution after 
the purification process finished and could result in unneeded effects as changing in size 
of AuNPs and aggregation [59, 60].  
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Purification still has significant challenges to produce NPs without any affection on their 
structures and properties. For instance, purification has been found to have a significant 
impact on the optical properties of CdSe-NPs [61, 62]. Also, AuNPs were rapidly 
decomposed in the presence of excess thiol ligand [28, 59]. Furthermore, AuNPs in 
aqueous solution are not easy to purify, as result of the similar solubility of both the 
AuNPs and the impurities [60, 63, 64].  
 
According to Sweeney, SF., et al., [59] colloidal NPs dispersed in non-hydroxylic 
solvents were separated using ultracentrifugation in an organic solvents which grant quick 
separation and high purification. By using this method colloidal NPs, synthesised and 
dispersed in an organic solution can be directly separated after production without transfer 
to an aqueous solution. This can avoid any possible aggregation of NPs [59].  
 
Biomedical application of NPs functionalised by biomolecules to form bio-conjugated 
systems is receiving much attention. However, purification of these NP bio-conjugates 
from unbound free bio-ligands such as peptides is still a significant challenge due to 
similar solubility. The purification of the NP bio-conjugate such as polypeptide linkers is 
important in biological applications [60]. 
   
Alele, N., et al., [65] demonstrated that, removal of excess of unbound peptides after the 
bio-conjugation stage through AuNPs synthesis was achieved via exploiting the sieving 
properties of commercial regenerated cellulose (RC) ultrafiltration (UF) membranes. The 
polymeric membranes were used in order to remove unbound peptides from mixtures 
with bio-conjugated AuNPs-peptide. The purification function is depended on separating 
components of various sizes; selection is narrowed down by porous polymeric 
membranes which control the separation mechanism based on pore size and solute size 
variation [65]. 
Where traditional purification methods for bio-conjugated NP are considered to have 
some disadvantages such as being highly time consuming, tendency of aggregation and 
precipitation, and waste of required solvents [65, 66]. 
 
Furthermore, the stabilisation agents that are used for the preparation of the nanoparticles 
are considered as toxic additives; such as Cetyltrimethylammonium bromide (CTAB), for 
this reason, the impurities of NPs must be removed before any biomedical applications 
[60, 65].  
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1.2 Functionalisation of gold nanoparticles 
Functionalisation of the NP surface is essential and can be achieved via the addition of a 
suitable protected ligands to the reaction solution. This will enhance stability of NPs and 
size control [67]. AuNP are usually coating with organic ligands. These ligands have to 
bind to the AuNPs surface and contain functional groups including carboxylate, 
phosphine, amine, or thiol groups [68].  
1.2.1 Functionalisation of AuNPs using protecting organic ligands  
In 1981 [26], AuNPs were synthesised in a non-polar organic solvent with phosphine as 
stabilising ligand for 1.4 nm AuNPs diameter. As well, AuNPs were stabilised with 
alkanethiols in 1993 by Mulvaney and Giersig, who illustrated the possibility of using 
thiols with a variety of chain lengths [26, 55]. Synthesis of highly stable AuNPs has been 
reported in the literature, using a mixture of citrate and thiol-containing ligands as coating 
agents [68, 69]. 
 
The chemical stability of mono-, di- and tri-thiol-stabilised AuNPs (2 nm diameter) was 
also investigated by Srisombat and co-workers [70]. They found excellent results when 
they stabilised AuNPs with di-thiols [28, 71].  
 
It is found that the reaction time strongly depends on the type of thiol ligand (aromatic 
thiol or alkyl thiol) and this time generally increased with increasing chain length. 
Reactions times are usually longer in case aromatic thiols, and normally require more 
than 12 h to complete the reaction and that producing AuNPs with different sizes [28, 
72]. 
 
Additionally, carboxylates such as trisodium citrate can also act as AuNP protecting 
ligands, due to electrostatic interaction with the NP surface [26, 73].  
 
In addition, some protecting ligands used to functionalised AuNPs contain more than one 
function group such as mercaptosuccinic acid, 3-mercaptopropanoic acid, p-
mercaptophenol, p-mercaptobenzoic acid, ω-bromoalkanethiols, and ω-carboxylic acid-
alkanethiols, which contains carboxylate and thiol functional groups [74]. For example, 
Sihai Chen and Keisaku Kimura [75], prepared different sizes of highly stabilised AuNPs 
in a single-phase system based on the reduction of gold (III) by NaBH4 in methanol using 
mercaptosuccinic acid (MSA) as the stabilising thiol ligand [75]. 
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1.3 Stability of colloids gold nanoparticles  
The stability of nanoparticles in solution is mostly dependent on the surface properties of 
NPs such as surface charge and protecting ligand structure [6]. Stable novel AuNPs have 
been synthesised and characterised with different ligands at different pH in this thesis. 
The pH-sensitive metal NP according to the present invention can be prepared by 
attaching a compound varying in charge with pH to the surface of the metal NP [6].  
 
A new synthetic route has been used for the synthesis of monodisperse AuNPs via varying 
the solution pH with controlled concentrations of HAuCl4 and reducing agent [44]. In 
addition, pH value was considered the important parameter, to control the size and shape 
of AuNPs. For example, the results showed that spherical AuNPs in the range of 10–20 
nm were observed at pH 7, where the results indicated the stability of AuNPs for exacts 
three months with only a little aggregation. It is noted that strong relationship between 
pH increasing and both of the reducing power and reaction rate increasing 
correspondingly and that could contribute to the formation of thermodynamic-favoured 
spherical particles [76]. 
 
In this thesis, AuNPs functionalised with different ligands were subjected to a study of 
stability over time at a variety of pH. A systematic analysis of the synthesis of the ligands, 
AuNPs and stability studies were carried out to determine the suitability of the AuNPs 
for both bio-recognition and drug delivery purposes. We used some different thiol-
containing ligands as modification ligands of AuNPs and evaluated the abilities of these 
thiol ligands for stabilising colloidal AuNPs with different pH values and gold salt 
concentrations. Different effects of various thiol ligands on the stability of AuNPs and 
that confirmed using UV / Vis spectroscopy and DLS (Dynamic light scattering). It was 
found that ligands containing (methoxy-benzene groups)-modified AuNPs were most 
stable compared to other thiol compounds containing (benzene or toluene). From the 
literature, it found the spherical AuNPs at pH values < 7 were not conserved and 
aggregation occurs quickly. However, partial stabilisation was observed for pH < 7, the 
situation improved drastically for pH values above 7. While for pH 8.0, a plasmon 
resonance peak was observed at about 530 nm for up to 3 h. and at pH 10.0, the peak 
position was remained at 524 nm and remained stable for up to 2 months [77].  
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Due to the importance of pH which is considered a key parameter for several biological 
processes and also a significant indicator for disease progression, such as endocytosis, (a 
process in which substances have been engulfed by cells, is involved with changing pH 
values from neutral to acidic (pH 6.2-4.5) [78, 79]). Tumour cells have an acidic 
microenvironment which is different from other normal cells, as result to the high 
metabolic rate and inadequate oxygen supply of tumour cells [80, 81]. This plays a 
significant role in cancer treatment nowadays, using AuNPs which are aggregated at low 
pH. The aggregates absorb far-red and near infrared (NIR), which can be used for 
photothermal therapies guaranteeing maximal tissue penetrations [82-84]. The NIR light 
irradiation is used as photothermal therapy of cancer cells without making any damaging 
for normal cells, which have pH at 7.4 [82].  
 
AuNPs have been fabricated with pH-aggregation behaviours of modifying their surface 
with mixed-charge self-assembly monolayers compromising negatively and positively 
charged thiol ligands. AuNPs can respond to pH change and form aggregates [83, 85]. 
For example, some of the negative charges would be shielded at lower pH due to the 
protonation of the carboxyl group in MUA (11-mercaptoundecanoic acid) which leads to 
rapid aggregations between AuNPs [83].  
 
For instance, the AuNPs coated by primary amines were dispersed under mildly acidic 
conditions such as pH 6. While, were not stable at pH 9, for the reason, the primary amines 
are no longer protonated at pH 9. It can be stressed that AuNPs can efficiently accumulate 
and form aggregates inside of cells. The accumulated AuNPs aggregates can destroy 
cancerous cells in response to the external illumination system. Furthermore, the AuNPs 
with proper surface ligand composition exhibited aggregation in a tumour of acidic pH. 
Investigations of pH-induced aggregation behaviours of spherical mixed charge-AuNPs, 
is mainly founded on small sizes (≤ 16 nm) nanoparticles [82]. 
 
pH-induced aggregations were obtained at pH 7.0, 7.8, and 9.2 at different size 15, 21, 
and 33 nm of mixed charge-AuNPs, respectively [82]. At significantly differing pH, the 
size of AuNPs is dependent on the initial pH of the aqueous solution. Thus, the 
stabilisation of AuNPs in pH > 7 can be due to the conversion of [AuCl4]
¯ to a less reactive 
[AuCl(4-n) (OH)n]
¯ anion, where (n) increases with pH increased (Figure 1.5) [77, 86,87].  
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Figure 1.5. Diagrammatic depiction of stabilisation of AuNPs [77]. 
At pH larger than 6.5, spherical AuNPs are obtained with diameter 15 nm [88]. In 
addition, it is noted that AuNPs were more broadly distributed at lower pH conditions. 
For example, at pH lower than approximately 3.8, AuNPs can no longer dispersed after 
completed preparation which is similar to the results collected from this thesis [88]. 
 
According to Nam, J., et al., [89] conjugated Doxorubicin AuNPs, 10 nm in size, were 
designed to aggregate in a mildly acidic environment within tumour cells to treat WHAT 
CANCER. Furthermore, they effectively accumulate in cancer cells up to 17 times more 
than the control due to enhanced permeation and retention [89]. The high tumour 
accumulation of AuNPs is thought to result from the efficient permeation into cancer cells 
through their small size and their aggregation capability, which can diffuse and penetrate 
deeply into the extracellular matrix of tumour cells [89].  
 
1.4 Biocompatibility of gold nanoparticles 
Researchers illustrated AuNPs are non-toxic and have minimal toxicity over a large range 
of concentration, encouraging researchers to use AuNPs in medical applications [15, 58, 
90]. Furthermore, AuNPs at higher concentrations inhibit both the production of reactive 
oxygen species (ROS) and reactive nitrite species (RNS). Also, AuNPs have confirmed 
biocompatible properties such as nontoxicity, non-immunogenic, and high tissue 
permeability without impeding cell functionality [58]. Recent advances of AuNPs, 
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conjugated with biomolecules have encouraged scientists to tailor AuNPs for purposes, 
such as, chemical reactions inside cells. The reason for the successful development of 
these challenging tasks depends on both surface structure design and their ability to 
synthesis AuNPs bio-conjugates with the desired sizes based on bio application [15]. 
 
There is a current interest in modifying the surface chemistry of AuNPs, due to excellent 
advantages of AuNPs in cancer treatment when compared with other metal NPs. These 
advantages are based on their enhanced scattering, absorption properties and efficient bio-
conjugation [91]. AuNPs also have shown to possess good ability in cancer cell imaging 
due to the strong scattering properties. Their strong absorption characteristics can offer 
the possibility to use them in photo-thermal therapy [22, 92]. It has been shown that 
apoptosis of cancer cells can be induced with less than half of the energy this is needed 
when HaCaT benign cells are incubated with anti-EGFR antibody conjugated AuNPs. 
According to the literature, it is found that the cancer cells require less than half the laser 
energy to be killed than the healthy cells [92].  
1.4.1 Principle of cationic cellular uptake of gold nanoparticles 
There are several studies about the cationic AuNPs [39, 93, 94]. These positively charged 
AuNPs have been used as scaffolds for DNA binding by Rotello, VM and co-workers 
[98]. This finding resulted from their interaction with negatively charged DNA, showing 
their transfection ability into a cultivated cell line. As well as, it is found that AuNPs with 
cationic average 68% were better and viable transfections vector in comparison with 
highly charged cationic AuNPs [39, 95]. 
Cationic AuNPs have been used as DNA transfection agents. For example, 
aminoethanethiol capped AuNPs of roughly 33 nm in diameter showed high transfection 
efficiency. Another example for transfection used cationic lipid coated AuNPs of 14 nm 
in size [39, 96, 97]. 
It is important to note that similar NPs have exhibited different mechanisms of entry into 
different cells. For example, the cationic AuNPs have the ability to target the nucleus after 
cross cell membranes. However, negative AuNPs and neutral AuNPs that have the same 
size and shape of cationic AuNPs cannot penetrate cell membranes [39, 98-101]. In 
addition, cationic AuNPs can bind to negatively charged groups of the cell membrane, 
and across the plasma membrane via generation of transient holes. Moreover, the positive 
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charge encourages AuNPs to interact with anionic phospholipids within the cell 
membrane and causing endocytosis [39, 102]. 
 
According to Cho, EC., et al, [39, 101] the neutral and negatively charged AuNPs such 
as (citrate- and poly vinyl alcohol (PVA)-coated AuNPs have a low affinity to interact 
with the cell membrane (Figure 1.6). However, positively charged AuNPs have a high-
affinity binding with cell membrane [39, 98]. 
 
 
 
Figure 1.6. Interactions between different surfaces charges of AuNPs with SK-BR-3 (human breast 
cancer) cells [39]. 
Cationic AuNPs modified with 2-aminoethanethiol, have a short alkyl chain, formed a 
complex with plasmid DNA, and could be transfected into cultivated cells as shown 
Figure 1.7 [100].  
 
Cationic AuNPs and the DNA complexes have been used functional gene delivery, in a 
strong controlled release manner of DNA at a desired site triggered via exogenous 
stimulation, such as light irradiation [97]. Also, attachment of DNA vaccine to AuNPs 
via protamine appears to stabilise the DNA. These Au–protamine–DNA conjugates 
supply the DNA resistance to physicochemical and temperature-accelerated degradation 
and prolong the DNA vaccine activity [103, 104]. 
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Figure 1.7. AuNPs functionalised by primary amine with their transfection ability into cultivated cells 
[97]. 
The phosphonioalkanethiol functionalised AuNPs was be suitable for therapy 
mitochondrial gene. It has been shown, when an antioxidant was attached to 
phosphonioalkanethiol, the resulting conjugate accumulated several hundred-fold within 
mitochondria in cells, blocked mitochondrial oxidative damage, and influenced 
mitochondrial redox signalling (Figure 1.8) [105]. Also, this conjugate has been found to 
block oxidative damage in isolated mitochondria and cells far more effectively in 
comparison with untargeted antioxidant counterparts due to their concentration within 
mitochondria [106-108].  
 
Moreover, it is showed that cationic lipophilic compounds which contained a 
triphenylphosphium group selectively have been accumulated in the mitochondria of 
carcinoma cells in comparison with healthy cells as consequence of the characteristically 
elevated plasma membrane potentials of neoplastic cells [105]. 
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Figure 1.8. Triphenylphosphonium cation used as non-viral DNA delivery vectors in gene therapy [105]. 
1.4.2 Physicochemical properties of cationic functionalised AuNPs inside of 
the extracellular fluid 
AuNPs enter the body by different ways such as dermal exposure, oral administration and 
intravenous injection, and then contact with bio-molecules such as lipids, proteins, and 
nucleic acids. Proteins and other biomolecules can be easily adsorbed onto AuNPs surface 
to form a protein corona around AuNPs when AuNPs enter biological fluids. This leads 
to decrease the free energy of surface AuNPs. Creation of a corona may change structures 
of adsorbed proteins and eliminate the proteins physiological function, causing the loss 
of original targeting capabilities via the high ionic strength and protein layer density 
around surface of AuNPs, that can induce several cellular responses such as, increased 
lysosomal permeability, activated cell apoptosis in different organs or tissues [109].  
 
Moreover, the composition NPs and surface charge are key determinants of protein 
adsorption, particularly with cationic AuNPs which interact with the protein’s negatives 
 18 
 
charge. Also, interactions of NPs with proteins can affect the biocompatibility of NPs and 
their internalisation in cells [39, 57, 110]. The formation of a corona of AuNPs protein is 
the main factor was for the nano-bio mediator to interact with the cells. From the 
literature, it is found that the S–S bonds were broken in order to form Au–S bonds, 
causing changes in the conformation of lysozyme on the surface of AuNPs, inducing 
protein unfolding and protein–AuNPs assembly formation, and resulting in protein 
aggregation [109].  
1.4.3 Toxicity of gold nanoparticles 
AuNPs toxicity studies have been contradictory, with interactions between AuNPs and 
tissues at the cellular level, intracellular and molecular level still misunderstood [111]. 
Although some studies have shown no cell toxicity after AuNPs interaction, other in vitro 
and in vivo studies have demonstrated the production of reactive oxygen species cell, 
mitochondrial toxicity, release of cytokines, necrosis and apoptosis [101, 111]. In order 
to be useful for cancer treatment, the AuNPs must be non-cytotoxicity for normal cells. 
This cytotoxicity has been much studied, and several parameters have involved the 
concentration, the nature of the ligands bonded to the AuNPs core and the targeted cells 
[54]. Furthermore, improvement of in vitro cytotoxicity was suggested that the delivery 
according to the AuNPs of anticancer drug could improve their power especially, perhaps 
via improved cellular uptake. AuNPs use near-infrared radiation to induce cytotoxicity 
effect, where toxicity of AuNPs depend on their concentration [112]. It also can 
significantly be seen that after 24 hours of incubation with bio-conjugates, AuNPs 
positive and negative, no particles showed significant toxicity at concentrations of 0.5 nM 
and 5 nM of AuNP [110]. 
 
According to results reported in 2008 some AuNPs are toxic for cancer cells at a 
concentration of 100 µM [54, 113], however not for immune cells. The precursors 
HAuCl4 and (CTAB) which are used for their synthesis are toxic at a concentration of 
100 µM. AuNPs functionalised by ligands positive charged are generally toxic at 
concentrations below those at which negatively charged ligands are cytotoxic. For 
example, AuNPs functionalised tri(methyl)ammonium-ended alkylthiolate ligands 
completed are more toxic compared with those ended with carboxylates [54, 114]. 
In addition, in previous study, 15 nm citrate capped AuNPs were toxic in cancer cells, but 
less toxicity from 1.4 nm AuNPs capped with triphenyl phosphine mono-sulfonate [101, 
 19 
 
115]. It was noted that toxicity was slightly higher for cationic NPs compare with the 
anionic ones, maybe due to a different interaction of NPs with cellular membranes [101].  
 
Additionally, 1.4 nm diameter of AuNPs causing cell death produced rapid necrosis via 
oxidative stress and mitochondrial damage, in a matter of hours [101, 115, 116]. AuNPs 
are synthesised with a variety of coatings, which also seems to influence the toxicity, for 
instance, triphenylyphosphine, a commonly used ligand functionalised AuNPs 1.4 nm 
appears to be more toxic particles comparing with similar size coated with glutathione. 
Toxicity appears to depend on the size and ligand type and as such can potentially be 
controlled [101, 117]. Additionally, increasing the hydrophobicity of the particles leads 
to increasing their cytotoxicity and also ROS production [26]. On the contrary, some 
researchers confirmed the AuNPs, even if not toxic, but are not totally bio-compatible. 
This confuse can be due to different factors influencing the potential toxicity of AuNPs 
which include surface chemistry, coating materials, shape, size, and biological target 
tested [118]. 
 
It is important to distinguish between cytotoxicity and cell damage. AuNPs that show 
little or no cytotoxicity by several standard tests, may still be able to cause serious damage 
to the cells. For instance, 13 nm AuNPs functionalised citrate are not toxic, according to 
an assay in a dosage in the skin cells, while the particles, are used the formation of 
abnormal actin filaments, leading to a decline of the proliferation of cell, motility and 
adhesion [39].  
 
There was no indication of any AuNPs effect could have on the cell metabolism or 
proliferation. This result is significant, given the increased absorption in the case cationic 
AuNPs bio-conjugates [110]. Furthermore, Colloidal AuNPs are well-known and safety 
in human cells have been characterised [92]. Substantially all cases showed a higher 
uptake of bio-conjugates for cationic surfactants compared with their anionic counterparts 
(Figure 1.9) [110].  
 
Maximum uptake (44.5%) was observed for 5 nm bio-conjugates cationic AuNPs after 3 
hours, and a dilution of 10 times of the particles leads to 31.5% of uptake in the same 
incubation period. This contrasts with the maximum of 5% of uptake was obtained in the 
best case internalisation with bio-conjugates anionic AuNPs (incubation of 5 nM 
concentration AuNPs at 3 hours) (see Figure1.9) [110]. Bio-conjugated AuNPs positive 
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surface charge can be responsible for more interaction with the cell membrane; can be 
attracted as result to of the inherent negative charge of phospholipid bilayers. From there, 
it seems that the AuNPs did not penetrate and passes through the membrane, but 
accumulated until the membrane is recycled and AuNPs internalised in endosomes, as 
revealed by TEM [110, 119]. Also, tumour tissues are more permeable and more 
heterogeneous in size larger in comparison with normal tissues [54, 120]. 
 
 
 
 
Figure 1.9. Intracellular Au-concentration as determined by ICP-MS analysis as a function of time. 
Where data present the average of three experiments with standard deviation [110]. 
1.4.4 Accumulation of gold nanoparticles in organism tissue 
AuNPs with the small size should be rapidly cleared from the interstitial space of cancer 
cells; compared with a large AuNPs size which has slow clearance from the tumour cells, 
due to the effective accumulation and high retention of the large AuNPs in the cancer 
region [89, 121]. 
 
The effects of using AuNPs and distribution depend on the way in which they are 
administered (subcutaneously, intramuscularly, or surface) and their size. The AuNPs 
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reach the lymph nodes more easily when their administration is subcutaneous. The 
administrations have been found to accumulate predominantly in the bladder, liver, and 
lungs regardless of size. In fact, 10 nm AuNPs accumulate in many tissues, while 200 nm 
AuNPs were detected mainly in the liver, bladder, and blood, brain, and pancreas [54, 
117, 122].  
 
According to Hirn and o-workers [123] the percentage of accumulation of the AuNPs in 
various organs and tissues was different based on their sizes and surface charge. The 
accumulation is increased with size decrease. Also, AuNPs 2.8 nm negatively or 
positively charged, were found in the spleen. Positively charged AuNPs have shown a 
significantly higher accumulation percentage (11.4%) than the negative AuNPs (8.6%) 
[123]. 
1.5 Application of gold nanoparticles in biology and medicine 
Multifunctional NPs have been developed via new experiments which aim to encapsulate 
both therapeutic and imaging agents in one nano-carrier and including more than one 
ligand on the surface. Thus, they have the capacity of targeted tumour imaging and the 
delivery of therapeutic agents [16]. 
1.5.1 Gold nanoparticles for cancer diseases 
There are several treatments for cancer including chemotherapy, radiotherapy, gene 
therapy, but all therapies have disadvantages such as effective on healthy cells. So, one 
of the significant challenges is to confine the treatment only to the tumour cell without 
causing damage to healthy cells [15, 111]. 
 
AuNPs have been used as carriers for delivery drug to target genes in desired cancer cells. 
Likewise, AuNPs used as multifunctional NP via combining diagnosis, imaging with a 
treatment of cancer diseases at the same time [15, 111, 124]. AuNPs have a high 
accumulation and more ability to penetrate in cancer cells than in healthy cells. This may 
be due to rich permeable vasculature around the tissues of cancer cells. However, the 
conventional therapy of cancer disease does not effectively differentiate between 
cancerous and normal cells [15, 93, 125]. 
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One of the important challenges in cancer therapy includes the low bioavailability and 
toxicity of cancer drugs. NPs can play a crucial role by delivering drugs in a targeted 
fashion to the cancer cells which will decrease the systemic toxicity of the anticancer 
drugs [126], also, NPs have the ability to improve on drug tolerability, circulation half-
life and efficacy [127].  
 
In addition, the AuNPs functionalised to be sensitive to pH were also used in order to 
stimulate the drug release triggered at a specific site of disease using the low pH condition 
of the tumour cells. The AuNP was stable at pH 7.4 and does not undergo hydrolysis for 
a long time. In contrast, at pH 5.0 the AuNP was rapidly and completely hydrolysed in 
2 h and the release of drugs from AuNP was remarkably faster at pH 5.0 compared at 
neutral pH [80]. Furthermore, about 9% to 15% of patients benefited from surgery by 
removed cancer tissue. For example, for all stages of pancreatic cancer, they found the 
median survival is 3-5 months from diagnosis [126]. It is predicted that, if NP carrying 
anticancer drugs can be supplied in a targeted manner, inhibition of tumour growth with 
a reduced toxicity can be achieved [10].  
 
In addition, there is a strong interest to modify existing drugs in order to improve 
pharmacokinetics, reducing the side effects and allowing the delivery of higher doses to 
the target tissues. An important manifestation of potential AuNPs multifunctional drug 
delivery has been the use of 5 nm AuNPs as a delivery vehicle, covalently bound to the 
active agent such as Cetuximab and Gemcitabine (see Figure 1.10). The payload of 
therapeutic pancreatic cancer drug can be achieved with minimal accumulation in the in 
the liver or kidney. Low gemcitabine doses (2 mg kg-1) resulting in 80% inhibition of 
tumour growth in an orthotopic model of pancreatic cancer in comparison with 30% 
inhibition with conjugated agents in combination [111, 128, 129].  
 
Patra, CR., et al., [126] illustrated that, only 30% to 40% AuNPs that bound gemcitabine 
was released after an incubation period of 6 hours, and about 45% was released from the 
nanocomposites over 24 hours. These results indicate stability of the nano-conjugates in 
a physiologic salt concentration [126]. 
It has been reported that, a dose of 250 mg/kg of gemcitabine in pancreatic tumour caused 
58% inhibition of tumour growth. However, a dose of 7.5 mg/kg did not inhibit tumour 
growth significantly [126].  
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Figure 1.10. Structure of Gemcitabine (left) and Cetuximab (right) (Figure is taken from 
https://pubchem.ncbi.nlm.nih.gov/compound/gemcitabine#section=Top  
It is obvious that, there was not any increased gemcitabine retention upon Nano-
conjugation compared with free gemcitabine alone. These results demonstrate that the 
observed effectiveness at a lower dose is due to the targeted delivery and not due to a 
greater retention of Nano-conjugation [126, 130]. In addition, in order to increase NP 
retention in tumour cells, NPs have been designed to reverse their surface charge from 
neutral / negative to positive at the tumour site as shown in the literature [127]. 
 
According to Patra, CR., et al., [10] combination NPs with drugs in chemotherapy has 
been demonstrated to be better than drugs alone for many solid tumours [10]. Recent 
reports have shown no effect of toxicity in mice up to 1 year after injection of AuNPs 1.9 
nm [126]. 
 
Hyperthermia has been used to induce apoptotic cell death in many cancer tissues. 
However, due to difficulties in heating deep tumours to therapeutic temperatures after 
initial treatment have limited the use of hyperthermia in the treatment of cancer. All 
recently nanomedical research offer the potential to specifically target metal NPs to 
tumour cells. [111, 131]. 
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1.5.2 Gold nanoparticles against bacteria  
Bio-applications of nanoparticles have increased markedly in recent years. It was detected 
that bacterial count in the liver was decreased about 20-fold after AuNPs conjugated 
ciprafloxicin were used as antibiotics compared to the free drug. The AuNPs are less toxic 
to biological system. The dose of antibiotics for the treatment purpose is often much 
higher than the dose required in order to kill the pathogens. This could produce toxic 
effects in the dose. Dose should be reduced by successful AuNPs antibiotic therapy and 
for this reason AuNPs have been used to address the problem associated with traditional 
antibiotics [132]. AuNPs functionalised by specific ligands offer significant effect in this 
field. For instance, the synthesis of thiol-stabilised AuNPs with core diameters between 
5-26 nm in this thesis, have an effect on some kinds of bacteria, (Chapter 6). Successful 
application of some of the AuNPs exhibited high antibacterial activity. Different 
concentrations of AuNPs were tested as anti-bacteria. High concentrations had a high 
effect on both kinds of bacteria including Escherichia coli and Staphylococcus aureus. 
This demonstrated that, the inhibition of a bacterium by AuNPs is dose-dependent [133, 
134].  
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Aims of the project 
The aim of this thesis is to synthesise and characterise novel cationic alkane thiolate 
derivatives, which are used to functionalise AuNPs for potential uses as alternative 
biorecognition and drug delivery systems. Within this research area, laboratory work was 
focused on the synthesis and stability of these AuNPs. Comparison between 
phosphonium-thiolates ligands (Ph3-P-(CH2)n-S2O3) with different aromatic groups such 
as benzene, toluene or trimethoxy-benzene has been carried out, in order to see potential  
effects on the stability of the functionalised AuNPs. The AuNPs synthesis conduct in one 
of two ways with reduction by a biphasic solvent system of DCM/water, and monophasic 
medium DMSO. The cationic phosphonium AuNPs investigate with their stability over 
time at a pH range of 3-11. AuNPs prepare by the reduction of KAuCl4 using different 
reducing agent power including sodium borohydride and ascorbic acid as biocompatible 
reducing agents, and that can be used to assess the hydrophobic, cationic properties of the 
AuNPs for use in biorecognition such as antibiotic. 
Outline of the thesis 
In Chapter 2, a brief description of the analytical methods employed to characterise all 
the novel compounds obtained in this thesis is outlined. The analytical devices used to 
include FTIR, NMR, ESMS, TEM, DLS and UV-Vis. Synthesis phosphonium cationic 
AuNPs in a two-phase liquid-liquid (DCM/H2O) and one phase (DMSO), described in 
Chapters 3 to 5. 
 
Chapter 3 contains the description of the synthesis of cationic AuNPs reduced by sodium 
borohydride as reducing agent in aqueous medium and the stability of AuNPs have been 
measured at different pH (3-11). The influence of the different ligands on the stability of 
AuNPs is investigated by TEM and UV-Vis measurements.  
 
Chapter 4 synthesis AuNPs by different reducing power including ascorbic acid as 
biocompatible reducing agent (weak) and NaBH4 (strong) are presented. Big sizes with 
less stability have been generated in the case of the ascorbic acid was used compared in 
the case of NaBH4. 
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Chapter 5 AuNPs have been stabilised through using protecting ligands such as phosphine 
oxide derivative ligands.  
Chapter 6 demonstrates the bio applications of cationic phosphonium AuNPs with 
average size from 8.0-11 nm, where AuNPs in this thesis offered ability to effect on some 
kinds of bacteria including, Gram- Negative Bacteria such as E. coli and the Gram-
Positive Bacteria like Staphylococcus aureus.  
 
Chapter 7 contains a summary of the conclusion and some suggestions for future work. 
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Chapter 2: Highly stable noble metal nanoparticles dispersed 
in biocompatible solvents: synthesis of cationic phosphonium 
gold nanoparticles in water and DMSO 
Ju-Nam, Y., Abdussalam-Mohammed, W., & Ojeda, J. J. (2016). Highly stable noble 
metal nanoparticles dispersible in biocompatible solvents: synthesis of cationic 
phosphonium gold nanoparticles in water and DMSO. Faraday discussions, 186, 77-93.  
2.1 Abstract 
Synthesis of novel cationic phosphonium AuNPs dispersible in water and 
dimethylsulfoxide (DMSO) for their potential use in biomedical applications is outlined 
in this chapter. All the cationic-functionalising ligands currently reported in the literature 
are ammonium-based species. Here, the synthesis and characterisation of an alternative 
system, based on phosphonioalkylthiosulfate zwitterions and phosphonioalkylthioacetate 
were carried out. Phosphonioalkylthiosulfate zwitterions are readily disproportionated 
into phosphonioalkylthiolates in situ during the synthesis of AuNPs, produced by the 
borohydride reduction of gold (III) salt. Syntheses of cationic AuNPs using these 
phosphonium ligands were carried out in water and DMSO.  
 
UV-Visible spectroscopic and TEM studies have shown that the phosphonioalkylthiolates 
bind to the surface of AuNPs, which are typically around 10 nm in diameter. The resulting 
cationic-functionalised AuNPs are dispersible in aqueous media and in DMSO, which is 
the only organic solvent approved by the U.S. Food and Drug Administration (FDA) for 
drug carrier tests. This indicates their potential future use in biological applications. In 
this chapter, the synthesis of a new family of phosphonium-based ligands, which behave 
as cationic masked thiolate ligands in the functionalisation of AuNPs is discussed. These 
highly stable colloidal cationic phosphonium AuNPs dispersed in water and DMSO can 
offer a great opportunity for the design of novel biorecognition and drug delivery systems. 
2.2 Introduction 
The ability of modifying noble metal NPs, such as AuNPs with various organic thiolate 
ligands makes them versatile systems and opens a range of possibilities for their use as 
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drug delivery systems [1-3], bio-sensing [4-6] and diagnostic applications. Ligands are 
introduced to the surface of the NP either to stabilise the particle and avoid uncontrolled 
aggregation, or to add functionality to the particle for biomolecular recognition, enhanced 
transport and anchoring properties [7]. Recent studies have shown that the size, shape and 
surface charge of NPs, in general, play crucial roles in their entry and subsequent access 
of NPs into living cells [6, 8-11]. For instance, cationic NPs are more effective penetrating 
into mammalian cells than anionic NPs due to electrostatic interaction between cationic 
NPs and negatively charged mammalian cells [12].  
 
NP surface functionalisation plays an important role in cellular uptake and producing 
cellular responses [13, 14]. However, information published in the literature on how 
functionalised NP surface characteristics, such as aromaticity and hydrophobicity, affect 
cellular internalisation processes is still unclear. Al-Hajaj, NA., et al., have shown that 
the functionalised quantum dots they produced with non-specified ligands were taken up 
by lipid host mediated endocytosis in human kidney and liver cells [15]. Designing and 
tailoring the surface of inorganic NPs with suitable ligands may potentially offer long-
term stability under a wide-range of conditions such as, high electrolyte concentration, a 
broad pH range, and biogenic or naturally occurring thiols [3]. 
 
Zhan, N., et al., have shown that quantum dots modified with multidentate lipoic ligand 
containing a zwitterionic head group can be highly biocompatible nanomaterials [16, 17], 
making them attractive nanodevices for clinical in vitro and in vivo imaging applications 
[18-20]. More recently, Rotello, VM., et al., have studied the behaviour of AuNPs with 
different hydrophobicities and the effect of surface functionality on hemolysis [21]. They 
observed a linear haemolytic behaviour with increasing hydrophobicity in the absence of 
serum media. Mcintosh, CM., et al., synthesised AuNPs capped with a mixture of 
octanethiol and 11-trimethylammonium-undecanethiol, and others functionalised with 
trimethylammonium cationic head groups on the surface can interact electrostatically and 
bind with the negatively charged phosphate backbone of 37 mer duplex DNA [22].  
 
As in these studies reported in the literature, the majority of the cationic species 
investigates and used are ammonium-based groups. Here in this chapter, cationic 
phosphonium-based groups are also described as alternatives to the ammonium functional 
groups. The phosphonium groups can offer a range of advantages including the 
availability of a broad range of organic derivatives, which allows of designing and 
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producing a wide variety of functionalised AuNPs. Their ability of triphenylphosphonium 
head groups to travel across cell membranes is well-known [23-26]. There are also several 
studies on the use of phosphines and phosphine oxides to stabilise NPs. However, there 
have been far fewer studies of the use of organophosphorus ligands [27-29]. 
 
Additional to imparting specific functionalities to NPs, their dispersion in water or any 
other biocompatible solvent is crucial for their use in biomedical or biological 
applications. Therefore, water should be the primary solvent to be used to disperse 
functionalised NPs. However, in many cases, the ligands used to protect and provide 
functionality to NPs, and the corresponding NMs produced are not soluble or dispersible 
in water. It would be highly beneficial to have a range of other biocompatible solvents. 
One potential alternative to water could be DMSO. According to the FDA, DMSO is a 
solvent derived from wood, which has been the subject of considerable interest for its 
potential as a drug. At present, the only human use for which DMSO has been approved 
is for interstitial cystitis, a bladder condition. DMSO is also known as a "carrier" 
chemical, it could deliver substances into the bloodstream through the skin [30].  
 
DMSO is a safe and successful component for encouraging the transdermal 
administration of both hydrophilic and lipophilic drugs to provide localised drug delivery 
[22, 31]. For all the reasons outlined here, DMSO was a chosen solvent to synthesise and 
disperse cationic phosphonium NPs described in this chapter. 
 
A publication was generated from this work, and the syntheses cationic AuNPs by 
reducing gold (III) salt in the presence of our cationic phosphonium ligands in DMSO 
was reported for the first time. Also the synthesis of a new cationic phosphonium ligand, 
such as, tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) used to functionalise the 
AuNP surface in DMSO was reported. Two previously reported phosphonium ligands, 
triphenylphosphoniopropylthiosulfate zwitterion (4C) [32] and (3-thioactylpropyl)- 
triphenylphosphonium bromide (5) [33], were used for this work to produce the cationic 
phosphonium AuNPs in DMSO and comparison purposes with the new ligand 
synthesised, tri(p-tolyl)phosphoniopropylthiosulfate (4).  
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2.3 Materials and Methods 
2.3.1 General Information 
All chemicals and solvents were purchased from Sigma-Aldrich and Fisher Scientific Ltd. 
For the characterisation of the ligands and functionalised AuNPs, several analytical 
techniques were used. TLC, ATR-FTIR, NMR, ESI-MS techniques were employed to 
characterise the phosphonium containing ligands. UV-Visible spectroscopy and TEM 
were used to characterise and obtain the size of the cationic phosphonium AuNPs. The 
stability of the colloidal AuNP solutions were monitored using UV-Visible technique. 
(a) Thin Layer Chromatography (TLC): Analytical thin layer chromatography was 
carried out on Merck silica gel 60 F254 plates by using mixtures of methanol: 
dichloromethane (DCM) as eluent system. 
(b) Attenuated Total Reflectance–Fourier Transform Infrared (ATR-FTIR) 
Spectroscopy: IR spectra acquisition was performed on solid samples using a Nicolet 
5700 FT-IR spectrometer equipped with Omnic software (version 7.1) and a Smart Omni-
Sampler (ATR cell with single reflectance germanium crystal). Each recorded spectrum 
is the average of 32 scans with a spectral resolution of 4 cm−1 from 400 to 4000 cm−1 on 
a dried sample, with a background spectrum recorded before each analysis. Spectra were 
measured and analysed and fitted using Origin software (Version 7.5) equipped with 
Peak-Fitting Module (PFM). 
(c) Nuclear Magnetic Resonance Spectroscopy (NMR): 1H NMR spectra were 
acquired on a JEOL 400MHz spectrometer. Data are reported as follows: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet. Appropriate solvents such as 
dimethylsulfoxide, chloroform, diethyl ether were used to dissolve the samples to a 
concentration of 15 to 40 mg ml-1 for 1H experiments.  
(d) Electrospray Ionisation–Mass Spectrometry (ESI-MS): ESI-MS analyses were 
generally performed on the Orbitrap XL using nano- electrospray in positive or negative 
ionisation mode. Orbitrap XL High resolution instrument gives accurate mass 
measurement over the full mass range in electrospray resolution: up to 100,000 (FWHM). 
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Mass Range: m/z 50–2000 or m/z 200–4000. Mass Accuracy: < 3 ppm RMS with external 
calibration; < 2 ppm RMS with internal calibration. 
 
All samples were initially solvated in 250µl of DCM before approximately 10µl of the 
solutions were added to 1ml of methanol with NH4OAc. A portion of these samples were 
added to a 96 well plate to be analysed by positive nano-electrospray.  
(e) Ultraviolet-Visible Absorption Spectroscopy (UV-visible): UV-visible spectra 
were obtained on a HITACHI U-2900 spectrophotometer with double beam principle 
system with data recording using Vision software version on Windows XP/2000. Samples 
were analysed in a UV-quartz cuvette of a 1 cm optical path. Appropriate dilutions to the 
original samples were carried out using either water or DMSO. 
(f) Transmission Electron Microscopy (TEM): A JEOL2100 field emission gun 
transmission electron microscope (FEG TEM) set at 100 KV was used for the analyses 
of the particles and obtained the TEM micrographs. Size distribution was obtained by 
counting and measuring over 150 AuNPs. Deposition method was used to prepare the 
samples for TEM analyses. A drop of a diluted colloidal solution of the functionalised 
AuNPs was placed and suspended on a Holey carbon coated copper grid. Then the grids 
were left to dry at room temperature.  
2.3.2 Cationic phosphonium ligand syntheses 
The syntheses of the triphenylphosphoniopropylthiosulfate zwitterion (4C) and ω-
thioacetylpropylphosphonium salt (5) were synthesised following methods previously 
reported [32, 33]. The tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) synthesis 
and characterisation are reported for the first time in this work. The synthetic protocols 
used to produce the three ligands are outlined in this section. 
2.3.2.1 Synthesis of tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) 
The synthesis of the 4 was carried out following the reactions showed in Scheme 1. In a 
round bottom flask with a reflux condenser a mixture of tri(p-tolyl)phosphine (1) (3.8 
mmol) with approximately bromo-propanol (15 mmol) were refluxed for five hours in 
acetonitrile (0.024 mmol) and the solid precipitate was collected and recrystallized from 
ethanol (Reaction 1, Scheme1). The yield was 70%. The resulting salt (2) was dissolved 
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in hydrobromic acid (0.18 mmol, 10 ml) (48%) in a round bottom under reflux five hours 
(Reaction 2, Scheme 1). The reaction mixture was left to cool down, the compound 
appeared as yellow oil (3). In order to prepare the tri-p-tolylphosphoniopropylthiosulfate 
zwitterion (4), a mixture of -bromopropyl-tri(p-tolyl)phosphonium bromide (3) (1 
mmol) and sodium thiosulfate (1.5 mmol) were refluxed for five hours in aqueous ethanol 
(1:1, 10 ml) (Reaction 3, Scheme 1). TLC was used in order to follow the progress of the 
reaction by using 20% : 80% methanol : DCM as mobile phase. All compounds were 
purified further by liquid-liquid extraction of the reaction mixture using DCM and by 
trituration with dry diethyl ether.  
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2.3.2.2 Synthesis of triphenylphosphoniopropylthiosulfate (4C) 
In order to obtain the 4C [32], three main chemical reactions were carried out. The first 
stage involved the synthesis of the hydorxylpropylphosphonium salt and this was 
generated by a quaternation reaction of triphenylphosphine (4 mmol) and the 
corresponding bromo-propanol (15 mmol) in acetonitrile under reflux for four to five 
hours. The resulting salt was dissolved in hydrobromic acid (48%) and reaction was 
carried out under reflux for five hours to obtain the ω-bromopropyltriphenylphosphonium 
bromide salt. The latter (1 mmol) then was treated with sodium thiosulfate (1.5 mmol) in 
ethanol / water under reflux for five hours in order to produce the 
phosphoniopropylthiosulfate zwitterion. Progress of all reactions were monitored by TLC 
using methanol:dichloromethane 1:4 ratio as the mobile phase. All the compounds were 
purified by dichloromethane extraction and re-crystallisation using diethyl ether.  
2.3.2.3 Synthesis of (3-thioacetylpropyl)triphenylphosphonium bromide (5) 
In order to obtain the 5, hydroxypropylphosphonium and ω-bromopropyltriphenyl- 
phosphonium bromide salts were also synthesised as described in the synthesis of 
triphenylphosphonio- propylthiosulfate zwitterion [32, 33]. Once the bromide salt (2 
mmol) was produced, this was reacted with potassium thioacetate (3 mmol) in a mixture 
of ethanol/water. The progress of the reaction was followed by TLC using a mobile phase 
of methanol:dichloromethane  in 1:4 ratio. The (3-thioactylpropyl)triphenylphosphonium 
bromide was isolated and purified by liquid-liquid extraction using DCM as the extracting 
solvent, and re-crystallisation of the bromide salt using diethyl ether. 
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2.3.3 Synthesis of cationic phosphonium gold nanoparticles in water and 
DMSO 
The preparation of colloidal cationic phosphonium AuNP solutions in water was carried 
out following the principals involved in the method developed by Brust and Schifrin, a 
two-phase liquid-liquid system [32]. Variations were done to this method due to the 
solubility of the phosphonium ligands synthesised. The method for the synthesis of 
colloidal cationic phosphonium AuNPs in DMSO is reported for the first time and was 
developed in a similar fashion as the previous methods. 
2.3.3.1 Cationic phosphonium gold nanoparticles dispersed in water 
Solutions of the phosphonium ligands zwitterion 4C and 5 was prepared in 20 mL of 
dichloromethane (DCM) (0.25 mmol and 0.30 mmol respectively) and potassium 
tetrachloroaurate (0.12 mmol) was also added to the DCM solution [32, 33]. This was 
vigorously stirred for 2 hours and until the potassium gold salt was totally dissolved. The 
reduction of the gold (III) to gold (0) in the presence of phosphonium ligand was carried 
out by adding drop by drop a freshly prepared sodium borohydride solution in water (3 
ml, 400 mM) with vigorous stirring. After 20 minutes of stirring, 15 mL of deionised 
water was then added to the mixture. The latter is kept stirring overnight. The initial DCM 
was removed from the aqueous phase, as the functionalised NPs transferred to this phase. 
Then, three liquid-liquid extractions were carried out using DCM in order to purify the 
cationic phosphonium AuNPs dispersed in water. 
2.3.3.2 Cationic phosphonium gold nanoparticles dispersed in DMSO 
In order to prepare the colloidal AuNPs in DMSO, solutions of the phosphonium ligands, 
4C, 5, and 4 were prepared in DMSO (0.25 mmol, 0.30 mmol, and 0.8 mmol 
respectively). The volume used for these solutions was 20 mL. A solution of potassium 
tetrachloroaurate (0.12 mmol) in DMSO (10 mL) was also prepared. Then both, ligand 
and gold salt solutions were mixed and stirred. The reduction was carried out by adding 
5 mL of freshly prepared aqueous solution of sodium borohydride (2.0 mmol) to the 
DMSO mixture. In order to remove the excess of ligands in each one of the gold colloidal 
solutions prepared, liquid-liquid extractions were carried out using diethyl ether. 
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2.4 Results and Discussion 
2.4.1 Synthesis of tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) 
The synthesis of the 4 involved the preparation of two intermediates, which were obtained 
and purified in order to get the zwitterion. The first compound synthesised was the 
hydroxylpropylphosphonium salt and this was obtained by the quaternisation of the tri(p-
tolyl)phosphine with bromopropanol as it is showed in Scheme 1. The hydroxypropyl-
tri(p-tolyl)phosphonium bromide was then treated with HBr in order to obtain the -
bromopropyl-tri(p-tolyl)phosphonium bromide. The latter is then reacted with Na2S2O3 
in aqueous ethanol.  
 
The resulting zwitterion was purified by trituration using diethyl ether. The final product 
had an oily appearance, yellow coloured. When studied by ESMS in positive ion mode, 
an ion corresponding to M+H+ was observed (459). The 1H NMR showed the distinctive 
chemical shift at 2.3 corresponding to the nine protons from the –CH3 attached to the 
aromatic ring. This chemical shift is the main difference between the tri(p-
tolyl)phosphoniopropylthiosulfate and the triphenylphosphoniopropylthiosulfate 1H 
NMR spectra. It can be assumed that the sulfur-sulfur bond of both tri(p-
tolyl)phosphoniopropylthiosulfate undergoes cleavage with the loss of the sulfite ion 
under reductive conditions as in the synthesis of gold colloidal NPs, as it was shown and 
reported in the case of the triphenylphosphoniopropylthiosulfate.  
 
This cleavage will allow the sulfur of the cationic phosphonium ligand to interact with 
the AuNP surface. As previously mentioned, these thiosulfate and thioacetate ligands are 
usually known as masked thiol ligands. For 4C and 5 similar results to the previously 
reported were observed when studied by IR, NMR and ESI-MS. Solubility tests were 
carried out to all three masked thiol ligands. They were soluble in methanol, ethanol, 
DMSO, chloroform and DCM. 
2.4.2 Cationic phosphonium gold nanoparticles dispersed in water and DMSO 
The 4C and 5 ligands have shown their ability to functionalised and stabilised AuNPs 
surface in water. For this work, another biocompatible solvent, DMSO, was used in order 
to assist with the solubilisation of more hydrophobic ligand 4, its interaction with AuNP 
surface, and then penetration into the lipophilic cell wall. These thiosulfates containing 
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salts are also known as Bunte salts. Shon, Y-S., et al., were the first in showing the 
production of alkanethiolate-AuNPs from Bunte salts [34].  
 
They used sodium S-dodecylthiosulfate and showed that the sulfur-sulfur bond of the 
thiosulfate salt undergoes cleavage and acted as the free thiol [32, 34]. Functionalised 
AuNPs dispersed in water were obtained when 4C and 5 ligands, and the two-phase 
liquid-liquid (DCM / water) method were used. However, when 4 was used as the 
protecting ligand with the same method, no transfer of these NPs to the water phase was 
observed, and, therefore, no stable gold colloidal NPs were obtained in water.  
Various attempts of synthesising phosphonium cationic AuNPs were carried out using 4 
as the stabilising ligand and the two phase DCM / water method. Concentration of this 
ligand was also increased to a double (80 mM) and same results were obtained. Therefore, 
in the case of 4, even increments in the concentration of the ligand did not help to obtain 
the functionalised AuNPs dispersed in water.  
 
DMSO was chosen as an alternative solvent to disperse the AuNPs functionalised with 4 
ligand. Due to the properties described in the introduction, DMSO was used to synthesise 
AuNP functionalised with the 4, and also be able to use more hydrophobic phosphonium 
ligands to fabricate carriers with potential abilities to permeate and penetrate the 
lipophilic cell walls.  
 
In order to prepare the colloidal AuNPs in DMSO, a reduction of gold (III) to gold (0) 
was carried out in the presence of 4 in DMSO, using sodium borohydride as the reducing 
agent. With this reducing method using DMSO as the dispersing solvent, a ruby – 
coloured colloidal solution of AuNPs functionalised with 4 was obtained. Using the same 
method in DMSO, other colloidal solutions of AuNPs functionalised using 4C and 5 as 
protecting ligands were also successfully obtained. Stability studies were also carried out 
in order to monitor over time the potential aggregation in the colloidal solutions prepared 
following this method.  
2.4.3 UV-Visible and TEM studies 
Using UV-Vis spectroscopy technique, formation of AuNPs in solution (either in water 
or DMSO) and as previously mentioned, stability of these colloidal solutions were 
followed. It is well-known that the dark-red colour of gold colloids dispersed in water 
reflects the surface plasmon band (SPB), which is a broad absorption band in the visible 
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region around 520 nm [35]. The SPB is due to the collective oscillations of the electrons 
at the surface of NPs (6s electrons of the conduction band for AuNPs) that is correlated 
with the electromagnetic field of the incoming light [36]. The maximum bandwidth is 
also influenced by the particle size [37-40]. It has been shown that for AuNPs of mean 
diameter of 9, 15, 22, 48, and 99 nm, the SPB maximum λmax was observed at 517, 520, 
521, 533, and 575 nm, respectively, in aqueous media [37, 41]. 
Evidence of the formation of AuNPs using the reduction method in DMSO was shown 
by UV-Visible spectroscopy technique. Using the DMSO as the blank, bands centred at 
519 (Figure 2.1, see UV-visible spectrum at time = 0), 519 (Figure 2.2, see UV-visible 
spectrum at time = 0) and 529 nm (Figure 2.3, see UV-visible spectrum at time 0) were 
observed in the resulting UV spectra corresponding to the burgundy gold colloidal 
solutions prepared with triphenylphosphoniopropylthiosulfate, (3-thioactylpropyl)- 
triphenylphosphonium bromide and tri(p-tolyl)phosphoniopropylthiosulfate, 
respectively. Their stability was also monitored by UV-Vis spectroscopy and the DMSO 
solutions showed to be stable at least for 12 weeks (Figures 2.1, 2.2 and 2.3). The colloidal 
solutions were stored in the dark and at room temperature.  
 
 
 
Figure 2.1. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 4C as 
protecting ligand. The different UV-visible spectra represent these NPs dispersed in water at time = 0, and 
DMSO at time = 0, 6 and 12 weeks. Where time = 0 is the initial time of the 4C-AuNP preparation. 
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As previously reported and repeated for this work for comparison purposes, the AuNPs 
synthesised using 4C and 5 as protecting ligands, and dispersed in water showed broad 
bands centred at 519 nm in both cases in the UV-visible spectra (Figures 2.1 and 2.2, 
respectively) [32, 33, 42]. When compared the UV spectra of the colloidal solutions of 
AuNPs functionalised with 4C in water and DMSO (Figures 2.1 and 2.2, see UV-visible 
spectra at t = 0 in water and DMSO), they did not show significant differences in the 
wavelengths. In our case the refractive index of the solvent DMSO has not shown to 
induce a shift of the SPB of our NPs as suggested in the literature [41]. 
 
 
 
 
Figure 2.2. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 5 as 
protecting ligand. The different UV-visible spectra represent these NPs dispersed in water at time = 0, and 
DMSO at time = 0, 6 and 12 weeks. 
 
The ligand shell also alters the refractive index and causes either a red or blue shift. This 
shift is especially significant with thiolate ligands, which are responsible for a strong 
ligand field interacting with surface electron cloud [38]. Similar evidence can be observed 
when compared the colloidal solutions in DMSO of AuNPs stabilised with 4C with the 
one corresponding to AuNPs functionalised with 4. Differences in wavelengths (519 and 
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529 nm, respectively) can be observed when ligands change in structure (see Figures 2.1 
and 2.3).  
The colloidal solutions of AuNPs functionalised using 4C (Figure 2.4, TEM1), 5 (Figure 
2.4, TEM2) and 4 (Figure 2.4, TEM3) as protecting ligands, were all analysed by TEM. 
Micrographs of all three AuNP samples showed spherical or semi-spherical shaped 
particles. Then, particle sizes for samples TEM1, TEM2 and TEM3 were obtained by 
analysing at least 150 particles per sample from several images taken.  
 
 
 
 
Figure 2.3. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 4 as 
protecting ligand. The different UV-visible spectra represent these NPs dispersed in DMSO at time = 0, 6 
and 12 weeks. 
 
All sample showed to be monodispersed and mean particle diameters were obtained by 
calculating the averages and standard deviations. For mean diameters obtained for the 
samples analysed were the followings: 11 ± 1 nm (TEM1), 8 ± 1 nm (TEM2) and 10 ± 
1 nm (TEM3). Samples TEM1 and TEM2 showed similar particle sizes to ones reported 
and synthesised using the two-phase DCM/water method [32, 33].  
 
These evidences are confirmed by the ones found in the corresponding UV-Visible 
spectra. Although, solvents used to disperse the NPs were different, the principle of the 
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reduction method used was the same and also the concentrations used for both methods, 
two phase DCM/water and DMSO, were similar. 
 
In the case of the 4 functionalised AuNPs, they could only be produced using the DMSO 
method. The corresponding UV-Visible spectrum showed that the SPB is centred at 529 
nm. With this evidence only, it could have been assumed that NPs were slightly larger in 
size than the ones functionalised with the 4C ligands, which showed bands centred at 519 
nm. 
 
 
 
(TEM1) 
(TEM2) 
(TEM3) 
Figure 2.4. Representative TEM micrographs of cationic phosphonium AuNPs synthesised using 4C 
(TEM1), 5 (TEM2), and 4 (TEM3) as protecting ligands in DMSO, and corresponding particle size 
histograms. 
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The slight blue shift observed in the UV-Visible spectrum of the 4 functionalised AuNPs 
might be due to the ligand shell altering the refractive index and interacting more strongly 
with the electron cloud of the NP surface, and not to the particle size. This evidence 
supports Su, KH., et al., experimental observations and results [38]. 
2.5 Conclusions 
The fabrication of cationic phosphonium AuNPs using 
triphenylphosphoniopropylthiosulfate (4C) zwitterion, (3-thioactylpropyl)triphenyl-
phosphonium bromide (5), and tri(p-tolyl)phosphoniopropylthiosulfate (4) zwitterion as 
protecting ligands and a reduction method in DMSO was reported for the first time; and 
also the synthesis of a new masked thiol, tri(p-tolyl)phosphoniopropylthiosulfate 
zwitterion (4). These Bunte salts and thioacetate ligands offer an advantage over the free 
thiol ligands as they showed better stability to air oxidation. The use of a biocompatible 
solvent such as DMSO to produce these NPs can represent an advantage for their potential 
applications as novel therapeutic agents, especially, when more hydrophobic ligands 
(tri(p-tolyl)phosphoniopropylthiosulfate zwitterion) are used to functionalised AuNPs, as 
they may have more affinity with the lipophilic cell walls. It was also shown that under 
reductive conditions in DMSO, the formation of these NPs occurred in the presence of all 
three cationic phosphonium ligands synthesised for this work.  
 
The formation and the stability over time of 4C, and 4 functionalised AuNPs in DMSO 
were confirmed and followed by UV-visible spectroscopy. Bands centred at 519 and 529 
nm, respectively, were observed in the UV-visible spectra, and those did not change over 
a period of 3 months. Changes in the ligands chemical structure can probably affect the 
refractive index of the colloidal solution and produce a shift to the left (blue shift). As 
previously mentioned, 4 functionalised AuNPs were successfully produced and dispersed 
in DMSO, however, these NPs could not be produced using the two-phase liquid/liquid 
(DCM / water) method and dispersed in water. The TEM analyses of the 4C and 4 
functionalised AuNPs showed a fairly good monodispersity and particle sizes of 8 and 11 
nm.  
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2.6 Characterisation of the cationic phosphonium ligands 
 
Hydroxypropyl-tri(p-tolyl)phosphonium bromide (2) 
IR spectrum showed absorption bands at the regions of 725–720 cm-1 ( CH2), 1600cm-1 
( C-O), 3100–3000 cm-1( CH-Aromatic), and 3344 cm-1 ( C-OH). 1H NMR spectrum 
gave signals at  1.8 (9H, s, 2CH3),  2.0 (2H, m, -CH2-),  2.6 (1H, s, OH),  3.4 (2H, 
m, P-CH2),  3.6 (2H, t, OH-CH2), and  7.3-7.5 (12H, m, Aromatic H) ppm. ESI-MS 
363 [M - Br], 364 [M – Br] + [H+]. 
 
-bromopropyl-tri(p-tolyl)phosphonium bromide (3) 
IR spectrum showed absorption bands at the regions of 677cm-1 ( C-Br), 748 cm-1 ( 
CH2), 988 cm
-1 ( P-CH2), and 3100–3000 cm-1( CH-Aromatic). 1H NMR spectrum gave 
signals at  2.3 (9H, s, -CH3),  2.4(2H, m, P-CH2),  3.8 (2H, m, -CH2-) and at 7.4 - 7.9 
(12H, m, Aromatic H) ppm. ESI-MS 427 [M]. 
 
Tri(p-tolyl)phosphoniopropylthiosulfate zwitterion (4) 
IR spectrum showed absorption bands at the regions of 725-720 cm-1, (CH2), 1329cm-1 
( S=O), 1400 cm-1 ( C-S), 3100–3000 cm-1 ( CH-Aromatic). 1H NMR showed a 
signals at  2.3 (s, 9H, 3CH3),  3.2 (t, 2H, P-CH2-CH2-CH2),  3.4 (t, 2H, P -CH2-CH2-
CH2),  3.6 (m, 2H, P-CH2-CH2-CH2),  7.24 (1H, CDCL3), and  7.3-7.6 (12H, m, 
Aromatic H) ppm. ESI-MS 459 [M + H+]. 
 
Triphenylphosphoniopropylthiosulfate zwitterion (4C) 
IR spectrum showed absorption bands at the regions IR spectrum showed absorption 
bands at the regions of 725–720 cm-1 ( CH2), 1330 cm1 ( S=O), 1345 cm-1 (C-S-), and 
3100–3000 cm-1 ( CH-Aromatic). 1H NMR spectrum gave signals at  2.2 (2H, m, P-
CH2-CH2-CH2),  3.3 (2H, m, P-CH2-CH2-CH2),  4.0 (2H, m, P-CH2-CH2-CH2) and at 
7.6 - 7.8 (15H, m, Aromatic H) ppm. ESI-MS 417 [M + H+]. 
 
(3-Thioactylpropyl)triphenylphosphonium bromide (5) 
IR spectrum showed absorption bands at the regions of 735–740 cm-1 ( CH2), 1345 cm-
1 ( C-S), 1470–1450 cm-1 ( C–H corresponding to bend-CH2), 1678 cm-1 ( C=O), and 
3100–3000 cm-1( CH-Aromatic). 1H NMR showed a signals at  2.4 (3H, s, -CH3),  2.9 
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(2H, m, P-CH2-CH2-CH2),  3.8 (2H, m, P-CH2-CH2-CH2),  4.1 (2H, m, P-CH2-CH2-
CH2), and  7.6-7.9 (15H, m, Aromatic H) ppm. ESI-MS 380 [M + H+]. 
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Chapter 3: Synthesis of potential pH-sensitive cationic 
phosphonium AuNPs in aqueous medium 
3.1 Abstract  
Nano-therapeutics is a rapidly progressing area of research and aims to improve 
therapeutic efficacy with minimal side effects by the selective augmentation of anticancer 
drug concentrations within tumour tissues, thus solving the problems presented by 
conventional chemotherapy.  
 
The main goal of this study describes the further development of phosphonioalkyl ligands 
in order to use in functionalised AuNPs. The AuNPs were functionalised with ligands 
including (3-thioacetylpropyl)triphenylphosphonium bromide, (3-thioacetylpropyl)-
tri(P-tolyl)phosphonium bromide and (3-thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)-
phosphonium bromide. The functionalised AuNPs were investigated with their stability 
over time at a pH range of 3-11. The synthesised AuNPs were primarily characterised by 
using both UV-visible spectra and DLS. 
 
The AuNPs synthesis were conducted in one of two ways with reduction by a biphasic 
solvent system of DCM/water, and monophasic medium DMSO. The synthesis of AuNPs 
with methoxy phosphonium head group containing ligands showed the most promising 
results in the pH trials. Clear evidence of the reduction of gold (III) to gold (0) and 
formation of colloidal AuNPs were obtained, as maximum absorbance peaks around 520 
nm were observed in the UV-Visible spectra. 
 
The stability study carried out over time. According to the DLS results, with samples of 
the functionalised AuNPs (3-Thioacetylpropyl)triphenylphosphonium bromide (5), (3-
thioacetylpropyl)-tri(P-tolyl)phosphonium bromide, and (3-thioacetylpropyl)-tris(2,4,6-
trimethoxyphenyl)phosphonium bromide, showed that, the AuNPs produced were in the 
range of 7.6 ± 1.4 nm to 14.30 ± 1.5 nm, 6.8 ± 1.30 nm to 12.8 ± 1.3 nm, and 5.9 ± 1.18 
nm to 14.0 ± 1.3 nm, respectively. With no clear sign of aggregation. For pH 3-11, 
plasmon resonance band peaks were observed between 519 to 536 nm in the UV-Vis 
spectra.  
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The pH study suggested that the optimum pH range for the AuNP colloidal samples to 
remain fairly stable is between pH 9.2 and pH 5.1. Within this range the diameters 
recorded by the DLS were 10.8 ± 0.9 nm in the case of (3-Thioacetylpropyl)-triphenyl- 
phosphonium bromide functionalised AuNPs, 9.6 ± 1.7 nm for (3-thioacetylpropyl)-tri(P-
tolyl)-phosphonium bromide functionalised AuNPs, and 9.6 ± 1.4 nm in the case of (3-
thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)phosphonium bromide functionalised 
AuNPs. 
 
In contrast, aggregation was observed in the DLS analyses for AuNP samples 
functionalised with (3-Thioacetylpropyl)triphenyl-phosphonium bromide at pH values 
higher than 8.2 ± 0.1 and lower than pH 5.5 ± 0.1, (3-thioacetylpropyl)-tris(2,4,6-
trimethoxyphenyl)-phosphonium bromide at pH higher than 9.0 ± 0.15 and lower than 
pH 3.3 ± 0.1 and (3-thioacetylpropyl)-tri(P-tolyl)phosphonium bromide at pH higher than 
9.1 ± 0.1 and lower than pH 5.1 ± 0.15. The aggregation of the AuNPs may be due to the 
electrostatic interaction between the cationic phosphonioalkyl ligands and the higher 
concentration of anions present in basic pH solutions. Moreover, also due to the attractive 
forces between these charge distributions of the different AuNPs, the repulsive forces 
within each particle are weakened, causing to a correspondingly lower resonance 
frequency. At pH lower than 4, it can be assumed that functionalised AuNP solution is 
fully protonated as the number of positive charges is significantly high. The increase in 
proton concentration results in ion exchange between protons and the thiolate groups; and 
therefore, in aggregation due to possible unprotected AuNPs. 
 
According to the literature, the environment around cancer cells is known to be mildly 
acidic with pH of 6.0 to 7.2, which is lower than in healthy cells (pH in the range of 7.2 
to 7.4). Based on this factor, pH sensitive functionalised metal NPs have shown abilities 
to induce cancer cell death via a photothermal therapy after aggregation. 
3.2 Introduction 
Over the past decades, cancer therapeutics has been developing as the research area that 
continues expanding and attracting interest. At present, cancer causes about > 8.2 million 
deaths annually worldwide [1, 2]. The overall field of nanotechnology was predicted by 
the American Foundation for Science to be worth $1 trillion in 2015. For all products and 
services associated [3], with Nano-medicine expected to contribute a projected $528 
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billion by 2019 [4], and although significant achievement has been made in the field of 
cancer therapy including surgery, chemotherapy, and radiation., Many patients still face 
unsatisfactory results due to severe drug side effects and reoccurrence of cancer [1, 2]. 
Consequently, the selective increase of anticancer drug concentrations inside tumour 
tissues remains a major challenge in improving therapeutic efficacy with minimal side 
effects [5]. 
 
The development of AuNPs for drug delivery offers a feasible solution for targeted and 
controlled delivery of anticancer drugs [6]. There are several obstacles that must be 
overcome in order to develop and improve existing cancer treatments to be effective, and 
reduce cancer drug doses and toxicity towards healthy proliferating cells. Use of AuNPs 
as alternatives to traditional treatments can potentially overcome multidrug resistance 
(MDR) against anticancer drugs [7]. 
 
Traditionally, cancer has been treated with a combination of drugs, chemotherapy, and 
surgery to maintain and remove the cancerous tissues present. Chemotherapy is a key part 
of anti-cancer therapy, but its effectiveness is often hampered by drug resistance [8-10]. 
Recent studies highlight that tumour microenvironment plays a predominant role in 
tumour cell proliferation, metastasis, and drug resistance [11]. To reduce the drug 
resistance and improve the specificity of the drug molecule, AuNPs can be employed 
depending on the type of a tumour being treated [12]. Traditional imaging techniques, 
such as dyes and pigments, remain crucial in diagnosis [13]. However, metallic AuNPs 
have gathered increasing attention in recent years as a novel tool for the diagnostic 
application such as imaging and diagnosis of tumour specific cells [14, 15]. Among these, 
metallic NPs in general, and AuNPs, in particular, have been gaining prevalence in 
medical application as unique drug delivery vehicles as a result to their special size, shape, 
and surface-dependent properties [5, 16]. In addition to this, their reported 
biocompatibility and non-cytotoxicity have made drug delivery the leading emerging 
application of AuNPs. Furthermore, the ease with which their surfaces can be 
functionalised also makes these NPs attractive for this application. Properly 
functionalised AuNPs can not only serve as a drug reservoir but also provide a long 
circulation time [5, 17, 18]. 
 
AuNPs can be used in conjunction with more traditional imaging methods during surgery 
to ensure that the efficiency of the operation is increased [19], due to the removal of all 
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cancerous tissues that may not have been clearly presented without increased image 
contrast. With certain functional groups added to the AuNPs, it has been observed that 
the fluorescence of AuNPs quantum dots can be seen by the unaided eye [20]. 
 
The pH sensitive metal NP based on this invention consists of a pH sensitive ligand that 
changes charge depending on the pH of the metal NP. For instance, according to the 
relevant literature, AuNPs are expected to change their surface charges from negative to 
positive under acidic conditions and the aggregations by electrostatic attractions, usually 
require two different types of particles with opposite charges. It was successfully showed 
that AuNPs could efficiently accumulate and form aggregates within cells, such as cancer 
cells that present an abnormal pH environment. The pH sensitive metal NP, based on this 
invention, can induce cell death through a photothermal procedure after aggregation. 
Therefore, this type of NPs could enable medical treatment using cell necrosis such as 
cancer treatment [2, 21-23]. 
 
The environment around abnormal cells like cancer cells are known to be weakly acidic 
within a pH of 6.0 to 7.2, in contrast, the healthy cell environment has been determined 
to be within a pH in the range of 7.2 to 7.4. Therapies for cancer using this property are 
under extensive study. For instance, poly-(3-aminoester) and hydrophilic polyethylene 
glycol, which can form micelle structures due to their own amphiphilicity and pH-
dependent ionisation, can deliver drugs to cancer cells depending on the change in pH 
and kill the cells. The compounds form conjugates (liposomes, complexes, and NPs) with 
therapeutic molecules in order to release them in compartments or cell tissues where the 
pH therefrom is acidic. Because the interactions between light and AuNPs are so strong, 
the AuNPs display big coefficients of absorption at resonant frequencies in comparison 
with organic dyes [2, 24, 25]. This property can be introduced to the AuNP itself by 
attaching a charged compound to the surface of the metal NP [2]. When the environment 
of metal NPs are changed from alkaline to acidic, at least a portion of the compounds on 
the metal NPs’surface are hydrolysed to give them a different charge, from what they had 
under an alkaline environment. During the charge change, the particles aggregate due to 
electrostatic interaction [2, 26]. 
 
It has been shown that the photoacoustic (PA) imaging signal produced from the 
developed melanin-like nanoparticle (MelNP), after exposure to mildly acidic conditions 
(for example, pH 6), is 8.1 times stronger compare to under neutral conditions. This unique 
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characteristic can be used for highly sensitive in vivo cancer target imaging according to 
the response to its acidic microenvironment [27]. The wavelength of light absorbed by 
the pH-sensitive metal NPs becomes higher as they aggregate. One of the greatest 
advantages of photothermal therapy based on the pH-sensitive AuNPs is that, the 
absorption wavelength or surface plasmon band of aggregates corresponding to the pH-
sensitive AuNPs introduced into cancer cells, shifts towards the right of the UV-Vis 
spectrum. Hence, this shift leads to the use of long-wavelength light, which can penetrate, 
deeply into the body, allowing the potential application of the pH-sensitive AuNP in 
photo-thermal therapy to cancer tissues located in regions deep beneath the skin [2]. 
Traditional photothermal therapy suffers from some drawbacks of being applicable just 
to cancer occurring at places a short distance from the skin, such as skin cancer due to its 
photosensitisers respond to short-wavelength light which could not penetrate deeply into 
the body. This disadvantages can be overcame via the pH-sensitive AuNPs [28, 29]. 
 
Due to the great light-harvesting effect and large surface area-to-volume of AuNPs, the 
thermal energy locally emitted from the AuNPs is sufficient to cause cell death. 
Furthermore, because cancer cells are highly vulnerable to heat compared to normal cells, 
the heat emitted from AuNPs, on which light is focused at a controlled intensity, can be 
locally insert to kill tumour cells without damaging normal cells selectively. Further, the 
heat released from the gold nano-shell absorbing the energy of electromagnetic pulses in 
the near infrared ray range can be used in order to destroy cancer cells selectively [2].  
3.3 Materials and Methods 
All chemicals and solvents were purchased from Sigma-Aldrich and Fisher Scientific Ltd. 
For the characterization of the ligands and functionalised AuNPs, several analytical 
techniques were used. TLC, ATR-FTIR, NMR, ESI-MS techniques were employed to 
characterise the phosphonium containing ligands. UV-Visible spectroscopy and Dynamic 
Light Scattering (DLS) were used to characterise and obtain the size of the cationic 
phosphonium AuNPs. Details regarding previously mentioned analytical techniques and 
synthesis of cationic phosphonium ligands can be found in Chapter 2. Experimental 
details of the synthetic procedure to obtain (3-thioacetylpropyl)-tri(P-tolyl)-phosphonium 
bromide and (3-thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)- phosphonium bromide, 
and their corresponding AuNPs, and DLS are outlined in this chapter. pH studies were 
carried out by using Jenway 3505 pH Meter / UK, that is a general purpose, laboratory 
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pH meter uses rotary controls for pH values. The pH meter provides better measurement 
accuracy than pH indicators. Moreover, pH meter requires extra calibration processes 
before pH can be used [30]. 
3.3.1 Cationic Phosphonium Ligand Synthesis 
The synthese of the (3-Thioacetylpropyl)triphenyl- phosphonium bromide (5) zwitterion 
were synthesised following methods previously reported [31, 32]. The compound (5) is 
shown in experimental section / Chapter 2. 
 
The synthesis and characterisation of (3-thioacetylpropyl)-tri(P-tolyl)-phosphonium 
bromide (4A), and (3-thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)-phosphonium 
bromide (4B) are outlined in the following sections.  
3.3.1.1 Synthesis of the (3-thioacetylpropyl)triphenylphosphonium bromide ligands 
The reactions followed to obtain (3-thioacetylpropyl)tri(P-tolyl)phosphonium bromide 
(4A) and (3-thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)phosphonium bromide (4B) 
are shown in Scheme 1. The compounds were synthesised via the reaction of tri(p-
tolyl)phosphine (1A) and tri(2,4,6-trimethoxyphenyl)phosphine (1B) (3.8mmol) with 
bromo-propanol (15 mmol) in a round bottom flask under reflux for approximately five 
hours. Acetonitrile (0.024 mmol) was the solvent used. The oil (in the case of 2A) and 
solid precipitate (for 2B) were collected and purified using diethyl ether and ethanol 
respectively (Reaction 1, Scheme1). The yield was 75%, 80% respectively. The resulting 
salts (2) were dissolved in hydrobromic acid (0.18 mmol, 10 ml) (48%) in a round bottom 
under reflux for five hours (Reaction 2, Scheme 1). Then, -bromopropyl-tri(p-
tolyl)phosphonium bromide (3A, 2 mmol) and -bromopropyl-tris(2,4,6-
trimethoxyphenyl)phosphonium bromide (3B, 2 mmol) were reacted separately with 
potassium thioacetate (3 mmol), stirring overnight at room temperature  in aqueous 
ethanol (1:1, 10ml) (Reaction 3, Scheme 1). The compounds appeared as the creamy and 
brown precipitates, 4A and 4B, respectively. TLC was used to monitor the reactions by 
using 10% methanol: 90% DCM as the mobile phase. Purification of ligands 4A and 4B 
were achieved by liquid-liquid extraction DCM: water, and further cleaning using diethyl 
ether. Melting points of purified 4A and 4B ligands were 90-93°C and 250-253°C, 
respectively. 
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Figure 3.1. Chemical structures of (3-thioacetylpropyl)tris(2,4,6-trimethoxyphenyl)phosphonium 
bromide (4B) and (3-thioacetylpropyl)triphenyl-phosphonium bromide (5). 
3.3.2 Synthesis of functionalised AuNPs using 4A and 4B ligands in DMSO 
The synthesis of colloidal cationic phosphonium AuNPs using 4A and 4B ligands in 
DMSO were carried out in a similar fashion as the previous cationic phosphonium 
AuNPs. For 5-AuNPs is shown in Chapter 2. 
 
DMSO was used as the biocompatible solvent, instead of water due to poor solubility of 
these ligands in water. (3-Thioacetylpropyl)tri(P-tolyl)phosphonium bromide – 4A and 
(3-thioacetylpropyl)-tris(2,4,6-trimethoxyphenyl)phosphonium bromide – 4B 
functionalised AuNPs were successfully obtained and dispersed in DMSO by using 
NaBH4 as reducing agent. However, AuNPs functionalised with 4A and 4B could not be 
obtained using water as the main dispersing solvent. 4A and 4B ligands were dissolved 
in DMSO (0.6 mmol, 0.30 mmol respectively). The volume of DMSO used to prepare 
these solutions was 30 ml. A solution of potassium tetrachloroaurate (0.12 mmol) in 
DMSO (10ml) was also prepared. Then both, ligands and gold salt solutions were mixed 
and stirred for four hours. The reduction of gold was carried out by adding 5 mL of freshly 
prepared NaBH4 aqueous solution (0.4 M) to the DMSO mixture.  
3.3.3 Dynamic Light Scattering 
In order to monitor any changes in the size of cationic phosphonium AuNPs with changes 
in pH, Dynamic Light Scattering (DLS) technique was used. DLS work was completed 
using a Zetasizer Nano ZS (Malvern Instruments Ltd) which is currently top of the range 
and can be used for measurement of size, electrophoretic mobility and zeta potential of 
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the nanoparticle sample. It is possible to assess both the size and the potential aggregation 
of the NPs present in the solution. The technology employed is referred to as Non-
Invasive Back Scatter (NIBS) technology and gives the maximum sensitivity along with 
the optimal size and concentration range. The sample was placed into a quartz-cuvette 
ensuring that it did not rise above the level specified on the equipment before being loaded 
into the sample compartment. Three measurements were taken from each sample after 
calibration of the equipment. The data collected were collated into a size distribution 
curve with an indication as to whether any aggregation of NPs was occurring [33]. 
3.4 Results and Discussion 
AuNPs have prepared with different ligands as protecting ligands including as mentioned 
above 5, 4A and 4B compounds. With changing in these ligands from benzene to toluene 
and methoxybenzene derivatives, the synthesis approach is described in experimental 
section. In order to see what different between 5-AuNPs, 4A-AuNPs, and 4B-AuNPs, as 
well as by changing the pH values. UV−vis absorption spectroscopy showed that the 
maximum absorption of 4A-NPs and 4B-AuNPs were at 523 nm and 518 nm respectively. 
The DLS results illustrated that the as-prepared 4A-AuNPs, 4B-AuNPs had good mono-
dispersion and their sizes were 6.8 ± 1.3 nm, 5.9 ± 1.2 nm respectively. All these 
phosphonium ligand’s structure were confirmed by ATR-FTIR, 31P, 1H NMR and ESI-
MS techniques before using them to functionalise AuNPs. Different sizes of AuNPs were 
generated with different stability in this Chapter. AuNPs were generally spherical shapes, 
and larger particles have been observed at lowest and highest pH values.  
3.4.1 Synthesis of 4A and 4B ligands 
 (3-Thioacetypropyl)-tri(p-tolyl)-phosphonium bromide (4A) and (3-thioacetylpropyl)- 
tris(2,4,6-trimethoxyphenyl)phosphonium bromide (4B) zwitterions involved the 
preparation of two intermediates, as are showed in Scheme 1. The resulting zwitterions 
were purified by trituration using diethyl ether. When studied by ESI-MS in positive ion 
mode, ions corresponding to [M-Br]+ were observed at 421.17 m/z for 4A and 649.22 m/z 
for 4B. 1H NMR (CDCL3) spectrum for 4A gave signals at  2.3 (3H, s, Ph-CH3), 2.4 
(3H, s, Ph-CH3),  2.5 (3H, s, Ph-CH3),  2.8 (2H, t, P-CH2-),  1.7 (1H, s, H2O of 
solvent), 3.3 (3H, s, CO-CH3),  3.4 (2H, t, -CH2-SCO),  3.5 (2H, m, P-CH2-CH2-CH2),  
and at 7.6 - 7.8 (12H, m, Aromatic H) ppm. IR spectrum showed absorption bands at the 
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regions IR spectrum showed absorption bands at the regions of 710 – 731 cm-1 ( CH2), 
1699 cm-1 ( C=O), 1313 cm-1 (C-S), and 3100–3000 cm-1 ( CH-Aromatic). 
 
1H NMR = (CDCL3) spectrum for 4B gave signals at  2.4 (2H, t, P- CH2CH2-CH2-),  
1.7 (1H, s, H2O of solvent) [34], 3.3 (3H, s, CO-CH3),  3.4 (2H, t, -CH2-SCO),  3.7 
(2H, m, -CH2CH2-CH2-),  5.6-6.3 (27H, s, Ph-OCH3), and at 8.0- 8.9 (6H, m, Aromatic 
H) ppm. IR spectrum showed absorption bands at the regions of 800-820 cm-1 ( CH2), 
1739 cm-1 ( C=O), 1591 cm-1 ( C-O), 1365 cm-1 (C-S-), 1155 cm-1 ( P=O) and 3104-
3000 cm-1 ( CH-Aromatic).  
 
The structure of compound 4A was confirmed from its correct spectral data. Thus, IR 
spectrum is used to detect functional groups and showed absorption band at the regions 
1699 cm-1 which confirm entry of carbonyl group ( C=O) to -bromopropyl-tri(p-
tolyl)phosphonium bromide (3) [35]. In addition, there were peaks at 1739 cm-1 and 1591 
cm-1, which corresponded to a carbonyl group ( C=O), and ether group ( C-O) bond in 
4B respectively. Signals expected for OH group at 3455 cm-1 is completely disappeared 
in 4A and 4B indicating to a formation and completed the reaction [35]. 
 
1H NMR spectra provided further evidence for the successful results (completed reaction) 
for 4A and 4B which confirmed the existence six protons from (-CH2-CH2-CH2-) attached 
to the aromatic ring at chemical shifts from 2.3-3.7 ppm to produce compound 4A and 
4B. Due to absence this group in the start material including tri(p-tolyl)phosphine (1A) 
in the case of 4A and tri(2,4,6-trimethoxyphenyl)-phosphine (1B) in the case of 4B. 
Furthermore, final products were confirmed by ESI-MS, and ions are corresponding to 
[M-Br]+ were observed at 421.17 m/z for 4A, and 649.22 m/z for 4B and (expected MW 
4A, 4B is 500.9 and 728.9 g/mol respectively [35]. 
3.4.1.1 Characterisation of the colloidal solutions of AuNPs functionalised with 4A 
and 4B by using UV-Visible and DLS studies 
The reduction of Au(III) to Au(0) can be handily followed by UV-visible absorption 
spectroscopy [36]. 
 
The solutions of functionalised 5-AuNPs, 4A-AuNPs, and 4B-AuNPs were analysed by 
using UV-visible and DLS. Several dilutions of the stock solution of colloidal AuNPs 
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were made and analysed by UV-Vis spectroscopy. This technique was used first in order 
to confirm AuNPs formation and then their stability. The latter was monitored every 
week. However, the UV-Vis spectra shown in Figures 3.3 and 3.4 are the monthly results. 
As previously mentioned, the stability of the colloidal solutions of 4A-AuNPs and 4B-
AuNPs were monitored for five and six months respectively, and no clearly SPB shifts to 
the right of the UV-visible spectra were observed. Therefore, it can be assumed that no 
major aggregation within the colloidal solutions occurred during this period of time. 
 
In particles, after storage for 5 and 6 months, suggesting high chemical and colloidal 
stability for these 4A-AuNPs and 4B-AuNPs. The shifted SBP to longer wavelength after 
six months can be seen via Figures 3.3 and 3.4 for 4A-AuNPs and 4B-AuNPs. Also, 
similar evidence can be observed when the colour of 4B-AuNPs solution changed from 
red to purple colour in Figure 3.2, which also confirmed the last results but this is not 
substantial enough to illustrate aggregation in the sample. In addition, this change is 
accompanied by change the 523 nm peak shifted to 530 nm after five months in the case of 
4A-AuNPs (Figure 3.3 see UV-visible spectrum at time = 0 and time = 5 months) and from 
518 nm to 529 nm after six months in the case of 4B-AuNPs. This is in reasonable agreement 
with the DLS results, where the 4A-AuNP and 4B-AuNP changed their sizes from 6.8 
±1.3 and 5.9 ± 1.2 in initial preparation to 18.3 ± 1.5 and 9.2 ± 1.7 after 5 and 6 months 
respectively. 
 
UV-Visible spectrum results are showed that, the SPB of AuNP functionalised by 4A is 
centred at 523 nm which is illustrating slightly larger in size than another’s ligands have 
functionalised AuNPs, and that confirm difference ligands that functionalised AuNPs 
under the same conditions, leading to different wavelengths with different stabilities of 
AuNPs as well. It is notable that compounds thiol-containing with specific chemical 
structures shown different affinities toward AuNPs, which possibly affect the colloidal 
stability of AuNPs and also improve its biocompatibility. The stability of nanoparticles 
in solution is mainly dependent on the surface properties of nanoparticles such as surface 
charge and ligand structure [37, 38]. 
 
According to the literature, the optical properties including the absorption maxima and 
absorption intensity are dependent on the size of NPs [39], and that clearly seen in our 
samples (Figures 3.3 and .3.4). Accordance with Mie theory, the surface plasmon 
resonance of the AuNPs is red shifted with an increase in particle size [40], whereas 
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Figures 3.3 and 3.4 illustrate shifted SPB toward right wavelength indicating to slightly 
increase in the size of AuNPs with the time. 
 
 
 
 
Figure 3.2. The colour comparison of initial (a) and after six months solutions (b) of 4B functionalised 
AuNPs.  
 
In addition, the colloidal solutions of 4A-AuNPs and 4B-AuNPs were all analysed by 
DLS then, particle sizes for samples were obtained by analysing at least 253 particles per 
sample from several results taken. All AuNPs samples have been showed spherical or 
semi-spherical shaped particles. It has been well established that for mean diameters 
obtained for the samples 4A-AuNPs and 4B-AuNPs analysed were the followings: 6.8 ± 
1.3 nm, 5.9 ± 1.2 nm respectively. It can be seen that the DLS results of 4A-AuNPs and 
4B-AuNPs are quite similar to the corresponding UV-Visible spectra results, which 
consider as evidence and confirmation each other. 
 
The DLS data can give an idea of finer details of the actual size of AuNPs [41]. However, 
there are chances to obtain biased results due to the nature of the size of the AuNP samples 
being assessed. For instance, if any contamination is present in the solutions, it will affect 
the results and the accuracy of the measurement. 
 
 
a
 
b 
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Figure 3.3. UV-Visible absorption spectra of the colloidal solutions of AuNPs functionalised using 4A as 
protecting ligand. The different UV-visible spectra represent these NPs dispersed in DMSO/water at time 
= 0, 1, 2, 3, 4, and 5 months. Where time = 0 is the initial time of the 4A-AuNPs prepartion. 
 
Figure 3.4. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 4B as 
a protecting ligand. The different UV-visible spectra represent these 4B-AuNPs dispersed in 
DMSO/water at time = 0, 1, 2, 3, 4, 5, and 6 months. 
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The bias could be overcome by carrying out a number of repetition of measurements per 
sample. AuNPs synthesised in this Chapter shown a small difference in size of AuNPs 
from 6.8 ± 1.3 nm in 4A-AuNPs to 5.9 ± 1.2 nm in 4B-AuNPs. Due to the change of the 
ligand from toluene to tris(2,4,6-trimethoxybenzene) head group, and to the nine electron 
donating groups (OCH3-Ph) in the 4B may increase the stability of AuNP [42]. 
3.4.2 pH stability study 
According to previous literature, it was found that the addition of acid and base to the 
AuNPs can be changing the ionic strength of the dispersion. For instance, it is noted that 
AuNPs were not stable in dispersion with a high concentration (above 0.1M) of a NaCl 
added and instantly lead to the aggregation [43]. 
 
The pH stability study conducted required the use both 5-AuNPs, 4A-AuNPs and 4B-
AuNPs. Before the experiments were begun, firstly, the Jenway 3505 pH Meter was 
calibrated via placing the probe in a buffer solution of known pH 7 and adjusting the 
display. The probe was then rinsed in deionised water and placed into a pH 4 buffer 
solution in order to create a slope. The display was once again adjusted to show the correct 
pH before finally being rinsed with double-distilled water. This calibration ensures 
accurate results when measuring solutions of unknown pH values. When storing the 
probe, a buffer solution of pH 4 was used to prevent the membrane in the probe becoming 
slow. Set volumes of 1M HCl and 1M NaOH (5-30 µL) were added step by step to a 
solution of AuNPs and deionized water (ratio of 1:2) with the pH being measured after 
each addition. As the pH fluctuated slightly, three readings were taken in order to take an 
average. The first reading was taken after about two minutes after adding the HCl with 
the second being recorded after roughly 10 minutes. The average of the two was presented 
as the pH of the solution.  
3.4.2.1 Study of the stability of 5-AuNPs in acidic conditions 
An acidic solution of 1M HCl was prepared to add to 5-AuNPs solution. During the 
experiment, the 5-AuNPs solution was continuously stirred to avoid aggregation and 
ensure even distribution of the HCl. 
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3.4.2.1.1 Stability study at pH < 7.5 - UV-Vis results 
The UV-visible absorption spectra of all the pH adjusted dispersions were recorded 
immediately after addition of the acid or base. The same spectra were also recorded after 
two months. The UV-Vis was conducted to assess the potential changes in SPBs of the 
gold colloidal solutions (AuNPs functionalised with 5) at different pH values lower than 
7.5. These analyses were carried out in order to determine whether aggregations occur or 
not. 
 
Run 1 
A 50 mL beaker was used to allow the addition of HCl solution. The 5-AuNPs was left 
to stir for about 10 minutes to evenly disperse them through the water medium.  
Table 3.1 tabulates appropriate amount of acid added in Run 1 of the acidic study and the 
corresponding pH of the solution measured. The peak of the absorbance of the pH is 
presented in order to assess whether the solutions were stable as the pH decreased. 
 
Run 2, 3 
Due to the need for better results, so the experiments were conducted triple times, with 
the ratios were kept constant. 5 mL of 5-AuNPs was combined into a solution with 10 
mL of deionized water. The solution was stirred for ten minutes before the experiment 
was commenced.  
 
Table 3.1 shows the amount of HCl (5-30 µL) added to the 5-AuNPs solution in order to 
lower the pH of the solution. The peak of the absorbance is also presented to assess 
whether any aggregation may have occurred with the change of pH.  
 
It is clear in all experiments Table 3.1 that peaks of absorption increase slight as the pH 
decreases; this is due to further amounts of 1M HCl were added to the 5-AuNPs colloidal 
solution. From the results illustrated, it can be suggesting that there is significant change 
with decreasing pH, indicated to aggregation may happen at low pH. This evidence is 
supported via the considerable shifting of the peak of the absorbance to the right of the 
spectra across the pH range used. The peaks of the absorbance shown in Table 3.1 give a 
range of wavelengths from 527 nm to 533 nm at pH values from 7.4 to 4. This result was 
obtained in all Run 1, Run 2 and Run 3 of the experiment furthering the reproducibility 
of the results presented. 
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Significant changes in SPBs recorded suggest that the colloidal 5-AuNPs solutions are 
mono-dispersed samples at natural pH (~pH = 7.3). In addition, Tables 3.1 and Figures 
3.5, 3.6 show the shape of the SPBs are changed in all experiments, which strengthen the 
assumption that there is obvious aggregation was occurred along just with low pH values 
in this chapter. According to the literature, it was described that the absorbance of AuNPs 
was changed with changing the pH value (pH 5.4 to 9.4), whereas at pH 6.4 noted an 
increase in the absorbance of AuNPs at 600 nm wavelength. Furthermore, the stability of 
AuNPs was decreased especially at pH 5.4 led to aggregation [37]. 
 
The aggregation of AuNPs caused to a sudden red shift in the absorption spectra of the 
AuNPs due to the important shortening of the distance between the NPs [37].  
Table 3.1. The amount of 1M HCl (5-30 µL) added and resulting pH of the 5-AuNPs solution along with 
the peak at different wavelengths and sizes diameter for (Run 1, 2 and 3), pH < 7.5. 
Run 1 Run 2 Run 3 
Amount 
of 1M 
HCl 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm). 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.4 
527-
528 
7.8±1.5 7.4 528 7.9 ± 1.4 7.3 527 7.6±1.4 
5 µL 6.9 529 8.6±1.7 6.8 529 8.8 ± 1.8 7.1 528 8.0±1.3 
10 µL 6.6 530 9.1±1.9 6.3 530 9.4 ± 1.3 6.5 529 8.7±1.4 
15 µL 6.4 530 9.6±1.4 5.6 531 
10.13±1.
6 
6.0 531 10.3±1.2 
20 µL 6.2 530 9.8±1.2 5.4 531 
10.38±1.
9 
5.8 531 10.4± 1.8 
25 µL 5.6 531 10.6±1.3 5.1 531 10.4± 1.3 5.5 531 10.5± 1.9 
30 µL 4 
532-
533 
14.7±1.5 4.3 532 13.2± 1.2 4.4 532 12.3 ±1.2 
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Figure 3.5. Data collected through UV-Vis across the pH range produced via adding HCl to the 5-AuNPs 
solution in (Run 1), pH < 7.5, where the HCl additions were from (5-30 µL). 
It was not expected to see aggregation with a range of pH 7.3 ± 0.1 to 5.1 ± 0.2 due to the 
excess of H+ ions present in the acidic solution being added to the AuNPs solution, 
illustrates did not cause a change to the properties of AuNPs [44]. The AuNPs themselves 
are weakly positively charged meaning that with a further excess of positive cations, they 
are not electrostatically attracted to each other which leads to prevent any aggregation 
may occur. A protonation or deprotonation change as the acidity of the solution changes, 
and causing change of nanoparticle properties [45]. 
3.4.2.1.2 Stability study at pH < 7.5 - DLS results 
Table 3.1 shown above the modal diameter size and corresponding standard deviation of 
each sample at decreasing pH. It can be observed that the sizes of the 5-AuNPs can be 
easily changed by changing the pH values, and the diameters are all within the same range 
at pH around 7 suggesting predominantly mono-dispersion of 5-AuNPs in the colloidal 
solutions. The narrowest size distribution was obtained at a pH 7.5 according to the 
literature [46]. The DLS data recorded is shown in Table 3.1 and Figure 3.6 for both the 
initial experiment and the repeats. 
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As before, the data for the two runs are presented comparatively for each experiment at 
varying pH for each analysis. DLS samples were measured at the same time UV 
measurements were carried out. It can be observed that the diameters of the 5-AuNPs at 
the decreasing pH are significantly in the different range. The colour of the well dispersed 
5-AuNPs is wine red and changed gradually with the addition of HCl (15-30µL) amounts. 
 
From the data collected, in Run 1, 2 and 3 (see Table 3.1), it is clear to see that, the 
diameters were changed from 7.6 ± 1.4 nm (pH = 7.3 ± 0.05, 0 µL HCl added) to 14.7 ± 
1.5 nm (pH = 4.0 ± 0.2, 30µL HCl added) which confirmed UV results, indicated 
aggregation. Studies have shown that decreasing pH values of AuNPs solution leads to 
large polyhedrons and other irregular particles [46]. The standard deviations from the 
modal size for 5-AuNPs solution around pH 7.3 are small and agglomeration of 5-AuNPs 
does not occur (see Figures 3.5, 3.6). From Table 3.1, it can be seen that the 5-AuNPs at 
low pH had bigger size than at pH neutral (pH = 7.3 ± 0.05), changing the colour from 
red to pink-purple colour. 
 
 
 
Figure 3.6. Data collected by using DLS analysis of the samples 5-AuNPs in (Run 1) to give the 
diameter size and standard deviations for each pH, pH < 7.5 and the HCl additions were from (5-30 µL). 
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This indicated to aggregation, which are confirmed by DLS and UV results (data 
presented in Tables 3.1). In general, a colloidal AuNPs with diameters of 5-20 nm exhibit 
a red colour, and have an optical absorption peak around 520 nm [47].  
 
In this Chapter, the change in the colour of the solution from deeply red colour to pink 
purple confirms the aggregation of the AuNPs at low pH. As mentioned earlies, the pH 
of cancerous cells is slightly acidic [5], so the aggregation suggests that the AuNPs would 
still be of use when entering the altered conditions of the tumorous tissue. AuNPs offering 
a strong pH-dependent adsorption cell membranes within a biological pH range (5.3-7.4) 
[48]. 
 
It is considering that pH plays a key role in several cellular processes and is an indicator 
for a pathological environment, AuNPs with pH-dependent membrane adsorption might 
find new applications in therapy and tumour diagnosis [48]. 
3.4.2.2 Study of the stability of 5-AuNPs in basic conditions 
The stability of AuNPs changed by increasing the pH gradually with 1M NaOH. The 
starting pH was approximately 7.5 ± 0.05 for all 5-AuNPs solutions, and the pH was 
increased with high NaOH concentration (30 µL) to pH = 11.3 ± 0.1 or until complete 
dissolution or aggregation of 5-AuNPs. The sample solutions were stirred gently, and an 
appropriate amount of NaOH was added to increase the pH values, the sample solutions 
were stirred for about 10 minutes. The pH was measured with the pH meter, the size and 
size diameter of 5-AuNPs were measured regularly with both UV and DLS, and the 
results were confirmed to each other. 
3.4.2.2.1 AuNPs in basic conditions of 1M NaOH 
5-AuNP prepared is highly stable and uniformly dispersed in the solution. It was stable 
for several months without any evidence for aggregation. It is known that any factor that 
affects the surface charge of AuNPs will result in aggregation of the AuNPs [49]. For 
example, pH is considering one from important factors that effect on the stability of 
AuNPs [50]. In this Chapter, pH of AuNPs solution has changed via added different 
amounts of 1M HCl as mentioned early and 1M NaOH. 1M NaOH in aliquots of between 
5 and 30µL were added to solution of 5-AuNP with continuous stirring to ensure adequate 
mixing. 
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This study shows the effect of pH in the range from pH = 7.5 ± 0.05 to pH = 11.3 ± 0.1 
on the stability of AuNPs. These observations are supported by DLS and UV-Vis. 
3.4.2.2.2 Stability study at pH > 7.5 - UV-Vis results 
UV-Visible absorption spectroscopy was used to study the peak of the absorption at 
different concentration of NaOH amounts (5-30 µL) throughout the experiment and also 
after nearly two months to give an idea of whether aggregation occurs within the samples. 
1M NaOH amounts were added to the AuNP solution to achieve the desired pH value. 
The pH of the solutions was increased to determine whether the 5-AuNPs present in the 
solution remains stable under such conditions. 
 
Run 1 
Table 3.2 contains the pH values of the AuNPs solution after the addition of each 
controlled volume of the base, along with the peak of the absorbance recorded. There is 
a distinct shift in the peak of the absorbance or SPB of the solutions to the right of the 
spectra as the pH increases. 
 
 
 
Figure 3.7. Data collected through UV-Vis at each pH recorded in (Run 1) of 5-AuNPs. It can be 
observed that the shape and height of the surface plasmon bands alter as the pH is altered and that the 
peak of the absorption shift towards 536 nm as will describe in detail in the following sections. pH > 7.5. 
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Run 2, 3 
Table 3.2 shows the data assembled through (Run 2, 3 as well) of the base pH of the 5-
AuNPs solution. From the data presented in Table 3.2, there is a clear shift in the peak of 
the absorption. The increase in absorbance illustrated in Tables 3.2 is associated with the 
dilution of the 5-AuNPs solution by set volumes of NaOH amounts as the pH increases. 
Both Run 1, 2 and 3 show a similar trend with the suggestion that aggregation of 5-AuNPs 
occurred due to the presence of excess OH¯ anions within the colloidal solution. Tables 
3.2 shows a clear shift in the peak of the absorbance and the data presented suggest a 
more significant shift from 527 nm to a maximum peak of the absorption of 536 nm. It 
can also be observed that shape of the peak broadens as the pH increases. This proposes 
the idea of aggregation between 5-AuNPs as the pH increases as well as the increases in 
the range of diameter size of the 5-AuNPs present in each solution [51]. This samples 
alteration in shape of the peaks is noted in (Run 1, 2, 3) verifying the results obtained.  
Table 3.2. A mount of 1M NaOH added (Run 1, 2, 3) and the corresponding pH value of the 5-AuNPs 
solution and maximum wavelength of the maximum absorbance peak observed, pH > 7.5. 
Run 1 Run 2 Run 3 
Amount 
of 1M 
NaOH 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm). 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.5 528 8.4 ±1.2 7.6 528 8.5±1.5 7.3 527 7.8±1.6 
5 µL 7.7 528 8.6 ±1.3 7.8 529 8.7±1.4 7.6 528 8.3±1.6 
10 µL 7.9 529 9.3 ±1.4 8.0 530 9.4±1.3 7.8 529 8.5±1.2 
15 µL 8.4 530 9.8 ±1.5 8.2 530 9.6±1.2 8.3 530 9.8±1.5 
20 µL 8.9 531 10.5±1.3 8.8 531 10.4±1.6 8.7 531 10.5±1.8 
25 µL 10.4 535 12.4±1.2 9.1 
530-
531 
10.2±1.9 9.2 531 10.8±0.9 
30 µL 11.3 536 14.3±1.3 9.7 532 11.4±1.2 10.3 532 12.7±1.3 
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3.4.2.2.3 Stability study at pH > 7.5 - DLS results 
Colloidal solutions of 5-AuNPs were also examined at different pH > 7.5 by using DLS 
technique as shown in Table 3.2 and Figure 3.8. Measurements were taken at 25°C and 
repeated ten times. The cuvette was washed with deionised water before and in between 
measurements. It is notable that the diameter size dramatically increases as the pH 
increases in both sets of data and the standard deviations vary significantly throughout 
the measurements. 
 
The DLS data measured is shown in Table 3.2 along with graphical representations of the 
raw data collected at each modal diameter size for each increased pH. It is noticeable that 
the data is varied across the pH range with an increase in diameter range from 8.4 ± 1.2 
nm to 14.3 ± 1.3 nm in (Run 1 at pH from 7.5 ± 0.1 to pH 11.1 ± 0.2). A similar increase 
from 8.5 ± 1.5 nm to 11.4 ± 1.2 nm in (Run 2 at pH from 7.6 ± 0.1 to pH 9.7 ± 0.1), and 
from 7.6 ± 1.6 nm to 12.7 ± 1.3 nm in (Run 3 at pH from 7.4 ± 0.15 to pH 10.1 ± 0.15). 
It was expected that the DLS data would show an increase in diameter size as aggregation 
occurred due to an excess of OH¯ anions present in the NaOH solution added [52]. 
 
The phosphonium ligands attached to the functionalised AuNPs give an overall positive 
charge to each particle. With an excess of OH¯ dispersed throughout the colloidal AuNPs 
solution, the positively charged AuNPs begin to aggregate due to ion exchange and 
electrostatic interactions occurring in the solution [53]. The increase in size-average 
particle diameter relative to that obtained at pH > 9.1, again clearly indicates significant 
aggregation, which indicates to the ligand 5 can be stabilised AuNPs.  
 
In this Chapter, we investigated the AuNPs show similar aggregation patterns in highly 
basic and lowly acidic conditions which are consistent with what is mentioned in the 
literature, whereas at pH, closer to neutral, the diameters recorded are within a range that 
could suggest a mono-dispersed solution [54].  
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Figure 3.8. Data of 5-AuNPs for measurements taken for DLS (Run 1) at increasing pH values, where 
1M NaOH additions were from (5-30 µL).  
In addition, it is noted that, the significant increase of λmax at high pH (>12.0) and low 
than 4, whereas at pH ˂ 4 redshift of λmax appears at 542 nm [55]. Spherical AuNPs with 
size 13 nm exhibited pH-induced aggregation in mild acidic intracellular environments, 
which showed a possibility for photothermal cancer therapy [55]. 
 
In addition, the aggregation of spheres AuNPs can be realised in a pH-induced manner, 
as mentioned in the literature, was realised via the formation of mixed charged surfaces 
which affected by pH change due to changing the composition of the oppositely charged 
ligands on the surface [23, 56]. 
3.5 Study of the stability of 4B-AuNPs in acid and basic conditions of 1M HCl 
and NaOH. 
The same procedure in the above sample has been used. It is important to mention that, 
the changing in pH value can affect the functional groups on the surface of AuNPs, 
accordingly, changes in the pH result in changes in AuNPs coverage. In the same hand, 
the pH value effects on the affinity between AuNPs and functional groups such as (3-
aminopropyl)-trimethoxysilane, that used to functionalise it [57]. The pH value of the 4B-
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AuNPs changed significantly and can be easily aggregated after the HCl, NaOH amounts 
(5 - 30 µL) were added.  
3.5.1 Acidic study UV-Vis and DLS results 
From the data collected, it would be suggested that the optimum pH range for the storage 
and use of the functionalised 4B-AuNPs was between pH 7.3 ± 0.1 and pH 3.0 ± 0.2 as 
within this range, the sizes are changed from 6.2 ± 1.6 nm to 13.8 ± 1.3 nm in 1M HCl 
addition (see Table 3.3, Figures 3.9 and 3.10). However, it was between pH 7.1 ± 0.1 and 
pH 9.0 ± 0.1 as, within this range, the size and standard deviations were changed from 
6.1 ± 1.17 nm to 9.6 ± 1.4 nm in 1M NaOH amount addition.  
 
It is noted that at higher pH, aggregation between the AuNPs occurred so storage and use 
of the AuNPs solution at pH above pH 8.8 or below pH 4.0 would render them unhelpful 
as the diameter would be too great to navigate through the tumorous cells [58]. According 
to Zhu, J., et al., AuNPs in the acidic solutions can be aggregated easily, and the 
absorption peak showed a clearly red-shift which also confirm our results in this Chapter 
[57]. 
 
In addition, the mean particle diameters and the width of the distributions are decreased 
as the pH of the solution increases. For example, at pH lesser than 5 wide size 
distributions of spherical particles are obtained. However, narrow size distributions are 
obtained at pH higher than 6 [46]. 
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Figure 3.9. Data collected through UV-Vis across the pH range produced by adding HCl to the 4B-
AuNPs solution in (Run 1) of the acidic study, pH ˂ 7.5 and the 1M HCl additions were from (0 - 35µL). 
 
 
Figure 3.10. Data collected through DLS analysis of the samples in (Run 1) to give the diameter size and 
standard deviations for each pH range produced by adding HCl to the 4B- AuNPs solution, pH ˂ 7.5. 
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Table 3.3. The amount of 1M HCl added and resulting pH of the 4B-AuNPs solution along with the peak 
wavelength and sizes diameter for (Run 1), pH ˂ 7.5. 
Run 1 Run 2 Run 3 
Amount 
of 1M 
HCl 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm). 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.4 519 6.3±1.3 7.3 519 6.2±1.6 7.3 519 6.5±1.6 
5 µL 7.1 518 5.9±1.2 6.5 518 5.7±1.2 7.1 518 5.9±1.13 
10 µL 6.7 518 5.8±1.2 5.2 522 7.2±1.4 6.8 518 5.6± 1.1 
15 µL 5.9 518 5.8±1.3 3.8 526 8.8±1.2 5.1 523 7.6 ± 1.2 
20 µL 4.9 522 7.0±1.3 3.3 
526-
527 
9.8±1.3 4.1 524 8.0 ± 1.6 
25 µL 3.9 525 8.5±1.6 3.0 528 10.9±1.4 3.8 525 8.5 ± 1.4 
30 µL 3.4 526 9.4±1.6    3.5 526 8.9 ± 1.8 
35 µL 2.7 532 13.8±1.3    3.1 527 10.4± 1.2 
40 µL       2.9 528 11.9± 1.3 
 
 
3.5.2 Basic study UV-Vis and DLS results of 4B-AuNPs 
AuNPs were aggregated at pH 10.8 and turned to blue colour as illustrated in the literature 
[57]. In this Chapter, 4B-AuNPs displays a significant change in their sizes and stabilities 
with pH increasing as shown in Table 3.4. 4B-AuNPs are highly stable with the change 
of pH except at high and low pH, which suggests of aggregation within the sample was a 
clear colour change from red to purple-blue. This is due to the shift in wavelengths as 
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seen in Figures 3.11 and 3.12 representing the UV-Vis and DLS data. The colour change 
observed can be seen in Figure 3.13 in acidic condition and in Figure 3.14 in basic 
condition.  
 
The purple-blue colour observed is associated with larger fully protonated AuNPs as 
expressed in the literature [51, 59]. There was a slightly clear colour change in the solution 
when the HCl amounts (pH ˂ 7.5) were dropped, refer to Figure 3.13 supporting the 
suggestion that a little bit aggregation occurred within the samples. However, in Figure 
3.14 (pH ˃ 7.5) the colour shift from deep red colour to purple colour due to slightly 
aggregation of AuNPs as well at the higher base.  
Table 3.4. The amount of 1M NaOH added and resulting pH of the 4B-AuNPs solution along with the 
peak wavelength and sizes diameter for (Run 1, 2, 3). pH ˃ 7.5. 
Run 1 Run 2 Run 3 
Amount 
of 1M 
NaOH 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm). 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.3 519 5.9±1.2 7.1 519 6.1 ± 1.1 7.1 519 6.0±1.3 
5 µL 7.6 523 6.7±1.2 7.5 523 6.6 ± 1.2 7.5 523 6.4±1.2 
10 µL 8.1 524 8.08±1.1 8.0 524 8.2 ± 1.6 7.9 523 8.05±1.3 
15 µL 8.6 527 8.6±1.5 8.4 526 9.2 ± 2 8.2 524 8.4±1.3 
20 µL 9.1 528 9.6±1.4 9.0 528 9.5±1.8 8.8 528 9.6±1.4 
25 µL 9.7 529 10.3±0.9 10.8 532 12.02±1.2 10.5 531 11.60±1.3 
30 µL 10.1 530 10.56±1.2 11.2 534 14.0±1.2    
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Figure 3.11. Data collected through UV-Vis across the pH range produced by adding 1M NaOH (5-30 
µL) to the 4B-AuNPs solution in (Run 2) of the basic study, pH ˃ 7.5. 
 
Figure 3.12. Data collected through DLS analysis of the samples in (Run 2) to give the diameter size and 
standard deviations for each pH range produced by adding NaOH to the 4B-AuNPs solution, pH ˃ 7.5. 
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Figure 3.13. The transition in colour for the aliquots taken during (Run 2) at (e) 0 µL and (f) 25 µL of 
the acidic pH study for 4B-AuNPs. pH ˂ 7.5. 
 
 
Figure 3.14. The transition in colour for the aliquots taken during (Run 2) at (d) 0 µL and (c) 30 µL of 
the basic pH study for 4B-AuNPs. pH ˃ 7.5. 
(d) 
(e) (f) 
(c) 
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At the arrange of pH 5.8-3.0, a red to blue colour change was observed. However, at pH 
8.0-8.8, the solution still has the original red colour. Furthermore, we observed that the 
colour change was sensitive to pH change. For instance, it is noted that AuNPs at pH 
(4.5–5.5) the solutions look purple-red colour. While at pH ˃ than 6.0 the AuNPs 
solutions look red colour [46]. DLS and UV-Vis measurements indicate good stability of 
AuNPs solutions with respect to pH changes except at low pH. In weak acidic condition 
(pH ~5-7), 4B-AuNPs were stables consequently the surface of the AuNPs becomes less 
negatively charged.  
3.6 Study of the stability of functionalised 4A-AuNPs in acid and basic 
conditions of 1M HCl and NaOH. 
pH was adjusted with either 1M NaOH or 1M HCl. The stability of NPs depended on the 
pH solution. For instance, it is known that carboxymethylated chitosan nanoparticles 
stability’s increased with increasing pH. However, the disadvantage of chitosan was its 
insolubility in near neutral pH. While it was soluble in acidic solutions (pH ≤ ∼6). The 
exact pH value depends on the properties of the ligands functionalised NPs, where the 
solubility in acidic solutions as a result to the protonation of amino groups in chitosan. In 
contrast, chitosan NPs were aggregated at the neutral and alkaline solution (pH 7 ∼8.5) 
which explained to neutralisation of an amino group in the chitosan [60, 61]. Different 
ligands as mentioned were functionalised AuNPs in this chapter and offered different 
stability with pH values changed.  
3.6.1 Acidic study UV-Vis and DLS results of add 4A-AuNP. 
As mentioned early with 5-AuNPs and 4B-AuNP, the same procedure is used. 
Characterisation and stability of the 4A-AuNPs were done by using UV-vis spectroscopy 
and DLS. The colour of the 4A-AuNP solution was changed from wine red to purple at 
both high and low pH indicating aggregation of the particles may be caused. While it was 
stable at natural pH (7 ~ 8) and the 4A-AuNP maintained the red wine colour indicating 
no aggregation took place. In this chapter, it is achieved stable AuNPs functionalised by 
4A with size variations at pH 7.7 ± 0.1 and pH 3.7 ± 0.3 respectively between 6.8 ± 1.4 
nm and 12.2 ± 1.3 nm when the concentration of 1M HCl amounts acid was varied. While 
the sizes were between 6.8 ± 1.30 to 11.9 ± 1.3 nm at pH 7.6 ± 0.1 and pH 10.7 ± 0.1 
respectively, with variety in 1M NaOH amounts.  
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For pH 7.7, plasmon resonance peak was observed at 523 nm which changed to 531 nm 
and 532 nm at pH 3.7 ± 0.3 and 10.7 ± 0.1 respectively. Similar results of 5-AuNPs and 
4B-AuNPs were collected for 4A-AuNPs in pH ˂ 7.5 where 4A-AuNP was aggregated 
at pH lower than 4.7 as illustrated in Table 3.5 and Figures 3.15, 3.16. 
 
Table 3.5. The amount of 1M HCl added and resulting pH of the 4A-AuNPs solution along with the peak 
wavelength for (Run 1, 2, 3). (pH ˂7.5).  
Run 1 Run 2 Run 3 
Amount 
of 1M 
HCl 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm). 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.7 523 6.8±1.4 7.8 523 6.8±1.38 7.8 523 6.8±1.3 
5 µL 7.1 524 7.1±1.2 7.2 523-524 7.0±1.5 7.3 524 7.0±1.6 
10 µL 6.8 524-525 7.9±1.6 6.7 524-525 7.7±1.8 6.9 525 7.8±1.3 
15 µL 6.3 525 8.1±1.9 6.1 526 8.0±1.6 6.2 526 8.2±1.8 
20 µL 5.7 526 8.6±1.8 5.8 527 8.5±1.8 5.7 527 8.6±1.4 
25 µL 4.9 527 9.2±1.2 5.1 526-527 8.8±1.4 5.2 526-527 8.8±1.3 
30 µL 4.1 531 11.4±1.4 3.4 532 12.8±1.3 4.7 528 9.0±1.7 
35 µL       3.7 531 12.2±1.3 
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Figure 3.15. Data collected through UV-Vis across the pH range produced by adding 1M HCl (5-30 µL) 
to the 4A-AuNPs solution in (Run 1) of the acidic study. (pH ˂ 7.5). 
 
 
Figure 3.16. Data collected through DLS analysis of the samples in (Run 1) to give the diameter size and 
standard deviations for each pH range produced by adding HCl (5-30 µL) to the 4A-AuNPs solution. (pH 
˂ 7.5). 
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Similarly, it is shown that the NPs in the pH 2.0 and pH 5.5 showed a red shift and 
broadening of their absorption band, where at pH 2.0 sample showed a more rapid change 
compare to the pH 5.5, which indicated to the aggregates. However, at pH 7.4 NPs 
solution showed no obvious absorption change and no noticeable aggregation occurred 
[21].  
3.6.2 Basic study UV-Vis and DLS results 
UV–Vis absorbance was measured after each pH change when 1 M NaOH (5-35 µL) 
amounts added, which showed a transition between 523 nm and 532 nm at pH 7.6 ± 0.1 
and 10.7 ± 0.05 values respectively and sizes measured by DLS at these pH values were 
6.8 ± 1.3 nm and 11.6 ±1.0 nm respectively as shows in Table 3.6, Figures 3.17 and 3.18. 
Table 3.6. The amount of 1M NaOH (5-35 µL) added and resulting pH of the 4A-AuNPs solution along 
with the peak wavelength and sizes diameter for (Run 1, 2, 3). (pH ˃7.5). 
Run 1 Run 2 Run 3 
Amount 
of 1M 
NaOH 
pH 
UV/Vis 
(nm) 
DLS 
(nm) 
pH 
UV/Vis 
(nm) 
DLS (nm) pH 
UV/Vis 
(nm) 
DLS 
(nm) 
0 µL 7.8 523 6.9±1.1 7.7 523 6.8 ± 1.4 7.6 523 6.8±1.3 
5 µL 8.1 524 7.5±1.7 7.9 524 7.2 ± 1.7 7.9 524 7.3±1.2 
10 µL 8.4 525 8.2±1.4 8.2 525 7.9 ± 0.8 8.1 525 7.7±1.2 
15 µL 8.8 526 9.1±0.9 8.4 526 8.3 ± 1.2 8.5 526 8.6±1.2 
20 µL 9.2 527 9.6±1.7 8.8 527 9.5 ± 0.9 9.3 528 9.8±1.2 
25 µL 9.8 528 10.5±1.5 9.1 528 9.7 ± 1.1 10.0 530 10.4±0.8 
30 µL 10.1 531 10.8±1.3 10.8 532 11.9 ± 1.3 10.7 532 11.6 ±1.0 
35 µL 10.6 532 11.3±1.3       
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There are a small number of larger AuNPs within the colloidal solution that were recorded 
within the measuring process that caused a bias as to the actual diameter size of the 
AuNPs present in the solution [54]. The closeness of values of diameter for importantly 
differing pH values indicated the size of 4A-AuNPs being relatively independent of 
adjusted initial pH of the aqueous solution, where different sizes generated at pH 
changing as confirmed as well in the literature [62]. For example, mean diameter of 
AuNPs using ascorbic acid as reducing agent at room temperature was determined by 
TEM and was found to be 36 ± 6, 31 ± 5, and 40 ± 5 nm for pH values of 6, 8 and 10 
respectively. AuNPs stabilised just via adjusting the initial pH conditions of the reaction 
solutions, where values of diameter for differing pH indicated the size of AuNPs being 
approximately independent of adjusted initial pH of the aqueous solution as mentioned in 
the previous study [62].  
 
The pH value affects the binding affinity between the AuNPs and functional groups. It 
also affects the electrostatic repulsion between the AuNPs and resulting in effects on the 
coverage of AuNPs. For example, AuNPs coverage decreased sharply when the pH value 
was increased from 4 to 8 [57]. The binding of these ligands in this chapter to the surface 
provides great stability to the AuNPs, which remained relatively mono-dispersed with 
different pH range for more than one month. 
 
AuNPs have been agglomerated in the living cells when it used in vivo or in vitro 
biomedical applications, due to the presence of electrolyte which is causing to reduce the 
stability of AuNPs. Thus, the stability is the main concern for AuNPs in all bio- 
applications. In addition, there is a possibility of pH changes when the AuNPs interact 
with both the body fluids and blood cells which may cause a change in its stability [51]. 
Li, H., et al., demonstrated that the ideal photothermal therapy based on AuNPs to be 
well-dispersed at the normal tissue at pH 7.4. However, exhibit pH-induced aggregation 
properties in the cancer cells acidic at pH 6.8 − 6.5. Furthermore, illustrated the cause of 
the aggregation of the AuNPs returns to present of surface ligands composition. 
photothermal therapy did not depend on the size of the formed AuNPs aggregates but 
influenced by the original size of the AuNPs that tend to aggregate in slight acidic pH 
[56]. 
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Figure 3.17. Data collected through UV-Vis across the pH range produced by adding 1M NaOH (5-30 
µL) to the 4A-AuNPs solution in (Run 3) of the basic study. 
 
Figure 3.18. Data collected through DLS analysis of the samples in (Run 3) to give the diameter size and 
standard deviations for each pH range produced by adding 1 M NaOH to the 4A-AuNPs solution. 
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3.7 Stability of 5, 4A and 4B-AuNPs with changing pH after one and half 
month. 
It is well to note that, the AuNPs solutions functionalised with 5, 4A and 4B were 
relatively stable with the change of pH in a particle in weak acidic and basic solutions. 
All samples still stable nearly two months after 1M NaOH and 1M HCl (5 - 30 µL) added, 
regarding UV - Vis and DLS results of 5-AuNPs solution (Run 3) in Figures 3.19 and 
3.20. The UV - Vis spectra obtained clearly indicate that the pH values were changed a 
little bit after about one and half month but AuNPs were stable somewhat, and there was 
not seen visible evidence for any clear extra aggregation, which ensure the importance of 
contributing our ligands in the stability of AuNPs.  
 
In addition, the 5-AuNPs under acidic pH additions associated to form bigger particles 
and the plasmon resonance band has been shifted as they grew; for example, the plasmon 
resonance band is shifted from 528 nm (at pH 7.0 ± 0.3) to 535 nm (at pH 3.8 ± 0.2), 
these results were confirmed by using DLS (see Figures 3.19, 3.20). 
 
 
 
Figure 3.19. Data collected through UV-Vis of 5-AuNPs solution (Run 3) after one and half month when 
(pH ˂7.5) in the left and (pH > 7.5) in the right. 
 
The size of 5-AuNPs was changed from 8.0 ± 1.2 at pH 7.3 to 14.9 ± 1.2 (at pH 4.4) after 
nearly two months when HCl added (30 µL), whereas it was 7.6 ± 1.4 to 12.24 ± 1.2 
before one and half month. In the same hand, the size was changed after one and the half 
month from NaOH addition, where DLS measures illustrated in Figure 3.20, the size was 
pH ˃ 7.5 pH˂ 7.5 
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7.8 ± 1.6, which changed to 12.7 ± 1.3 after 30 µL NaOH added. After one and the half 
month, the size changed from 8.3 ± 1.4 (at pH 7.8) to 14.1 ± 1.2 (at pH 11.4) respectively. 
That is clearly indicative of pH-induced aggregation of AuNPs at higher amounts of HCl 
added. As well, the particles remained slightly stable in the presence of a different 
concentration of NaOH amounts in the dispersing medium, except the high concentration 
of NaOH amounts added.  
 
The aggregates at different pH were comparatively stable over one month might due to 
the expected hydrophobic environment between aggregated AuNPs that can expel water 
molecules and the aggregation of AuNPs shown stabilities against hydrolysis as 
mentioned in the literature [22]. As stated in the previous literature, AuNPs solution at 
pH 2.44 have some precipitates after nearly a week, however at pH 7.09 is quite stable 
without any precipitate during one month, which in turn confirms our results [50]. The 
stability of the AuNPs studied over the course of six months suggests that the AuNPs 
would be beneficial over time under the conditions of the human body as once 
functionalised, as they are less likely to aggregate unnecessarily [63]. 
 
 
 
Figure 3.20. Data collected through DLS analysis of 5-AuNPs solution (Run 3) after one and half month 
in both acidic conditions, pH < 7.5 (in the left) and basic conditions, pH ˃ 7.5 (in the right). 
3.8 Conclusions  
In this part of the work, functionalised AuNPs were successfully synthesised and 
characterised at different pH values. The studies presented in this chapter were conducted 
pH˂ 7.5 
 
pH ˃ 7.5 
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to assess the properties and stability of colloidal AuNPs manufactured for the potential 
used in alternative bio-recognition and drug delivery systems.  
From previous work, it was understandable to know that, some ligands were harder to 
synthesise compared to others with each having unique properties. For instance, the 
ligands synthesised with (phenyl) groups head gave more crystalline structures than those 
with ligands contain a (tolyl) or (trimethoxy-benzene) that resulted in viscous waxy 
liquids. ATR-FTIR, NMR, ESI-MS studies confirmed the structure of the ligands in this 
Chapter. 
 
From the synthesis of functionalised AuNPs, it was clear to see that the most versatile 
ligands were those containing methoxy groups such as 4B or contain tolyl group such as 
4A, which produced stable AuNPs. Methoxy and tolyl groups are an ideal moiety to 
incorporate into a ligand, as they are donator groups and contribute electrons to the phenol 
group and increasing the stability of nanoparticles [64]. This changes the stability of the 
AuNPs within a solution as the electronegative charge is shifted. As well as, the AuNPs 
with shorter chain ligands synthesised produced a more crystalline structure than longer 
chain ligands that was easily soluble in solvents making these ligands ideal for use in 
biological media [65]. 
 
The data collected with regards to the stability of AuNPs over time supported the results 
proposed in published literature [65]. It was obvious that over the 6 months period, the 
stability of the AuNPs remained constant with no important shifting in the peak of the 
absorbance observed using UV-Vis. Previous work has illustrated that the AuNPs 
manufactured can remain stable over long periods of time [32, 65]. However, it is also 
imperative that the AuNPs remain stable within the body over shorter periods of time 
for therapeutic reasons [63].  
 
All the experimentations were performed thrice, as a result of the pH stability study, it 
was proposed that the optimum pH of the 5-AuNP solution was between pH 7.3 ± 0.05 
and pH 4.0 ± 0.2 as this gave a diameter size range of 7.6 ± 1.4 nm.to 14.7 ± 1.5 nm. 
Whilst aggregation occurred clearly during the acid pH study in low acidic pH. However, 
in base pH study, it was pH 7.5 ± 0.05 and pH 11.3 ± 0.1 as this gave a diameter size 
range of 7.6 ± 1.6 nm.to 14.3 ± 1.3 nm. The stability of the solution at these pH was 
measured using UV-Vis data which showed that the peak absorbance wavelength 
 98 
 
observed did not shift, except high pH, suggesting a consistent size of AuNP 
monodispersed within the solution [59].  
 
In addition, AuNPs functionalised by 4B was between pH 7.3 ± 0.1 and pH 3.0 ± 0.2 as, 
within this range, the size and standard deviations are within the range between 6.2 ± 1.6 
nm to 13.8 ± 1.3 nm in HCl addition, which showed clearly aggregation at high addition. 
While, in NaOH addition, it was between pH 7.1 ± 0.1 and pH 9.0 ± 0.1 have an average 
diameter of 6.1 ± 1.17 nm to 9.6 ± 1.4 nm respectively with a narrow size distribution. 
Whereas stable 4A-AuNPs with size variations at pH 7.7 ± 0.1 and pH 3.7 ± 0.3 
respectively between 6.8 ± 1.4 nm and 12.2 ± 1.3 nm when the concentration of HCl acid 
was varied, While the sizes were between 6.8 ± 1.30 to 11.9 ± 1.3 nm at pH 7.6 ± 0.1 and 
pH 10.7 ± 0.1 respectively with variety in 1M NaOH amounts added. AuNPs are found 
to show similar transition pH ranges, regardless of the different protecting ligands used, 
and this expectation is experimentally confirmed. 
 
The stability of the AuNPs experienced in the acidic pH study suggests that despite the 
weakly acidic nature of tumorous tissue [66], it would be possible for the manufactured 
AuNPs to selectively enter the cells required and remain stable for a suitable time period 
for treatment to be completed. This is because of the hydrophobic nature of the 
synthesised ligands introducing an affinity with the lipophilic cell walls. Not only do the 
hydrophobic and cationic properties of the surface coating of the AuNPs aid cell 
penetration, it also provides a pathway for ion exchange within the biological media of 
the cell [67]. 
 
The evidence presented for the stability of functionalised AuNPs at slightly lower pH (Ex 
5 - 6.5) is significant as it is well documented that the pH of cancer cells is weakly acidic 
[66]. Whilst the work presented was conducted in vitro; future work should include in 
vivo biological test by cellular internalisation of the phosphonium ligand coated AuNPs. 
This analysis could be achieved using a biophysical technique, such as flow cytometry 
where the cells are suspended in a stream of fluid and passed by an electronic detection 
apparatus. Finally, because pH plays an important role in many cellular processes, so 
from this chapter, it is found that the size and shape of the AuNPs could be easily 
controlled via varying pH additions under acidic and basic conditions. AuNPs with pH-
dependent membrane adsorption might use in soon future in tumour therapy and 
diagnosis.
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Chapter 4: Green synthesis of positively charged 
biocompatible gold nanoparticles in water: use of ascorbic 
acid as reducing agent. 
4.1 Abstract 
Well-monodispersed AuNPs were prepared by the reduction of KAuCl4 using sodium 
borohydride and ascorbic acid as reducing agents. Due to using different reducing agent 
power, we obtained different results for AuNPs that were functionalised with same 
ligands. The effect of two different reducing agents on size and stability of the colloidal 
cationic phosphonium AuNPs was investigated. Their formation and stability was 
monitored by using UV−Vis absorption spectroscopy, transmission electron microscopy 
(TEM) and dynamic light scattering (DLS). Small sizes with higher stability during a 
period of time were generated when NaBH4 was used as reducing agent. 
 
AuNPs functionalised by tri(phenyl)phosphoniopropylthiosulfate (4C) (3-
thioactylpropyl)-triphenylphosphonium bromide (5) and tri(p-tolyl)phosphoniopropyl- 
thiosulfate (4) zwitterion via using NaBH4 as reducing agent in H2O / DMSO as solvent, 
the maximum absorption bands centred at 519, 519 and 529 nm respectively. While, when 
the ascorbic acid is used as reducing agent, the maximum absorption of AuNPs 
functionalised by these ligands were centred at 542, 575 and 557 nm respectively. For (6-
thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)-phosphonium bromide (8B) showed little 
difference between two methods, whereas the absorbance centred at 522 nm in the case 
of NaBH4 and at 528 nm in the case using ascorbic acid as a reducing agent. 
 
ATR-FTIR, NMR, ESI-MS techniques can be employed to identify the kinds of 
functionality of ligands attached to the AuNPs. 
 
In this research, we proposed the bio-reducing agent, ascorbic acid, to synthesise the 
AuNPs, when compared to AuNPs fabricated by using NaBH4 as reducing agent. We 
studied the relationship between the reducing agents and the stability / sizes of AuNPs. It 
was found that, various sizes with different stabilities occurred based on various reducing 
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agent used in this Chapter, where AuNPs of different sizes are known to produce 
contradictory results sometimes in vivo and in vitro bio application 00. 
 
All these results in this Chapter, confirmed that KAuCl4 could be reduced during the 
green synthesis of AuNPs through ascorbic acid, and the same protect ligands used in the 
case of NaBH4. KAuCl4 – NaBH4 system produced small sizes with small mean deviation 
and indicated spherical shape. However, they were nearly poly-dispersed and poly-shaped 
for most process conditions when KAuCl4 – ascorbic acid system was used as reducing 
agent. Different sizes of AuNPs usually have different bio-applications. Development of 
more environmentally friendly and biocompatible synthetic ways is one of the main aims 
to allow their use in biomedical applications. Ascorbic acid has been used as a benign 
naturally available reducing agent to synthesise AuNPs, due to its high water solubility, 
low toxicity, and biodegradability. In this chapter, a green synthesis methodology used in 
order to produce positively charged biocompatible AuNPs for possibility biomedical 
applications is outlined. 
4.2 Introduction 
A considerable amount of gold nanoparticle (AuNP) synthetic methods have been 
reported in the literature in recent years. AuNP surface has shown to interact with various 
organic thiolate ligands, making them versatile nanodevices for their potential use in drug 
delivery, imaging and biosensing applications. Therefore, the development of more 
environmentally friendly and biocompatible synthetic routes is one of the main aims to 
allow their use in biomedical applications. One of the most used reducing agents for noble 
metal salt reduction is sodium borohydride, a strong and excellent hydrides source. 
However, other reducing agents such as sodium citrate, ascorbic acid, and tannic acid are 
reported to be green alternatives to sodium borohydride [1-4]. Their use represents 
significant progress in the development of methodologies for the green synthesis of 
biocompatible AuNPs in their colloidal form. 
 
Malassis, L., et al., [1] recently developed a one-step, green synthesis using biocompatible 
ascorbic acid. The authors used this compound as reducing and stabilising agent and 
carried out the synthesis at room temperature. They successfully synthesised different 
size gold (8 – 80 nm) and silver (20 – 175 nm) NPs by controlling the pH of either the 
metal salt solution or the ascorbic acid solution. Another example of the synthesis of NPs 
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using ascorbic acid is the one reported by Lin, SM., et al., [4]. They developed another 
green synthetic method to produce D-penicillamine-template copper NPs via ascorbic 
acid reduction. The authors aimed to use these NPs as mercury ion sensors. Cao, Y., et 
al., [5] reported a methodology to synthesise silver NPs by using tannic acid, another 
green alternative to sodium borohydride. The authors used the tannic acid as reducing and 
stabilising agent, carrying out the synthesis in a water bath at a controlled temperature of 
30°C. The size of NP in a range of 7 – 66 nm were observed and the samples were 
monodispersed, and that silver NPs coated with tannic acid showed better colloidal 
stability when compared to citrate stabilised silver NPs [5].  
 
The chemical reduction of gold salts in the presence of a variety of stabilisers, such as 
e.g. donor ligands, to produce zerovalent metal colloids in aqueous or organic media is 
considered one of the most powerful and well known synthetic methods in this field [6]. 
Ascorbic acid is a vitamin C, which participates in several biochemical reactions. As an 
influential part of the organism biochemistry, it has an antioxidant effect which is 
considered one of its best known biological functions [7]. Ascorbic acid has been used as 
a benign naturally available reducing agent to synthesise AuNPs, because of its high water 
solubility, low toxicity, and biodegradability [8].  
 
In addition, metal NPs exhibited good uniform size when using ascorbic acid [9]. On the 
other hand, it is observed that the absorption peak of the nano-composite without ascorbic 
acid was quite narrow and symmetrical, indicating a narrow size distribution of NPs. 
However, after the ascorbic acid is added, a wider size distribution is considered by the 
broadening of the absorption peak of the blue mixture which confirms the induced growth 
of the nanoparticles [10]. The ascorbic acid diffuses to the surface of the NPs where 
electron transfer takes place causing the formation of the atoms and following growth of 
the clusters to NPs, the colour changed from colourless to blue [10, 11]. 
 
According to Luty-Błocho, M., et al., it is noted that AuNPs processing with the HAuCl4 
– NaBH4 system produced small sizes with small mean deviation and indicated spherical 
shape. However, they were poly-dispersed and poly-shaped for most process conditions 
when HAuCl4 – ascorbic acid system was used as reducing agent [12]. Furthermore, the 
amount of ascorbic acid plays a significant role in determining the size and shape of the 
AuNPs [13, 14]. AuNPs have peak wavelength between 530 and 540 nm. Sizes changes 
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between 10 and 23 nm were measured when varied quantities of the ascorbic acid were 
added [13]. 
 
Some researchers have used sodium hydroxide with ascorbic acid to reduce gold salt, 
because it’s addition to a concentrated aqueous solution of HAuCl4, causing neutralisation 
of its acidity and that as result to the rapid formation of hydroxyl-Au complexes such as 
(AuCl3(OH)
−, AuCl2(OH)2
−, AuCl(OH)3
− and Au(OH)4
− with (pK1 = 8.3, pK2 = 7.5, pK3 
= 6.4, and pK4 = 5.4) respectively as result of the progressive substitution of Cl−. The 
concentration of these species highly depends on the pH of the reaction mixture [14, 15]. 
In addition, it is notable that, the HAuCl4 in aqueous solution consists of [AuClx(OH)4-x] 
when (x ˃ 2) at low pH but [AuClx(OH)4-x] when (x < 2) at high pH. These influences on 
the synthesis, structure, and property of AuNPs colloids [16].  
 
In addition, according to Ziegler, C and EychmüLler, A, the spherical particles were 
generated by using of the mixture of ascorbic acid as reducing agent and sodium citrate 
as stabiliser ligands. Where this method proceeded, nontoxic and easy to remove 
stabilisers, low poly-dispersity and the large size range, which can be offered an excellent 
new method that can be applied in many fields of nano science [17].  
 
Jana, NR, et al., shown that, AuNPs can be produced by controlling their sizes by using 
of either strong or weak reducing agent mixture. The nucleation rate was controlled via 
varying the ratio of strong (NaBH4) reducing agents and weak reducing agent (ascorbic 
acid), where noted NaBH4 predominantly induced nucleation, while ascorbic acid 
induced growth. For instance, small size (< 5 nm) produced as result to high ratios of 
NaBH4 which induced rapid nucleation. In contrast, when lower ratios of NaBH4 were 
used, AuNPs with broad size and shape distributions were produced because the 
nucleation rate was very slow and the may also causing NPs aggregates. The NaBH4 –
ascorbic acid method gives 4-10 nm AuNPs with varying concentration of the gold salt 
[18].  
 
In this Chapter, a green synthesis methodology to produce positively charged 
biocompatible AuNPs for potential biomedical applications is outlined. As previously 
reported, the use of functionalised AuNPs in therapeutic purposes is promising. A 
synthesis of cationic phosphonium AuNPs was developed, by reducing gold (III) salt 
using ascorbic acid, a greener alternative to sodium borohydride. We also describe the 
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synthesis of new cationic phosphonium ligand (6-thioacetylhexyl)-tris(2,4,6-trimethoxy- 
phenyl)phosphonium bromide  (8B) and tri(p-tolyl)phosphoniohexylthiosulfate (9A) 
zwitterion used to functionalise the AuNPs surface in mixture H2O / DMSO. Two 
previously reported phosphonium ligands, triphenylphosphoniopropylthiosulfate (4C) 
zwitterion [19], (3-thioactylpropyl)triphenylphosphonium bromide (5) [20], tri(p-tolyl)- 
phosphoniopropylthiosulfate (4) and (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)-
phosphonium (8B) were used for this work to produce the cationic phosphonium AuNPs 
in H2O / DMSO with NaBH4. Same NPs were also produced using ascorbic acid as 
reducing agent in aqueous solution.  
4.3 Materials and Methods 
All chemicals used were purchased from Sigma-Aldrich and Fisher Scientific Ltd. All 
reagents were used as received without further purification. All solutions were prepared 
with redistilled water. All the glassware was washed using aqua regia solution (HCl / 
HNO3, 3:1), followed rinsing thoroughly with distilled water before use. 
4.3.1 Cationic phosphonium ligand syntheses 
Different techniques have been approved for synthesis various dimensions of 
nanoparticles and in order to functionalise their surface for improving their applications 
[21-23]. The main challenges in developing different strategies are their low poly-
dispersity with high purity [23].  
4.3.1.1 Synthesis of tri(phenyl) (4C) and tri(p-tolyl)phosphoniopropylthiosulfate (4) 
zwitterion 
Synthetic method outlined in Chapter 2.  
4.3.1.2 Synthesis of (3-thioacetylpropyl)triphenylphosphonium bromide (5). 
Synthetic method outlined in Chapter 2. 
4.3.1.3 Syntheses of the (6-thioacetylhexyl)triphenylphosphonium bromide 
derivatives ligands 
The syntheses of (6-thioacetylhexyl)triphenylphosphonium bromide (8D), (6-
thioacetylhexyl)tri(p-tolyl)-phosphonium bromide (8A) and (6-thioacetylhexyl)-
tris(2,4,6-trimethoxyphenyl-phosphonium bromide (8B) are shown in Scheme 1. The 
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compounds were synthesised via reaction of tri(phenyl)phosphine (1D), tri(p-
tolyl)phosphine (1A) and tris(2,4,6-trimethoxyphenyl)-phosphine (1B) (3.8mmol) with 
approximately bromo-hexanol (15 mmol). In a round bottom flask with a reflux 
condenser were refluxed for five hours in acetonitrile (0.024 mmol). A Pale yellow, 
brown oil and brown solid were collected, and recrystallized from diethyl ether (Reaction 
1, Scheme1). The yield was 70%, 65%, and 75% respectively.  
 
The resulting salts (6D), (6A), (6B) were dissolved in hydrobromic acid (0.18 mmol, 10 
ml) (48%) in a round bottom under reflux five hours (Reaction 2, Scheme 1). Then a 
mixture of -bromohexyl-tri(phenylphosphonium bromide (7D), -bromohexyl-tri(p-
tolyl)phosphonium bromide (7A) and -bromohexyl-tri(1,3,5-trimethoxy- 
phenyphosphonium bromide (7B) (2 mmol) and potassium thioacetate (3 mmol) were 
stirring overnight at room temperature in aqueous ethanol (1:1, 10ml) (Reaction 3, 
Scheme 1). The compounds looked like a yellow oil, brown oil and brown precipitate 
respectively (8D), (8A), (8B). TLC has used to monitor the reactions by using 20% 
methanol: 80% DCM (dichloromethane) as a mobile phase. The (6-thioacetylalkyl)- 
triphenylphosphonium bromide ligands (8D), (8A), (8B) were achieved by DCM 
extraction of the mixture of reaction and purified by diethyl ether. The yield was 65%, 
70%, and 75% respectively. The compounds (8D), (8A) and (8B) looked like a yellow 
oil, brown oil and white precipitate respectively, with a melting point of 8B at 206 - 208 
°C. 
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4.3.1.4 Synthesis of tri(phenyl)phosphoniohexylthiosulfate derivatives zwitterion 
The synthesis of the tri(phenyl)phosphoniohexylthiosulfate zwitterion was carried out 
following the reactions showed in Scheme 2. In a round bottom flask with a reflux 
condenser a mixture of -bromohexyl-tri(phenyl)phosphonium bromide, -bromohexyl-
tri(P-tolyl)-phosphonium bromide (7D), (7A) (1 mmol) and sodium thiosulfate (1.5 
mmol) were refluxed for five hours in aqueous ethanol (1:1, 10 ml) (Reaction 1, Scheme 
2). TLC was used in order to follow the progress of the reaction by using 10 %: 90 % 
methanol: DCM as a mobile phase. The compounds (9D) and (9A) looked like a white 
precipitate with a melting point at 64-66°C and a brown oil respectively and were purified 
diethyl ether. The yield was 62 %, 74 % respectively. 
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4.3.2 Protecting AuNPs by synthesis of phosphonium-monolayer using 
protecting ligands including thioacetate and thiosulfate ligands using NaBH4 
reduction in (H2O/DMSO) and comparison with ascorbic acid reduction in 
water  
AuNPs are generally synthesised via the reduction of gold salts, nucleation and growth 
of metallic particles in solution. An aqueous synthesis is commonly nowadays carried out 
by the citrate-reduction route, which produces AuNPs with a narrow and mono-modal 
size distribution. By varying the reaction conditions, the average particle diameter can be 
controlled between about 2 – 200 nm [24, 25]. 
 
The synthesis of functionalised AuNPs was carried out using either NaBH4 or ascorbic 
acid as the reducing agent to promote the formation of Au0 and colloidal AuNPs. 
4.3.2.1 Synthesis of cationic phosphonium gold nanoparticles by NaBH4 in H2O / 
DMSO 
AuNPs functionalised by (4C), (5), and (4) zwitterion using NaBH4 in DMSO are shown 
in experimental section / Chapter 2. 
 
The triphenyl (8D), tri(p-tolyl) (8A), (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)-
phosphonium (8B), (9D), and (9A) zwitterions were used to protect AuNPs. All these 
ligands have the same preparation technique, which is described below. 
 
8D, 8A, 8B, 9D, and 9A-AuNPs were prepared in DMSO 0.8 mmol, 0.25mmol, 0.3 
mmol, 0.4 mmol and 0.21 mmol respectively. The volume of DMSO used for these was 
30 mL. A solution of potassium tetrachloroaurate (0.12 mmol) in H2O (10 mL) was also 
prepared. Then the ligands and gold salt solutions were mixed, and stirred for five hours. 
The reduction was carried out by adding 5 mL of a freshly prepared aqueous solution of 
NaBH4 (2.0 mmol) to the H2O / DMSO mixture. In order to remove the excess of ligands 
in each one of the gold colloidal solutions prepared, liquid-liquid extractions were carried 
out using diethyl ether. 
 
4.3.2.2 Syntheses AuNPs using ascorbic acid as reducing agent 
The reduction of gold (III) salts using ascorbic acid (C6H8O6) was a one-pot reaction using 
water as a solvent. The reaction equation of this reaction is as follow:  
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2 [AuCl4]
− + 3C6H8O6 = 2Au + 8 Cl
−+ 3C6H6O6 + 6 [H]
+    [8]. 
4.3.2.2.1 Synthesis of AuNPs functionalised by triphenylphosphonio- 
propylthiosulfate (4C) zwitterion, (3-thioactylpropyl)triphenylphosphonium 
bromide (5), tri(p-tolyl) phosphoniopropylthiosulfate (4) and (6-thioacetylhexyl)-
tris(2,4,6-trimethoxy- phenyl)phosphonium bromide (8B) ligands zwitterion using 
ascorbic acid as reducing agent. 
Functionalised AuNPs were synthesised via the following procedure. The phosphonium 
ligands, 4C, 5, 4 and 8B (0.03, 0.022, 0.026, and 0.024 mmol, respectively) were 
dissolved in 25 ml deionised water under a stirring speed of 800 rpm in a 60°C water bath 
for two hours. After the ligands were dissolved, 0.027, 0.020, 0.021, and 0.012 mmol of 
KAuCl4 salt dissolved in 10 ml of deionised water was added to each respective ligand 
solution. The reaction solutions were observed to change from colourless to yellow, and 
the solutions were left to stir for a further four hours until the yellow colour changed to 
colourless. Solutions of 0.013, 0.0089, 0.0099 and 0.0054 mmol ascorbic acid in 3 ml of 
deionised water were freshly prepared and added to each of the colourless gold ligand 
solutions. Stirring was continued over moderate heat (40 °C water bath).  
 
Once the gold-ligand solution had stirred for approximately half an hour, 0.1M NaOH 
solution (1mL) was added dropwise until a permanent colour change occurred. The final 
solutions were left to stir overnight to encourage functionalisation of the AuNPs and no 
extra change in colour took place, indicating the reactions were completed. 
 
Samples were taken and analysed using UV-Vis, TEM, and DLS techniques to measure 
the size of AuNPs and to assess whether agglomeration had occurred between the 
particles [26, 27].  
4.4 Results and Discussion 
AuNPs were synthesised by varying experimental conditions in this chapter. It verified 
their sizes combining two different methods. Both NaBH4 and ascorbic acid were used as 
reducing agents, and different sizes were noted by using three complementary techniques 
including DLS, UV-Vis, and TEM. This tended to give comparable results in the case of 
mono-dispersed particle distributions. 
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4.4.1 Syntheses of 4C, 5, 4, 8D, 8B, 8A, 9D, and 9A ligands 
Syntheses of 4, 5 and 4C have shown in Chapter 2. Synthesis of 8D, 8B, and 8A are 
shown in Scheme 1. Compounds 9D and 9A are shown in experimental section / in 
Scheme 2 as well. ATR-FTIR, NMR, ESI-MS have used for confirming these ligands are 
discussion below.  
 
The resulting zwitterions were purified by trituration using diethyl ether. When studied 
by ESI-MS in positive ion mode. Ions corresponding to [M-Br]+ was observed at 421.174 
m/z for 8D. IR spectrum showed absorption bands in the regions of 719 – 727 cm-1 ( 
CH2), 1738 cm
-1 ( C=O), 1372 cm-1 (C-S-), and 3093–3000 cm-1 ( CH-Aromatic). 
NMR: (DMSO), 1H NMR spectrum gave signals at  3.4 (2H, t, Ph3-P-CH2-),  3.3 (3H, 
s, CO-CH3-),  2.7 (2H, t, -CH2-SCOCH3),  2.5 (1H, s, DMSO (solvent)) [28],  2.3 
(2H, m, -CH2-),  1.5 (2H, m, -CH2-),  1.3 (2H, m, -CH2-),  1.2 (2H, m, -CH2-) and at 
7.7 – 7.9 (15H, m, Aromatic H) ppm.  
 
Compound 8B is going to characterising in Chapter 6. Compound 8A showed absorption 
bands in the regions IR at 723 – 720 cm-1 ( CH2), 1700 cm-1 ( C=O), 1345 cm-1 (C-S-
), 1120 cm-1 ( P=O) and 3100 – 3000 cm-1 ( CH-Aromatic). NMR: 31P (CD2CL2) = 
24.5 ppm, 1H NMR spectrum gave signals at  3.7 (9H, s, Ph-3CH3),  3.4 (2H, t, Ph3-P-
CH2-),  3.3 (3H, s, CO-CH3),  2.4 (2H, t, CH2- SCOCH3),  1.7 (2H, m,-CH2-),  1.4 
(2H, m, -CH2-), 1.3 (2H, t, -CH2-), 1.2 (2H, t, -CH2-), 5.6 (1H, s, CD2CL2 (solvent) 
[29], and at 7.4 – 7.7 (12H, m , Aromatic H) ppm. ESI-MS 467.14 [M-SCOCH3]+. 
 
In addition, Compounds 9D and 9A were confirmed by ESI-MS in positive ion mode. 
Whereas, ions corresponding to [M-S2O3H]
+ and [M + H]+ were observed at 345.17 m/z 
and 501.16 respectively.  
 
IR and NMR were extra evidence for 9D, whereas IR spectrum showed absorption bands 
at the regions of 722–720 cm-1 (  CH2), 1338 cm-1 ( S=O), 1411 cm-1 (C-S-), and 3100–
3057 cm-1 ( CH-Aromatic). NMR: 31P (CDCL3) = 24.7 ppm, 1H NMR spectrum gave 
signals at  3.6 (2H, t, -CH2-SSO3),  3.2 (2H, t, -CH2-P),  1.6 (2H, m, -CH2-),  1.5 (2H, 
m, -CH2-),  1.4 (2H, t, -CH2-), 1.3 (2H, t, -CH2-P-), and at 7.6 – 7.7 (15H, m, Aromatic 
H) ppm. 
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More information was collected for 9A by using IR and NMR. IR spectrum showed 
absorption bands in the regions of 723 – 720 cm-1 (CH2), 1315 cm-1 (S=O), 1379 cm-1 
(C-S-), and 3100 – 3024 cm-1 ( CH-Aromatic). NMR: 31P (CD2CL2) = 24.8 ppm, 1H 
NMR spectrum gave signals at  3.4 (9H, s, Ph-CH3),  2.7 (2H, t, CH2-S),  2.4 (8H, t, 
-CH2-),  1.5 (2H, t, -CH2-P), 5.6 (1H, s, CD2CL2 (solvent) and at 7.5 – 7.7 (12H, m, 
Aromatic H) ppm. 
 
The clear evidence for produced 8D and 8A are the existence of the SCOCH3 group in 
these compounds, which is not present in -bromohexyl-triphenylphosphonium bromide 
derivatives (7D, 7A). IR spectra confirmed the absorbance at 1738 cm-1 and 1700 cm-1 
for ketone group ( C=O) group in 8D and 8A respectively. Further evidence for 8D and 
8A was the absence of the OH group in IR region at 3200-3400 cm-1, which has existed 
in intermediate 6D and 6A [30].  
 
8D and 8A were also confirmed by 1H NMR spectroscopy which showed the (COCH3) 
group present at  3.3 (3H, s, CO-CH3) for both 8D and 8A as shown in the previous 
studies [31, 32]. In addition, present twelve protons -(CH2)6 attached to the aromatic ring 
at chemical shifts from 1.2-3.4 ppm to produce compounds 8D and 8A, this group is not 
presented in start materials -bromohexyl-tri(phenyl)phosphonium bromide (7D) and -
bromohexyl-tri(P-tolyl)-phosphonium bromide (7A). 
 
When 8D and 8A studied by ESI-MS in positive ion mode. Ions corresponding to [M-
Br]+ and [M-S-COCH3] were observed at 421.174 m/z and 467.14 m/z respectively. 
While, expected MW 8D is 500.9 g/mol, and expected MW 8A is 542.9 g/mol. 
 
Furthermore, 9D and 9A have thiosulfate group (S2O3) and this is indicated from IR 
spectroscopy which absorbanced at 1338 cm-1, also occurred absorbance’s at 1131 cm-1 
and 1207 cm-1 for vibrations of asymmetric and symmetric S=O and S=S bonds 
respectively. The literature showed that, peaks emerge in the regions 1150–1050 cm–1 
and 1400–1200 cm–1, which are characteristic of the vibrations of symmetric S=O and 
S=S bonds respectively within the thiosulfate ion. However, the asymmetric stretch of 
S=O bond was at 1420 – 1300 cm-1 [33, 34], and this group was absented in start material 
1D and 1A. 
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1H NMR spectroscopy confirmed 9D and 9A which showed signals of (CH2)6 group at  
1.3-3.6 ppm for, only this group in 1H NMR can be considered as evidence for producing 
9D and 9A, which as mentioned in result section above, was absent in start materials. In 
addition, NMR:  31P (CDCL3) spectrum gave signals at = 24.7 ppm for 9D, and  31P 
(CD2CL2) of 9A was 24.8 ppm. 
 
ESI-MS was also confirmed producing compounds 9D and 9A. Whereas, ions 
corresponding to [M- S2O3H]
+ and [M + H]+ were observed at 345.17 m/z and 501.16 m/z 
respectively. However, expected MW 9D is 458 g/mol and expected MW 9A is 500 
g/mol. 
4.4.2 Characterisation of the colloidal solutions of AuNPs using NaBH4 in 
comparison with ascorbic acid as reducing agent via using UV-Visible and 
DLS studies 
It is known that shape of the UV–visible spectra give different information about the size 
of the AuNPs [14]. 
 
By using different reducing agents, AuNPs with different diameter were prepared. UV-
Vis and DLS were regularly used to measure the size and size diameter, and to see the 
stability of AuNPs solutions through periods of time. Comparison between two methods 
is discussed in this chapter and clearly explains the effect of reducing agents on the size 
of AuNPs prepared, and also on their stabilities [35]. When a reducing agent such as 
sodium borohydride was used, smaller AuNPs with a diameter from 3-5 nm have been 
prepared [36]. AuNPs of different sizes are known to produce different results which 
might find application in vivo and in vitro bio application [35].  
 
From the previous study, metal NPs can be soluble in many solvents such as (ethanol, 
DCM, toluene) depending on the polarity of the capping agent such as thiol ligands, which 
have a great affinity for noble metal surfaces, whereas the highly stable NPs were 
generated. Capped NPs which can be repeatedly isolated and re-dissolved in common 
organic solvents without showing any signs of decomposition, such as particle growth or 
loss of stability [37].  
 
Syntheses of AuNPs were carried out using all these ligands in this Chapter with varying 
results. Synthesis 4C-AuNPs, 4-AuNPs and 5-AuNPs in H2O/DMSO by using NaBH4 as 
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reducing agent are explained in detail in Chapter 2, while, 8B-AuNPs is explained in 
Chapter 6. The synthesis of AuNPs using 4C, 4, 5 and 8B ligands were successful with 
both directions, in the case of NaBH4 and ascorbic acid as reducing agents. The rest of 
ligands were unable to dissolve in an aqueous solvent and there are unsuitable for the 
synthesis route using an ascorbic acid as reducing agent in order to functionalised AuNPs.  
 
The unsuccessful syntheses formed a black bulk material solution that was unchanged by 
continuous stirring to the red colour. Multiple repeat syntheses were carried out for each 
ligand with changing condition of the experiment. Including the concentration of 
reactants, temperature and time of reaction. In order to eliminate the possibility of 
experimental error. Each synthesis was unsuccessful and resulted in the same black bulk 
material. This could be due to poor the solubility of the ligands in the water. AuNPs 
solutions were stored in the dark under ambient atmosphere and temperature and were 
reducingly taken for analysis using UV-Vis and DLS to determine the formation and 
stability of the AuNPs manufactured.  
 
AuNPs functionalised by 8D (see Figures 4.1,4.2), 8A (see Figures 4.3,4.4), 9D (see 
appendix G, Figure G4.1, G4.2), and 9A-AuNPs (see appendix G, Figures G4.3, G4.4) 
were produced via using NaBH4 as reducing agent. Similar results were obtained and the 
peaks of absorbance were centred at 532, 523, 516 and 535 nm respectively. 
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Figure 4.1. UV-Vis for the stability of the 8D-AuNPs dispersed in H2O/DMSO, using NaBH4 as reducing 
agent at time = 0, 1 and 2 months. Where time = 0 is the initial time of the frish 8D-AuNPs synthesed.  
 
 
Figure 4.2. The size and standard deviation of each diameter range measured by DLS, and was taken at a 
different time value for 8D-AuNPs, where time = 0 is the first time of the fresh 8D-AuNPs synthesised 
using NaBH4 as reducing agent. Where time = 0 is the initial time of the 8D-AuNPs preparation. 
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Figure 4.3. UV-Vis for the stability of the 8A-AuNPs dispersed in H2O/DMSO, using NaBH4 as reducing 
agent at time = 0, 1, 2, 3, 4, 5, and 6 months respectively. Where time = 0 is the initial time of the 8A-
AuNPs preparation. 
 
Figure 4.4. The size and standard deviation of each diameter range taken at a different time value for 8A-
AuNPs, using NaBH4 as reducing agent by using DLS. 
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These results were confirmed by DLS as shown in Table 4.1. Whereas, 8D, 8A, 9D and 
9A-AuNPs sizes diameter were in the range of 32 ± 2 nm, 8.8 ± 1.6 nm, 6.9 ± 1.3 nm and 
33 ± 2.2 respectively. Figures 4.1 displays the UV-Visible spectra of fresh AuNPs 
solutions (time = 0) and the same solutions after 1 and 2 months for 8D-AuNPs, also 9D-
AuNPs stayed stable for 2 months (see appendix G, Figure G4.1, G4.2). Figure 4.3 shows 
8A-AuNP stay stable for 0, 1, 2, 3, 4, 5, 6 months respectively, and 9A-AuNP stays stable 
for 8 weeks as well (see appendix G, Figures G4.3, G4.4). With no sign of degradation or 
aggregation through DLS or UV-Visible absorption spectroscopy analysis for all these 
AuNPs solutions, this indicates that the particle sizes were not changed over this period.  
 
It was expected that the NaBH4 synthesised AuNPs would be smaller than the ascorbic 
acid synthesised nanoparticles owing to NaBH4 being a stronger reducing agent [12]. 
 
From Chapter 2, it can be seen that, AuNPs functionalised by 4C, 5 and 4 ligands using 
NaBH4 as reducing agent have bands centred at 519 (Figure 2.1, see UV-visible spectrum 
at time = 0), 519 (Figure 2.2, see UV-visible spectrum at time = 0) and 529 nm (Figure 
2.3, see UV-visible spectrum at time 0) respectively.  
 
In contrast, as shown in the UV–Vis spectra (see table 4.2, Figures 4.5, 4.7 and appendix 
G, Figure G4.5), when the ascorbic acid is used as reducing agent, the maximum 
absorptions of 4C, 5, 4-AuNPs are centred at 542, 575 (see Figures 4.5 - 4.8) and 557 nm 
respectively (see appendix G, Figures G4.5, G4.6). 
Table 4.1. 8D, 8A, 9D and 9A-AuNPs solutions in H2O/DSMO using NaBH4 with the UV-Vis and DLS 
studies. All these types of AuNPs prepared as described in experimental section. 
Name of AuNPs Peak wavelength (nm) Diameter size (nm) 
8D-AuNP 532 nm 32 ± 2 nm 
8A-AuNP 523 nm 8.8 ± 1.6 nm 
9D-AuNP 516 nm 6.9 ± 1.3 nm 
9A-AuNP  535 nm 33 ± 2.2 nm 
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For 8B-AuNP, there was not a lot of difference between the two methods. The absorbance 
centred at 522 nm using NaBH4 and at 528 nm using ascorbic acid as reducing agent, (see 
Table 4.2 and appendix G, Figure G4.7). 
 
The stabilities of AuNPs used ascorbic acid in this Chapter were low compared with 
AuNPs used NaBH4. AuNPs prepared by ascorbic acid appear to have higher wavelength 
than for NaBH4. This was also confirmed by DLS results with the AuNPs diameter being 
smaller when NaBH4 was used as reducing agent. The most commonly weak reducing 
agent used to reduce many metal ions in the solution phase is L-ascorbic acid, which 
forms complexes with comparatively low stability constants [38].  
 
It is having been identified that the reducing potential of the ascorbic acid depends on the 
pH of the solution. The ascorbic acid exists in the protonated form, (AscH2) at pH below 
4.1. With increasing of the pH, it transforms into ascorbate form, AscH−. However, at pH 
above 11.6, it is completely deprotonated to form, (Asc2−) [39]. 
 
Table 4.2. Comparison between the 4C, 5, 4 and 8B-AuNPs solutions according to the UV-Vis, TEM and 
DLS measurements. The results were in the case of ascorbic acid [40] and in the case of NaBH4 as 
reducing agents. 
Name of 
AuNPs 
Peak wavelength 
(nm) 
TEM Diameter size (nm) 
NaBH4 AA NaBH4 AA NaBH4 AA 
4C-AuNP 519 nm 542 nm 11±1 nm  8.7± 1.2 nm 17 ± 1.5 nm 
5-AuNP 519 nm 575 nm 8 ±1 nm  7.3 ± 2 nm 74 ± 3.9 nm 
4-AuNP 529 nm 557 nm 10±1 nm 11±1.8 nm 9.6 ± 2 nm 36.3± 2 nm 
8B-AuNP 522 nm 528 nm 7±1.2 nm 8±1.6 nm 9.2 ± 0.9 nm 13 ± 1.2 nm 
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Therefore, the ascorbic acid has different reducing power with regard pH. Spherical 
AuNPs can be produced with high mono-dispersity when initial pH of the ascorbic acid 
solution is indeed controlled [41]. Au NPs with averages diameter of 18, 10 and 7 nm, 
were generated from a HAuCl4 / ascorbic acid mixture with low poly-dispersity indices 
of 0.4, 0.3 and 0.2 at a pH of 10.2, 10.7, and 11.1 respectively [39]. Furthermore, AuNPs 
were generated by using ascorbic acid as reducing agent with different size. UV-vis 
showed different absorbance at 540, 542, 545, 547, and 550 nm, relating to different sizes 
of indicating AuNPs diameter [8]. The goal of adding NaOH into the ascorbic reaction 
system in our experimental was to change the acidity of AuNPs solution because AuNPs 
are not stable at low pH as mentioned in the literature, also study reports have clearly 
indicated the influence of pH on the growth of the nanoparticles [42].  
 
Sau, TK.,et al., illustrated that, ascorbic acid was not enough to reduce of Au(III) ions to 
AuNPs and for this reason NaOH combined ascorbic as mixture reducing agent [43]. In 
addition, it is noted that, ascorbic acid was a weak reducing agent and unable to reduce 
the silver ion in order to produce AgNPs. However, with increased the pH of the solution 
via adding NaOH, which increase the reducing power of ascorbate. Where this result 
confirmed that Ag ions are not reduced under (lower pH when using weaker reducing 
agent) reaction conditions [44].  
 
It was proposed that in comparison between ascorbic acid and ascorbate, where the latter 
is a stronger reducing agent than ascorbic acid. For instance, ascorbic acid’s pka is 4.1. 
Also at pH higher than 4.1, most of ascorbic acid, turn into ascorbate. More ascorbate in 
the solution indicates faster reduction of Au ion to atomic Au on the tip facets. Usually 
having a pH higher than 4.1 lead to form longer Au nanorods [45]. 
 
It was not possible to achieve a synthesis of phenyl- and tolyl-phosphine with six carbons 
functionalised AuNPs in comparison with tris(2,4,6-trimethoxyphenyl) containing 
ligands. Using ascorbic acid became this reducing agent is not as strong as NaBH4, which 
was used previously. The lack of success could also be due to other factors such as alkyl 
chain length, monolayer quality and the nature of the substrate [46]. 
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Figure 4.5. UV-Vis for the stability of the 4C-AuNPs dispersed in aqueous solution at time = 0, 1, 3, 4, 5, 
6, and 7 weeks respectively. Using ascorbic acid as reducing agent. 
 
 
Figure 4.6. The size and standard deviation of each diameter range taken at a different time value for 4C-
AuNPs as reported by DLS study. Using ascorbic acid as reducing agent. 
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Figure 4.7. UV-Vis study for the stability of the 5-AuNPs dispersed in aqueous solution at time = 0, 1, 3, 
6, and 8 weeks respectively. Using ascorbic acid as reducing agent.  
 
 
Figure 4.8. The size and standard deviation of each diameter range taken at a different time value for 5-
AuNPs as reported by DLS study. Using ascorbic acid as reducing agent. 
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The only ligands containing tris(2,4,6-trimethoxyphenyl)phosphine derivatives were able 
to functionalise AuNPs. According to Fevre, MV., et al., tris(2,4,6-trimethoxyphenyl) 
phosphine was used as an organic catalyst for the Group Transfer Polymerization (GTP) 
of methyl methacrylate (MMA) and tert-butyl acrylate (tBA). Only tris(2,4,6-
trimethoxyphenyl)-phosphine (TTMPP) was able to bring about the controlled GTP of 
both monomers at room temperature in contrast with trialkylphosphines and tributyl- 
phosphine [47]. In addition, the GTP of MMA could also be performed in bulk, whilst 
maintaining good control over molar masses and dispersity. This is because of the 
moderate activity of the TTMPP catalyst compared to other nucleophiles, such as N-
heterocyclic carbenes, ligands containing this group have previously been confirmed as 
successful [47].  
 
Moreover, TTMPP is considered are good catalyst precursor in important reactions such 
as hydrogenation, hydroformylation, and polymerization became both oxygen and 
phosphorus atoms in its structure which are good donors [48]. TTMPP is a relatively 
strongly basic phosphine (pKa = 11.2) [47, 48] compared, for instance to triphenyl- 
phosphine, Ph3P (pKa in CH3NO2 = 2.73) [49]. As well as, it was given an order of 
decreasing basicity of P(4-CH3OC6H4), > P(4-CH3C6H4), > P(4-C1C6H4)3 > P(C6H5)3. 
Because donate groups such as a (OCH3) raising the apparent basicity’s of the phosphines, 
and causing large changes in the basicities of these phosphines [49]. Furthermore, 
modification ligands such as thiol ligands contain (methoxy-benzene groups) modified 
AuNPs found to be most stable compared to other thiol compounds contain (Benzene or 
Toluene) [50].  
4.4.2.1 Characterisation of AuNPs using transmission electron microscopy 
The TEM is considered the perfect device for the characterisation of structural and 
chemical at the nanoscale, which can be easily producing information about 
nanostructured materials [51]. The colloidal solutions of AuNPs functionalised using 8B 
(Figure 4.9, TEM4.1) when NaBH4 was used as reducing agent. While, (Figure 4.9, 
TEM4.2) and (Figure 4.9, TEM4.3), show 4, 8B as protecting ligands for AuNPs in case 
ascorbic acid used as reducing agent, whereas all analysed by TEM. Micrographs of all 
three AuNPs samples showed spherical or semi-spherical shaped particles. Then, particle 
sizes for samples TEM4.1, TEM4.2 and TEM4.3 were obtained by analysing at least 150 
particles per sample from several images taken. 
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It is known that, in order to determine the larger particles is formed due to the aggregation 
of small particles or as result to the growth of separated particles, TEM used for this 
reason according to the literature [17]. 
 
In this Chapter, TEM shows that most of the AuNPs are spherical in shape and a mono-
dispersional state without obvious aggregations. Furthermore, TEM image of 8B-AuNP 
analysis results are presented in Figure 4.9 (TEM4.1), which shows size and size 
distributions for 8B-AuNP when NaBH4 used and were approximately 7 ± 1.2 nm in size 
and the shape is almost spherical as mention in the previous study [40]. Similarly, the size 
of 8B-AuNP was detected by DLS 9.2 ± 0.9 nm. The average size of 8B-AuNP increased 
to 8 ± 1.6 nm according to TEM results when pH of the solution was changed via using 
ascorbic acid as reducing agent. The size became bigger compare in the case of NaBH4 
with less stability as mentioned above (see Table 4.2, TEM4.3).  
 
According to Sun, K., et al., the AuNPs prepared in aqueous solution using an ascorbic 
acid as reducing agent was nearly spherical and the average sizes were about 7 – 8 nm. 
Which also confirmed by using UV-Vis, where a strong absorption peak occurred at 
roughly 540 nm indicates the formation of AuNPs [8]. While, according to Khan, Z., et 
al., monodispersed spherical gold particles prepared (shape ranging from 80 nm to 5 mm) 
via reducing Au(III) with iso-ascorbic acid at 20°C [14]. 
 
It is well known that, the reduction by iso-ascorbic acid is equivalent in reducing 
properties with ascorbic acid but biologically is considered inactive [52]. Furthermore, 
iso-ascorbic acid (an isomer) has also utilised instead of ascorbic acid. However, reports 
of stabilisation without any other surface functionalisation are scarce [50].  
 
Similar results were collected of 8B-AuNP by DLS, where give 13 ± 1.2 nm in the case 
of ascorbic acid. The size was observed to increase slightly with time as illustrated in 
UV–Vis spectrophotometer results. However, remained almost unchanged a lot when 
NaBH4 was used. While some aggregation to larger particles occurs when ascorbic acid 
was used, which demonstrated big size with less stability. This may be explained due to 
reduce the stability of a weak reducing agent, which is not efficient enough to reduce 
efficiently lead to low pH as illustrated in the literature [10, 40]. As well as, 4-AuNPs 
illustrated small size when NaBH4 used in comparison in the case of ascorbic acid, as 
observed by TEM where size was 10 ± 1 nm in the case of NaBH4, and DLS also 
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confirmed the size which was 9.6 ± 2 nm. It is found that AuNPs when produced using 
ascorbic acid have a narrow size distribution (31 ± 5, 36 ± 6, and 40 ± 5 nm) and can be 
readily stabilised via adjusting the initial pH of the reaction solutions [50].  
 
Same situation in 8B-AuNP was noted when ascorbic acid used in case 4-AuNP, size 
increase to 11 ± 1.8 nm and DLS was 36.3 ± 2 nm. Aggregates, which observed after 
many weeks in DLS and UV results of samples taken during early stages of the 
preparation and weekly.  
 
Many experiments carried out to understand effect of ascorbic acid as reducing agent 
through AuNPs preparation. For example, AuNPs synthesised by using ascorbic acid as 
a reducing agent occurred spectrum consist a single SRP band at 550 nm in the whole 
UV–visible region (350 – 800 nm), where the peak at 550 nm is shifted to higher 
wavelength nearly to 600 nm when a higher ascorbic acid concentration used. The 
intensity of SRP band also declines with increase in ascorbic acid concentration [14]. 
Kim, F., et al., illustrated that, ascorbic acid / HAuCl4 ratio play a significant role during 
the growth of AuNPs [14, 53]  
 
In addition, as mentioned early, smaller AuNPs are normally produced by using stronger 
reducing agents such as NaBH4, phosphorus, tetrakis(hydroxymethyl)phosphonium 
chloride. While, larger size particles (diameter 25–110 nm) were produced by using 
ascorbic acid [43] as reductant which confirm our results in this Chapter. 
 
According to DLS results, 4-AuNPs changed from 36.3 ± 2 nm to 50 ± 2.2 after 10 weeks 
in the case of ascorbic acid. 8B-AuNP changed from 13 ± 1.2 nm to 31 ± 2 after 10 weeks. 
However, 8B-AuNP changed from 9.2 ± 0.9 nm to 20.4 ± 1.7 nm after 11 weeks when 
NaBH4 used. In addition, 4C-AuNP and 5-AuNP with ascorbic acid were changed from 
17 ± 1.5 nm and 74 ± 3.9 nm to 39 ± 2.1 nm (after 7 weeks) and 101 ± 12 nm (after 8 
weeks) respectively. AuNPs have shown larger sizes based aggregates are present after 
several weeks from the synthesis of AuNPs, thus confirming a low stabilising potential 
in ascorbic acid solution. While AuNPs are often stable for long periods of time in the 
case of NaBH4. According to the previous study, DLS results can be less accurate in case 
poly-disperse or agglomerated NPs where DLS is more sensitive to bigger particles [35]. 
In addition, a single TEM image may not be totally representative of the entire sample. 
[54].  
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Figure 4.9. TEM micrographs of cationic phosphonium 8B-AuNPs using NaBH4 as reducing agent 
(TEM4.1), 4-AuNP (TEM4.2), and 8B-AuNP (TEM4.3) as protecting ligands in case ascorbic acid had 
used, and corresponding particle size histograms. 
TEM4.2 
TEM4.1 
TEM4.3 
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Moreover, literature data showed that, it is observed a very good agreement between some 
analysis technic used to characterise AuNPs such as the electron microscopy and disc 
centrifuging data. While, DLS was slightly larger diameters compared with mentioned 
technic, which explained to that, DLS measures the hydrodynamic diameter rather than 
the natural one of the AuNPs [35]. In general, DLS data presented in this Chapter were 
in agreement with TEM images to some extent. 
4.5 Conclusion  
In summary, ascorbic acid is an essential nutrient for humans and some other animal 
species also having antioxidant properties. It is well to know that redox chemistry of 
ascorbic acid plays a significant role in human nutrition as well as in the synthesis of 
advanced nanomaterials of noble metal. For this reason, the studies on the mechanism of 
redox reactions of ascorbic acid in biological systems has become important to bio-, 
inorganic-, and surface-chemists nowadays [14]. 
 
In this work, we present the size-controlled synthesis of AuNPs by chemical reduction 
method using ascorbic acid and NaBH4 as reducing agent. The AuNPs were produced 
directly and simply by the reduction of Au (III) with two different reducing agents, 
including sodium borohydride and ascorbic acid. All of these methods can successfully 
produce AuNPs regardless of a type of reducing agents. This study shows that there are 
fundamental differences between two methods with several different properties of 
AuNPs. Based on these observations, clear evidence of the reduction of gold (III) to gold 
(0) and formation of colloidal AuNPs were obtained, as a maximum absorbance at 519, 
519 and 529 nm was observed in the corresponding UV-Visible spectra for 4C, 5 and 4-
AuNPs respectively when NaBH4 was used.  
 
The stability study carried out over time. According to the UV and DLS results, with a 
sample of the functionalised AuNPs showed that, the AuNPs synthesised by using NaBH4 
was stable for a long time (nearly up to 6 months), compared to 4C, 5 and 4-AuNPs used 
ascorbic acid as reducing agent, which stay stable maximum for 10 weeks at 542 nm, 575 
and 557 nm respectively. DLS was in the range of 17 ± 1.5 nm, 74 ± 3.9 and 36.3 ± 2 
respectively. With no sign of degradation or aggregation through DLS or UV-Visible 
absorption spectroscopy analysis where. The particles show good shape and size 
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uniformity in addition to good long-term stability. The two reducing agents lead to the 
low poly-dispersity and the formation of only spherical particles. 
 
Tables 4.1, 4.2 summarises all the results of varying the reducing agent in this Chapter. 
By using three complementary techniques (TEM, DLS and UV-Vis), AuNPs over a size 
range of 7.3 ± 2 to 9.6 ± 2 nm (diameter) were prepared by NaBH4 as reducing agent. The 
AuNPs were associated with a larger size in the case when a weak reducing agent 
(ascorbic acid) was used, where size range was 13 ± 1.2 nm to 74 ± 3.9 nm. 
 
Different preparation of colloidal AuNPs is essential to produce different sizes and offer 
different stabilities, because biocompatible AuNPs have increased significant attention in 
current years for potential applications in bio-diagnostics, and nano-medicine as result of 
their interesting size-dependent [55]. 
 
Development of more environmentally friendly and biocompatible synthetic methods is 
one of the main goals to contribute in biomedical applications. Green methods used to 
synthesis AuNPs by using ascorbic acid as bio-reducing agent was important nowadays, 
especially within the biological cells due to its low toxicity [50].  
 
In final, TEM, DLS, and UV characterisation suggest that AuNPs can be obtained via 
using bio-reducing agent (ascorbic acid) and NaBH4 as well. 
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Chapter 5: Synthesis AuNPs functionalised by phosphine 
oxide derivatives in DMSO 
5.1 Abstract 
Several nano-particulate carrier systems including polymeric nanoparticles, dendrimers, 
liposomes, metal and magnetic nanoparticles are being widely investigated especially for 
drug delivery of siRNA, gene, tumour targeting therapy, bio-imaging and bio-sensing [1]. 
The chemistry of phosphorus, and organic phosphonium salts are considered to act as 
lipophilic cations, which are accumulated in the cell's mitochondria. AuNPs 
functionalised by phosphonium were accumulated by cells and TEM confirmed that, they 
are localised in the mitochondria [2]. 
 
In the past few decades important progress have been made in controlling AuNPs via 
using thiol / phosphine ligands as protecting ligands. AuNPs stabilised by phosphine 
ligands offer broad applications such as catalysis, sensing, imaging, and new therapeutic 
approaches including biological imaging, and immunoassay. In addition, these 
nanoparticles have been used as staining agents in labelling of biological molecules such 
as proteins. For example, the use of a phosphine ligand as a stabiliser enables easy 
replacement by thiolated surfactants, which may extend the solubility of the nanoparticles 
in aqueous media for nano-biotechnology. 
 
In this Chapter, AuNPs have been stabilised through using protecting ligands such as 
phosphine oxide derivative ligands. These ligands include (3-thioacetylpropyl)di-(p-
tolyl)phosphine oxide (12A), (3-thioacetylpropyl)diphenylphosphine oxide (12D), (3-
thioacetylpropyl)thiodiphenylphosphine oxide (15) and (3-thioacetyl-N-
ethylmethylamine)diphenylphosphine oxide (18) via NaBH4 as reducing agent in DMSO 
which is reported for the first time in this Chapter. Stability of AuNPs solutions has been 
measured using UV/ Vis and DLS devices. All samples were stable for 5 months. UV-
Vis absorbance of AuNPs functionalised by these ligands 12A, 12D, 15 and 18 were 
centred at 542, 530, 527 and 529 nm respectively. DLS confirmed UV results and sizes 
were 26 ± 3.5 nm, 10.2 ± 2.7 nm, 7.9 ± 1.7 nm, 9.6 ± 1.9 nm. 12A-AuNP was produced 
with different reducing agents.  
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When biocompatible ascorbic acid was used as a reducing agent, 12A-AuNP offered 
slightly different results in comparison with when NaBH4 was used, the stability was less 
than in the case of NaBH4 and only remind for a few weeks with obvious aggregation 
being noted. The SPB centred at 544 nm of 12A-AuNPs (in the case of ascorbic acid) and 
the size was 28 ± 2.2 nm, which changed to 47 ± 2 nm after nearly 8 weeks. In addition, 
AuNPs functionalised by ligand 15, which contains a dithiol group, has the smallest size 
compared to other ligands in this Chapter with high stability for approximately 5 months, 
indicating the dithiol group enhances colloidal stability of AuNPs as shown in the 
previous literature. AuNPs have different applications based on their sizes and function 
groups used [3].  
 
Diphenylphosphine derivatives functionalised AuNPs were used against bacteria. For 
instance, 1,1,1-tris(diphenylphosphinomethyl)ethane [CH3C(CH2PPh2)3] and 1,1,1-tris-
(diphenylphosphinomethyl)ethanetrisulphide [CH3C(CH2P(S)Ph2)3] used for 
stabilisation of small AuNPs, where the AuNPs were more active against Gram (+) 
bacteria, such as., Staphylococcus aureus compared with Gram (−) bacteria. Among the 
two AuNPs, the ligand [CH3C(CH2PPh2)3] stabilised AuNPs shown higher activity [4]. 
Thus, there is an important need in order to provide new AuNPs, based on original 
ligands, to give access to an increased variety of applications. 
5.2 Introduction 
The protection and surface modification of AuNPs from the environmental impact are 
important requirements for many applications especially in bio-applications [5]. 
Recently, AuNPs have become more popular because of the possibility of them being 
used in photothermal therapy. The light collected on the surface of AuNPs is emitted by 
several processes, including electron-electron scattering and electron-lattice vibrations, 
with the concomitant production of heat [6]. However, problems with the core-shell 
particle structure include that of the development of biological ligands for effectively 
detecting specific tumour cells, and conjugating them to the metal. There is, therefore, a 
need for metal NPs that can selectively detect various cancer cells.  
 
It is important to stress that, nanotechnology is an emerging field that is potentially 
changing the way diseases are treated via drug delivery with curcumin. Recent 
investigations have established several approaches in order to improve the bioavailability, 
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and to increase the plasma concentration, also to enhance the cellular permeability 
processes of curcumin [7].  
 
The Au-sulphur interaction is the common studied organo-Au system, due to a strong 
bonding between Au-thiolate. Also weakly binding such as nitrogen-Au, phosphine-Au 
where the monolayer in this case can be removed for further applications [8]. The past 
few decades have been important progress in controlling AuNPs by using thiol / 
phosphine ligands as protecting ligands [9]. 
 
In addition, there are some protection groups such as S-acetyl, S-cyano, and S-(N-
ethylcarbamoyl) that have been used to functionalise AuNPs [10-13].  
 
Furthermore, α, ω-thiolates or aromatic thiol, which is used in order to prepare Self-
assembled monolayers (SAMs) are more sensitive to air oxidation and form disulphides 
and other oxidised products. Oxidation of thiols leads to forming thiolate radicals via loss 
of the sulphur-bound H atoms. However, thiocyanates were easily synthesised stable thiol 
derivatives, which assembled directly on Au surfaces without any additional support 
reagents required [14-16]. Furthermore, thioacetate derivatives were a more stable 
alternative to thiols due to de-protection in situ of the corresponding thiolate via reaction 
with a small amount of base such as aqueous ammonium solution, which then forms a 
SAMs on the gold substrates [14]. According to Piotrowski. P., et al., the deprotected 
aromatic S acetyl-derivatives were used in order to modify both a gold electrode and 
AuNPs surfaces, which play an important part in controlling the thickness of the self-
assembled fullerene layer [17]. 
 
Moreover, according to Vorfalt, T., et al., the thioacetate was used as a protective group 
in the Cavitands compounds which undergo cleavage in the presence of reducing agents 
such as LiAlH4 leading to the formation of the corresponding hemi-carcerands and SH 
groups [18]. From the literature, the study has been shown that AuNPs functionalised 
with cavitands contain two thiols were very stable. In contrast, two amine-functionalised 
cavitands with AuNPs tended to aggregate within a day [19], which confirm our results 
in this chapter. 
 
Furthermore, Maya, F., et al., [15] illustrated that Au substrates could be linked with 
thioacetate tail groups without prior conversion to the analogical thiolate. Also, similar 
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coverage of the relative surfaces has been shown by literatures [15, 20], such studies used 
a higher concentration of thioacetate ligands with longer adsorption time, which in this 
case, ammonium hydroxide is not needed. It should also, be acknowledged that, the self-
assembly of alkanethiols such as (HS(CH2)nX) or disulphides (S(CH2)nX2) where (X ) is 
CO2 -, SO3 -, PO3 
-2, OH, N(CH3)3
+, CH3) have by far the most studied processer, using 
Au as the solid substrate [21, 22]. Mixed SAMs of alkane thiolates on Au have been 
shown to resist non-specific adsorption of proteins [23, 24]. Also, SAMs were used for 
covalent immobilisation of biomolecules such as antibodies onto the surface of AuNPs 
[21, 25].  
 
The principle of using SAMs is uncomplicated: whereas, an alkane chain of 10-18 units, 
is equipped with a head group of the thiol (S-H) with a strong preferential adsorption to 
the substrate, Au(ш). The (S-H) head groups have been bound to the Au as a thiolate (Au-
S-(CH2)nX), in order to form a well-structured monolayer with the tail groups formulating 
a carriage outwards from the surface. In addition, several varities of functional groups 
can be used on the surface under the following limitations: firstly, they do not compete 
with the thiol in the case of adsorption to the substrate; secondly, they should also not 
react with thiols; and finally, they are not too bulky thus permitting close packing of the 
hydrocarbon chains [26]. In addition, secondary phosphine oxides (SPOs), have been 
used to functionalise AuNPs, with different electronic properties which were synthesised 
by using NaBH4 as a reducing agent to get small NPs (size 1.2–2.2 nm) [27].  
 
According to Cano, I.,. et al., who used SPOs in the first time as stabilising ligands for 
AuNPs, where generated stable and homogeneous AuNPs 1.24 ± 0.16 nm, and have used 
in particular for catalysis hydrogenation, which was very little precedent. Where the SPO 
plays a fundamental role in granting the highest activity and selectivity in the catalytic 
hydrogenation of α,β-unsaturated aldehydes by NPs where phosphines directly attached 
to the AuNP surface, by a Au−P(O)R2 binding mode [28], and SPOs ligands are more 
donating than many trialkylphosphines [29]. In the same way, the AuNPs functionalised by 
aryl-substituted SPOs were more active catalysts for the highly chemo-selective 
hydrogenation of substituted aldehydes in contrary, with AuNPs containing alkyl SPOs 
that showed low activity and selectivity. This was because aromatic SPOs ligated to 
AuNPs present a strong polarity in their P=O bonds [30]. Moreover, the complex 
[tBu(naphthalen-1-yl)-P(OH)AuCl]2 used as a precursor for AuNPs that proved to be very 
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active catalysts used for the hydrogenation of substituted aldehydes, which confirms SPO 
ligands were successfully coordinated to gold (I) salt [31]. 
 
Synthesis of phosphine oxide can be extremely useful by interacting with biomolecules 
via hydrogen bonds. For example, 11-mercaptoundecanylphosphonic acid, R-P(O)(OH)2 
have a wid range of biological activity such as enzyme inhibitors. In the same way, 
phosphonic acid groups can be acting as hydrogen-bond donor via groups of P-OH and 
as electron acceptors through oxygen in P=O [32]. Moreover, those phosphonic acids 
were quite useful for introducing pendant polar functional groups into metal oxide 
surfaces [33]. While, bi-functional molecular linkers, such as the mercaptopropionic acid 
(MPA) has used in order to attach the QDs to metal oxides for getting the best control in 
a specific manner. However, some materials such as ZnO are not compatible with these 
molecules as a result of their pH sensitivity [34]. 
 
In addition, an air-stable and homogeneous AuNPs functionalised by tert-
butyl(naphthalen-1-yl)phosphine oxide as a supporting ligand via NaBH4 as a reducing 
agent. AuNPs were found to be highly active catalysts for the hydrogenation of 
substituted aldehydes, giving high conversions and chemo-selectivity for a wide type of 
substrates [28]. 
 
This Chapter gaves a description of the stabilisation of AuNPs through using protecting 
ligands such as the phosphine oxide/thiol derivatives ligands, which also promotes 
interactions with biomolecules through hydrogen bonds. Ligands contain phosphine have 
been used to functionalise AuNPs and offered significant bio applications. For example, 
1,1,1-tris (diphenylphosphinomethyl) ethane [CH3C(CH2PPh2)3] and 1,1,1-tris-
(diphenylphosphino methyl)ethane trisulphide [CH3C(CH2P(S)Ph2)3] used for stabilising 
AuNPs and produced small core diameter. These AuNPs were more active against Gram 
(+) bacteria, such as, Staphylococcus aureus compared to Gram (−) bacteria. Among 
these two AuNPs, the AuNPs ligand [CH3C(CH2PPh2)3] displayed higher activity [4]. 
Ligands combining phosphorus centres and sulfur centres are especially interesting. Both 
phosphorus and sulfur are excellent ligand donor atoms for a wide range of metals, 
Phosphinothiols contain a phosphine group and a thiol function separated by an organic 
bridge, such as phosphinothioformamides were used in catalytic applications [35]. 
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Thioacetate ligands have recently been used as an alternative to thiols acting as masked 
thiolate ligands for the function of AuNPs. Chapter 5 will describe the synthesis of 
phosphonioalkylthioacetate ligands and phosphine oxide derivative ligands with their 
stabilities. The stability of colloidal AuNPs is of great importance for their practical 
applications in many fields such as Nano-optoelectronics, catalysis and bioassays. For 
this reason, many ligands have chosen to stabilise AuNPs including thiol, disulfide, 
phosphine, phosphine oxide, amine, and carboxylate [36]. 
 
The biggest exploited side of phosphine derivatives is their ability to bind transition 
metals. The ligands were selected due to their ability to stabilise an especially wide variety 
of metal centres, for example, the secondary phosphine oxides present a notable 
dichotomy in their coordination method [37]. 
5.3 Materials and Methods 
All chemicals used were purchased from Sigma-Aldrich and Fisher Scientific Ltd. All 
reagents were used as received without further purification. All solutions were prepared 
with redistilled water. All the glassware was washed with aqua regia solution (HCl / 
HNO3, 3:1), following being rinsed thoroughly with deionised water before used. 
5.3.1 Cationic phosphonium ligand synthesis 
The synthesis of the (3-thioacetylpropyl)diphenylphosphine oxide (12D) was prepared 
according to a reported procedure [38, 39]. While, the (3-thioacetylpropyl)di-(p-tolyl)-
phosphine oxide (12A), (3-thioacetylpropyl)thio-diphenylphosphine oxide (15), and (3-
thioacetylethyl-N-methylamine)diphenylphosphine oxide (18) synthesis and 
characterisation are reported for the first time in this Chapter. The synthetic protocols 
used to produce the four ligands are outlined in this section.  
5.3.1.1 Synthesis of (3-thioacetylpropyl)di-(p-tolyl)phosphine oxide(12A) and (3-
thioacetylpropyl)diphenylphosphine oxide (12D) 
The synthesis of the (12A) phosphine oxide and (12D) are shown in Scheme 1. The 
compounds were prepared via alkaline hydrolysis of hydroxypropylphosphonium salt (2) 
in the first stage in order to get the (hydroxypropyl)di(p-tolyl)phosphine oxide and 
(hydroxypropyl)diphenylphosphine oxide (10 A, D) respectively. Hydroxylpropylphos- 
phonium salt (2 A, D, 1mmol) was dissolved in approximately 1.5 mL of ethanol, and the 
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mixtures were heated with 2mL of 20% aqueous NaOH solution .In the next stage, the 
(10 A, D) were dissolved in hydrobromic acid (48%, 5mL) and refluxed for five hours to 
obtain the corresponding bromopropylphoshine oxide (11 A, D). The final stage, involved 
bromopropylphoshine oxide (11 A, D, 2 mmol) reacted with potassium thioacetate (3 
mmol) in a mixture of aqueous ethanol (4 mL). The mixture as a solution was stirred at 
room temperature in order to get the (12 A, D). The reaction mixture was left stirring 
overnight under nitrogen. TLC is used to observe the progress of the reaction by using 10 
% CH3OH: 90 % DCM as a mobile phase. The (12 A, D) were purified by diethyl ether 
and ethanol to generate a brown powder and yellow oil respectively.  
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5.3.1.2 Synthesis of (3-thioacetylpropyl)thio-diphenylphosphine oxide (15) 
The synthesis of compound 15 was carried out following the reactions showed in Scheme 
2. In a round bottom flask with a reflux condenser a mixture of diphenylphosphinic 
chloride (13) (0.71 ml) (3.8 mmol) with approximately (0.331ml) (15 mmol) from 3-
chloro-1-propanthiol in 5 ml DCM under reflux 7 hours. The corresponding a white 
precipitate has occurred (14) and it’s mp was 170 °C. Then the salt (14) (2 mmol) (0.6 
gm) was reacting with potassium thioacetate (0.34 gm) (3 mmol) in an aqueous ethanol 
(10 mL). The reaction mixture was left stirring over night at room temperature under 
nitrogen. TLC was used to monitor the progress of the reaction, using 10 % methanol: 90 
% DCM as a mobile phase. Compound 15 was obtained after extracted by using DCM 
(10 mL, 3 times) of the reaction mixture and all the extracts were combined and dried 
with MgSO4 and rotary evaporated. The precipitate formed 15 was collected by filtration, 
and purified by diethyl ether to yield a cream coloured powder. 
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5.3.1.3 Synthesis of (3-thioacetylethyl-N-methylamine)diphenylphosphine oxide (18) 
In a round bottom flask with a reflux condenser a mixture of diphenylphosphinic chloride 
(13) (0.71ml) (3.8 mmol) and approximately (1.63 ml) (15 mmol) from (2-
methoxyethyl)methylamine (16) in 5 ml DCM was reflux for six hours. The 
corresponding a a yellow precipitate occurred 17 as shown in Scheme 3. Then the salt 17 
(2mmol) (0.57gm) was reacting with potassium thioacetate (0.34 gm) (3 mmol) in 
aqueous ethanol (10 mL) and the reaction mixture was left stirring over night at room 
temperature under nitrogen. TLC was used to monitor the progress of the reaction, using 
10 % methanol: 90 % DCM as a mobile phase. Compound 18 was obtained after being 
extracted by DCM (10 mL, three times) of the reaction mixture and all the extracts were 
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combined and dried with magnesium sulphate anhydrous MgSO4, and rotary evaporated. 
The product 18 was purified by ethanol to give a yellow powder.  
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5.3.2 Synthesis of phosphine oxide gold nanoparticles derivatives in DMSO 
using NaBH4 as reducing agent 
The method for the synthesis of colloidal cationic phosphonium AuNPs with our ligands 
in DMSO in this chapter is reported for the first time and was developed, similarly as the 
previous methods [38]. 
 
In order to prepare the colloidal AuNPs in DMSO, solutions of the phosphonium ligands 
derivatives, including, 12A, 12D, 15 and 18 (0.57 mmol), (0.4 mmol), (0.6 mmol), (0.8 
mmol) respectively, were prepared in DMSO 25 ml. A solution of potassium 
tetrachloroaurate (0.8 mmol) in H2O (10 mL) was also prepared. Then both, ligands and 
gold salt solutions were mixed and vigorously stirred for roughly 4 hours at room 
temperature until the colure was changed from yellow to colourless. The reduction was 
carried out by adding 5 mL of a freshly prepared aqueous solution of sodium borohydride 
0.4 M to the DMSO mixture. In order to remove the excess of ligands in each one of the 
gold colloidal solutions prepared, liquid-liquid extractions were carried out using diethyl 
ether. 
5.3.3 Synthesis AuNPs using (3-thioacetylpropyl)di(p-tolyl)phosphine oxide, 
in aqueous solution using ascorbic acid as reducing agent 
Several attempts were made to functionalise AuNPs by 12D, 15 and 18 in aqueous 
solution with ascorbic acid without any good results, despite changed ligands / Au salt 
ratio and ascorbic acid concentration. A possible explanation is the poor solubility of 
these ligands in the aqueous solution. However, good results were collected when 12A 
was used to functionalised AuNPs in aqueous solution. The detailed synthesis of the 
AuNPs in aqueous solution with ascorbic acid was shown in experimental section / 
Chapter 4. 
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5.4 Results and Discussion 
ATR-FTIR, 31P, 1H NMR and ESI-MS techniques have been used to characterise all the 
ligands that were prepared in this Chapter before being used to functionalise AuNPs. 
Stability of 12 (A, D)-AuNPs, 15-AuNPs and 18-AuNPs are confirmed via using UV-
visible absorption spectroscopy and DLS. The measurements of AuNPs solution are taken 
regularly to see any changes such agglomeration / aggregation which may occur. 
5.4.1 Synthesis of 12A and 12D  
The synthesis of 12A and 12D are shown in Scheme1 including three stages with two 
intermediates. The first compound was generated by an alkaline hydrolysis of 
hydroxylpropylphosphonium salt (2) as the first stage to obtain (hydroxylpropyl)di-(p-
tolyl)phosphine oxide and (hydroxylpropyl)diphenyl-phosphine oxide (10 A, D) 
respectively [39]. The (10 A, D) were then treated with (48 %) HBr in order to generate 
the corresponding bromopropylphosphine oxide (11 A, D). 12A and 12D were then 
obtained via reaction of the latter (11 A, D, 2 mmol) with potassium thioacetate (3 mmol) 
in aqueous ethanol (5ml) at room temperature. The reaction mixture was left stirring 
overnight. The resulting products (12 A, D) were purified by trituration using diethyl 
ether. The final product was powder, brown coloured with a melting point at 119-120°C 
and yellow oil respectively. The yield was 70 % and 67 % respectively.  
 
When 12 A and 12D studied by ESI-MS in positive ion mode, ion corresponding to [M 
+Na]+ and [M + H]+ were observed at 369.10 m/z and 319.09 m/z respectively. Expected 
MW 12A and 12D are 346 g/mol, 318 g/mol respectively. 
 
IR spectrum of (12A) showed absorption bands at the regions of 725 – 720 cm-1 ( CH2), 
1738 cm-1 ( C=O), 1345 cm-1 (C-S-), 1217 cm-1 ( P=O) and 3100 – 3000 cm-1 ( CH-
Aromatic). NMR: 31P (CD2CL2) = 32.0 ppm, 1H NMR showed the distinctive chemical 
shift at  2.6 (2H, t, P-CH2-CH2-CH2),  2.3 (2H, t, P-CH2-CH2-CH2),  1.9 (2H, m, P-
CH2-CH2-CH2),  3.3 (3H, s, Ph-CH3),  3.4 (3H, s, Ph-CH3),  2.4 (3H, s, CO-CH3), 5.6 
(1H, s, CD2CL2 (solvent)) [40], and at 7.4 - 7.8 (8H, m, Aromatic H) ppm. Where IR of 
(12D) showed absorption bands at the regions IR spectrum at the regions of 699 – 710 
cm-1 ( CH2), 1739 cm-1 ( C=O), 1340 cm-1 (C-S-), 1217 cm-1 ( P=O) and 3100 – 3000 
cm-1 ( CH-Aromatic). NMR: (DMSO), 1H NMR spectrum gave signals at 3.6 (2H, t, P-
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CH2-CH2-CH2),  3.4 (2H, t, CH2-S-CO),  1.9 (2H, m, P-CH2-CH2-CH2),  2.4 (3H, s, 
CO-CH3),  2.5 (1H, s, DMSO-(solvent)) [41], and at 7.4 – 7.8 (10H, m, Aromatic H) 
ppm. 
 
The evidence to generate compounds 12A and 12D are occurring carbonyl group (C=O) 
in IR at 1738 cm-1 and 1739 cm-1 respectively. In addition, ( P=O) [42], stretching 
absorption appeared at 1217 cm-1 for 12A and 12D. In the same hand, it is noted that there 
are singles in 1H NMR at  2.4 for (3H, s, CO-CH3) in both 12A and 12D respectively 
which confirmed the literature [43, 44]. 31P NMR (CDCl3) analysis provided a single 
sharp peak at 32 ppm conforming producing the 12A compound. According to Jeong, K., 
et al., 31p has changed from 24 ppm to 39 ppm as result of oxidation and hydrogenation 
whereas peak shifted up-field and down-field respectively [42]. 
5.4.2 Synthesis of (3-thioacetylpropyl)thio-diphenylphosphine oxide (15) 
Synthesis NPs in organic solvents have been published for a wide range recently [45]. 
Stability of NPs, depend on the environment and are fundamentally adjusted by the 
ligands. It is well known that disulfide ligands enhanced colloidal stability of AuNPs 
compared to monothiols [45-47]. For example, it has been found that peptides with mono-
, dithiol and amine ended were more stable compared to peptides with no thiol groups in 
their structure. In addition, QDs containing S and Se were unstable in the case of presence 
of a mono-dentate thiol, while poly-thiol ligands were effectively employed as capping 
agents. Similarly the poly(methacrylic acid) (PMAA) was incorporated with a thioether 
group in order to the stabilising cobalt NPs to be stored for up to eight weeks in 
comparison when pure PMAA (without thioether group) used which were stable for up 
to 11 days. This indicates the significance of thiol groups in stabilising metal NPs [45, 
48, 49]. 
 
The synthesis of the compound 15 is shown in Scheme 2 in two stages. The first 
compound was generated via reaction of diphenylphosphinic chloride (13) with 3-chloro-
1-propanthiol to generate salt (14) as the first stage, which was reacting with potassium 
thioacetate in aqueous ethanol (5 ml) at room temperature. The reaction mixture was 
stirring overnight. The resulting product 15 was purified by trituration using diethyl ether. 
The final product was a powder, creamy coloured with a melting point at 219-220°C. The 
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yield was 77 %. When the compound studied by ESI-MS in positive ion mode, ion 
corresponding to [M + H]+ was observed at (351.06). Expected MW 15 is 350 g/mol. 
IR spectrum for 15 showed absorption bands at the regions of 722 cm-1 ( CH2), 1685 
cm-1 ( C=O), 1306 cm-1 (C-S-), 1191 cm-1 ( P=O) and 3070 – 3000 cm-1 ( CH-
Aromatic). NMR: 1H NMR spectrum gave signals at  5.6 (1H, s, CD2CL2 (solvent) [40]. 
 2.4 (3H, s, CO-CH3),  3.4 (2H, m, CH2-),  3.5 (2H, t, P- S-CH2-),  3.2 (2H, t, CH2-
S-CO) and at 7.4 – 7.8 (10H, m, Aromatic H) ppm. These protons are affected by an 
electron withdrawing groups such as phosphine oxide. Protons of a methyl group in 
(COCH3) has weaker shielding effect than those between thiol and thiol groups as 
expected [42, 50]. 
5.4.3 Synthesis of (3-thioacetyl-N-ethylmethylamine)diphenylphosphine oxide 
(18) 
Ligand-NP affinity is greatly dependent on the natural of NP surface and the ligand head 
group. Other sulfur functional groups such as thiocarbamates (O-thiocarbamates, 
ROC(=S)NR2) and S-thiocarbamates, RSC(=O)NR2) can be used as ligands for a variety 
of transition metal-based NPs. However, they have lower affinity toward the NP surface 
than thiols [45, 51, 52].  
 
Stabilisation of metal NPs by suitable organic groups such as amines derivatives have 
been widely used. The main difference between function by thiols or amines is the 
stability of the NPs. Metal NPs have bigger sizes when functionalised by amines than in 
the case of thiol ligands, as a result there is weaker bonding between NPs and amines. 
While, both of them can be complementary. For instance, peptides are linked to AgNPs 
via both the thiol and amine functions [53].  
 
The synthesis of compound 18 is shown in Scheme 3. The first compound was generated 
via reaction of diphenylphosphinic chloride (13) with (2-methoxyethyl)methylamine (16) 
to produce salt 17 as the first stage, which was reacting with potassium thioacetate in 
aqueous ethanol (5ml) at room temperature. The resulting product 18 was purified by 
trituration using diethyl ether. The final product was powder; yellow coloured with a 
melting point at 248-250 °C. The yield was 85 %. When studied by ESI-MS in positive 
ion mode, ion corresponding to [M-COCH3]
+ was observed at 290.13 m/z. While expected 
MW for 18 is 333 g/mol. IR spectra showed absorption bands at the regions of 726 – 720 
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cm-1 ( CH2), 1737 cm1 ( C=O), 1375 cm-1 (C-S-), 1177cm-1 ( P=O) and 3100 – 3000 
cm-1 (  CH-Aromatic). NMR: 31P (CDCL3) = 30.0 ppm. 1H NMR spectrum gave signals 
at  1.8 (1H, s, H2O of CDCL3 solvent) [40].  2.4 (3H, s, CO-CH3), 3.3 (3H, s, N-CH3), 
 3.0 (2H, t, CH2-N-),  3.5 (2H, t, CH2-S-) and at 7.6 - 7.8 (10H, m, Aromatic H) ppm.  
 
All these ligands were soluble in methanol, ethanol, DMSO, chloroform, and DCM. 31P 
NMR (CDCl3) analysis provided a single sharp peak at 30 ppm conforming producing 
compound 18. Sharp single peaks indicate the high purity of compound 18 [42]. As well 
as, carbonyl peaks showed at 1737 cm-1 (C=O asymmetric stretching) and 1728cm-1 (C=O 
symmetric stretching) and 716 cm-1 (C=O banding), with the C–N peak at 1373 cm-1 
suggesting complete 18 compound [42]. 1H NMR introduced further evidence to ensure 
compound 18 was produced. For instance, present 4H of (CH2)2 at  3.0-3.5 ppm, which 
was absent in start meterial (13). 
5.4.4 Stability of gold nanoparticles using (12A), (12D), (15), and (18) in 
DMSO by using NaBH4 and ascorbic acid as reducing agents 
Secondary phosphine oxide ligands were used as NP stabilisers, where synthesis of air-
stable and uniform AuNPs was generated using these ligands, which showed high 
catalytic activity. In a similar way, aryl secondary phosphine oxide presents a strong 
polarity of the P=O bond, and this ability is lost compared with aliphatic phosphine oxides 
ligands used to functionalise AuNPs [28]. The synthesised AuNPs primarily confirmed 
by a colour change from colourless to blushing red, were further systematically 
characterised by using UV/ Vis spectroscopy and DLS.  
 
AuNPs can be synthesised in different sizes and various media according to the desired 
application and can easily be functionalised with small drug molecules, polymers, and 
biomaterials for many potential applications [54]. AuNPs are chemically highly active 
towards biological molecules and have the potential to alter the fate of chemical reactions 
inside cells and modulate cellular signalling pathways and cellular function according to 
the size effect. The TEM imaging demonstrated that AuNPs were spherical in nature and 
can pass via the cell membrane due to their intrinsic properties to bind to carbon-bonded 
sulfhydryl (–C–SH or R–SH) group [55]. 
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In this Chapter, DMSO was used for dissolving these ligands due to their poor solubility 
in water. However, these hydrophobic ligands have shown their ability to functionalise 
and stabilise the surface of AuNPs in DMSO for more than 6 months. Their interaction 
with AuNPs surface, cause them to a penetrate into the lipophilic cell wall. Due to 
reduction conditions which could be removing acetyl groups from the original structure 
of the ligands to form Ph2P=O(CH2)3S
¯ in the solution which can form a strong covalent 
bond to the AuNPs surface [38].  
 
Several attempts of synthesising phosphonium AuNPs were carried out by using current 
ligands as the stabilising ligand with the two phase DCM / water method [38], but the 
attempts were unsuccessful despite adjusting synthetic conditions such as variety in 
concentrations of ligands and gold salts. In contrast, aggregations and coagulate to bulk 
gold occurred immediately after a reducing agent (NaBH4) was added to the mixture 
solutions. This aggregation may have been due to poor affinity to water or 
dichloromethane (DCM), the nature of the ligands not only caused stability of the AuNPs 
but also effected their properties such as solubility in polar or nonpolar solvents [56].  
 
Colloidal AuNPs were prepared in DMSO, a reduction of Au (III) to Au (0) was carried 
out in the presence of 12(A, D), 15 and 18, in DMSO, using NaBH4 as the reducing agent. 
With this reducing method using DMSO as the dispersing solvent, a red coloured 
colloidal solution of AuNPs functionalised with all ligands was obtained which stayed 
stable for nearly six months with no clear evidence for aggregation.  
5.4.5 UV-Visible and DLS studies 
Evidence for formation of colloidal AuNPs was observed in the UV- visible spectrum of 
the fresh and ageing solutions. A broad band was shown at 520 nm, which indicated a 
reduction of Au (III) to Au (0) and the size of the particles were in the range 5-10 nm 
according to the values for similar thiolate-capped AuNPs reported in the literature [38]. 
Furthermore, AuNPs were characterised by a peak at 520 – 535 nm in the UV–Vis 
spectrum which was 12 ± 2 nm [57]. Figures (5.1, 5.2, 5.3, and 5.4) show the stability of 
AuNPs at nearly six months. Evidence for the formation of AuNPs using the reduction 
method in DMSO was shown by UV-Visible spectroscopy technique. DMSO was used 
as the blank. Bands centred at 542 (Figure 5.1, see UV-visible spectrum at time = 0), 530 
nm (Figure 5.2, see UV-visible spectrum at time 0), 527 (Figure 5.3, see UV-visible 
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spectrum at time = 0), and 529 nm (Figure 5.4, see UV-visible spectrum at time 0). They 
were observed in the resulting UV spectra corresponding to the Burgundy AuNPs 
colloidal solutions prepared by 12A, 12D, 15 and 18 respectively.  
When the compared, the UV spectra of all the colloidal solutions of AuNPs functionalised 
with 12A, 12D and 15 in DMSO (Figures 5.1, 5.2 and 5.3, see UV-visible spectra at time 
= 0), they did not show a significant changes in the wavelengths. 
 
 
Figure 5.1. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 12A 
as protecting ligand. The different UV-visible spectra represent these AuNPs dispersed in DMSO at time 
= 0, 1, 2, and 3 months. Solutions prepared using different dilution factors. 
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Figure 5.2. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 12D 
as protecting ligand. The different UV-visible spectra represent these nanoparticles dispersed in DMSO at 
time = 0, 1, 2, 3, and 5 months respectively. Solutions prepared using different dilution factors. 
 
 
Figure 5.3. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 15 as 
protecting ligand. The different UV-visible spectra represent these AuNPs dispersed in DMSO at time = 
0, 1, 3, and 5 months. Solutions prepared using different dilution factors. 
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Figure 5.4. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 18 as 
protecting ligand. The different UV-visible spectra represent these AuNPs dispersed in DMSO at time = 
0, 1, 2, and 3 months respectively. Solutions prepared using different dilution factors. 
 
Figure 5.5. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 12A 
as protecting ligand using ascorbic acid as reducing agent. The different UV-visible spectra represent 
these AuNPs dispersed in aqueous solution at time = 0, 1, 3, 5, 7 and 8 weeks respectively. Solutions 
prepared using different dilution factors. 
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In this study, the refractive index of the solvent DMSO has not shown to induce a shift of 
the SPB of AuNPs as suggested in the literature [38]. Slight differences in wavelengths 
(542 and 530 nm 527 nm, respectively) can be observed when ligands change in structure 
(see Figures 5.1, 5.2 and 5.3). However, 18-AuNP gave a wavelength of 529 nm (Figure 
5.4) which contains a nitrogen atom instead of S atom in its structure has not offered any 
important differences with other ligands contain S atoms. However, time of stability was 
only a maximum of 3 months compared with 12A, 12D and 15-AuNPs, most of which 
are stable until the fifth month, this may be due to the tertiary amine containing ligand-
coated AuNPs which are no longer protonated and cause aggregation faster than ligands 
contain thiol as demonstrated in previous researches [58]. Existence a tolyl group in 12A 
has not a lot of advantages for stability AuNPs using sodium borohydride as reducing 
agent compared with other ligands, however, it is played significant difference for the 
stability of AuNPs when ascorbic acid has used as a reducing agent (see Figure 5.5), 
which is illustrated in this Chapter.  
 
The colloidal solutions of AuNPs functionalised using 12A, 12D, 15 and 18 as protecting 
ligands were all analysed by DLS as well. Then, particle sizes for samples were obtained 
by analysing at least 253 particles per sample from several results taken. All four AuNPs 
samples showed spherically shaped particles. AuNPs functionalised by ligand 15, which 
contains dithiol group has the smallest size in this Chapter with high stability for 5 
months, indicates to significant dithiol group to enhanced colloidal stability for AuNPs 
as shown in the literature [58, 59].  
 
Mean diameters obtained for the samples 12A, 12D, 15, 18-AuNPs analysed were as 
follows: 26 ± 3.5 nm, 10.2 ± 2.7 nm, 7.9 ± 1.7 nm, 9.6 ± 1.9 nm, respectively. It can be 
shown that the DLS results of AuNPs are similar to the corresponding UV-Visible spectra 
results, which confirmed each other. The corresponding UV-Visible spectrum showed 
that the SPB of AuNPs functionalized by 12A is centred at 542 nm, which is slightly 
larger than those where other ligands have been used to functionalise AuNPs in this 
Chapter and when NaBH4 was used as reducing agent. Similar size has been measured 
for 12A-AuNP when ascorbic acid was used as reducing agent instead NaBH4 and the 
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SPB was centred at 543 nm with a red shift is observed after 8 weeks at 550 nm indicating 
to lose the colloidal stability and form aggregates.  
 
However, the stability of 12A-AuNP used NaBH4 was greater than in case where ascorbic 
acid was used, whereas the 12A-AuNP was stable for nearly to 4 months with no obvious 
aggregation noted in UV and DLS results. While with ascorbic acid the solution stays 
stable just for 8 weeks with clearly in changing in its size, where it was 28 ± 1.5 nm (pink 
coloured) in initial preparation and became 47 ± 2 after 8 weeks, which indicated clearly 
to aggregation. In contrast, 12A-AuNP was 26 ± 1.5 nm in the case of NaBH4, and 
changed to 38 ± 2.2 nm illustrated to big size occurred after four months indicated to 
agglomeration (loosely bonded between NPs) but no evidence for any aggregation 
(strongly bonded between nanoparticles) was happened. These results confirming to big 
size of AuNPs solution can be produced when ascorbic acid used as reducing agent in 
comparison in the case of NaBH4 which produce a small sizes as mentioned in the 
literature [60].  
5.5 Conclusion 
Derivatives of phenyl phosphine such as triphenyl phosphine have been used to increase 
the stability of AuNPs via their phenyl range, which provides high stability to AuNPs as 
result to oxidation resistance to the phosphine itself. For this reason, phenyl phosphine 
derivatives have chosen in this chapter to functionalise AuNPs [61-63]. The fabrication 
of phosphine oxide AuNPs using (12A), (12D), (15), and (18) as protecting ligands which 
consider a newly masked thiol, also the reduction method in DMSO is reported here for 
the first time. 
 
It has been shown that these ligands are strongly stabilised to air oxidation, as a result, to 
strongly bound to the AuNPs surface, which may be due to high solubility in DMSO. 
Also, these ligands functionalised AuNPs gave good stability in DMSO due to poor 
solubility in aqueous solution. It is seen that, different sizes and different stability of 
AuNPs were noted with changing in structure of protected ligands, such as changing a 
phenyl group head in 12D to tolyl group in 12A. Also, present dithiol group in 15 and 
amine group in 18 showed a slightly different in the stability of AuNPs as demonstrated 
in the discussion section. All of these properties of these ligands would promise smart 
AuNPs in DMSO to be a new efficient agent for cancer targeting or photothermal therapy. 
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While in most cases of AuNPs that are not stabilised by these ligand molecules in water, 
due to often poor stability to external factors is observed, and only 12A has been 
generated in aqueous solution and ascorbic acid as reducing agent. Control of AuNPs size 
is an important factor for many applications, especially in bio-applications. 
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Chapter 6: Antimicrobial activities of novel gold nanoparticles 
agent against Escherichia coli and Staphylococcus aureus 
bacteria 
6.1 Abstract 
Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) are among the major 
cause of diarrheal infections for a human. These bacterial infections have been treated 
using different types of antibiotic drugs. In contrary, antibiotic resistant bacteria are the 
reason why new antimicrobials need to be developed. It is better to explore new 
antibacterial agents instead of tradition antibiotics with reduced unwanted side effects.  
 
In this Chapter, we used non-pathogenic bacteria including (E. coli NCIB 8277 and S. 
aureus ATCC 6538P) which do not cause disease for human or any another organism. 
The development of multi-drug-resistant (MDR) bacteria has become dangerous to 
community health [1]. Where, antibiotic resistant bacteria cause millions of infections. 
That leads to thousands of deaths every year in the U.S., according to a report published 
by the U.S [1]. 
 
Additionally, due to significant continuously decrease in the number of approved 
antibiotics in the past decade, an urgent need for discovery a novel antibacterial and 
strategies of treatment are an important goal nowadays [1, 2]. That is why AuNPs were 
chosen in this Chapter and used for this purpose. AuNPs exhibit novel chemical and 
physical properties due to their unique properties such as small size and high surface area 
to volume ratio. Currently, modern researches have been made an attempt to examine the 
bactericidal efficacy of AuNPs on bacteria in particle on non-pathogenic bacteria. 
 
The main achievement of this Chapter is presented the effect of functionalised AuNPs on 
non-pathogenic bacteria, where different affects were noted depending on different 
functional groups used to modify AuNPs. AuNPs with average size from 8.0-17 nm were 
used and surface modified using different ligands including 
triphenylphosphoniopropylthiosulfate (4C), (6-thioacetylhexyl)tris(2,4,6-trimethoxy- 
phenyl)-phosphonium bromide (8B), tris(2,4,6-trimethoxyphenyl)- 
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phosphoniopropylthiochloride (2C) and (3-thioacetylpropyl)tri(p-tolyl)phosphonium 
bromide (4A). 
 
Different doses of these AuNPs including four concentrations for the 4 µL (low dose) 
solution contained 0.181 µg AuNPs, 8 µL contained 0.363 µg AuNPs, 15 µL contained 
0.68 µg AuNPs, and 30 µL (high dose) contained 1.36 µg AuNPs, were utilised in order 
to check the antibacterial mechanism against two non-pathogen bacteria. Then, from 
these doses, the zones of inhibition were studied by the Agar well diffusion method and 
IC50 have been calculated. The stabilised AuNPs with high concentration (30 µL) 
exhibited excellent antibacterial sensitivity to both E. coli and S. aureus, which may be 
suitable choice of overcoming bacterial resistance, and should be tested on clinical 
isolates in the future. 
6.2 Introduction 
Staphylococcus aureus and Escherichia coli are the most common species of gram-
positive and gram-negative bacteria, respectively. Nowadays, the emergence of resistant 
S. aureus and E. coli strains against many of antibiotics has been observed worldwide. 
Many researchers have tried to develop new, effective antimicrobial reagents at low cost 
and free of resistance [3-5].  
 
Antimicrobial drug resistance is considered one of the most serious threats to global 
health to appear in the 21st century. For example, in the USA approximately 11,000 
people die annually as result to methicillin-resistant S. aureus (MRSA) infections [6]. 
Furthermore, there are over 1.3 million deaths each year due to Mycobacterium 
tuberculosis (TB) infections according to the World Health Organisation (WHO), with 
roughly 17,0000 deaths because of multidrug resistant (MDR) strains [7]. In September 
2013, extensively-drug resistant (XDR) TB accounted for 10 % of all MDR-TB 
diagnoses, with 92 countries having about one or more reported cases [8]. Additionally, 
about 300 million cases of severe illness have caused annually around the worldwide, due 
to bacterial infections, also the threat generated by bacterial infections have been 
increased by MDR bacteria due to infections [9]. For this reason, novel strategies are 
needed in order to discover antimicrobial compounds may contribute to the limited acute 
infection associated with E. col and S. aureus with avoiding any resistance drugs may 
happen. 
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Metal NPs have been utilised in therapeutic applications, and also in fundamental studies 
on bacterial behaviour. Furthermore, it has been pointed that, to various NPs causing to 
differences in toxic responses between Gram-negative (such as E. coli), and Gram-
positive (like S. aureus) bacteria. Many studies have shown a remarkably higher toxicity 
of NPs to Gram-positive bacteria compared to Gram-negative ones [10-13]. It is 
demonstrated that cationic AuNPs possessed toxicity against bacteria [9, 14]. In addition, 
NPs functionalised with non-antibiotic molecules have antimicrobial activity, which 
depended upon their composition on the surface. NPs surfaces displays a great potential 
for antimicrobial therapy [9, 15] 
 
The NPs have an antibacterial effect through their direct interaction with the cell and 
causing the weakness of basic metabolic functions [12, 16]. Also, nanomaterials are 
considered medical revolution recently, to give new promising drugs in order to control 
resistant bacteria infections [17, 18]. 
 
Biomedical applications of AuNPs have been rapidly increased with great attention 
currently, and broadly used as a catalyst for medical therapy, gene therapy, diagnostic 
and biological purposes [19-21]. For example, triphenylphosphinegold (I) complexes 
were used for the treatment of cancer tumours, psoriasis, HIV infections and also shown 
considerable antimicrobial activity [22]. 
 
AuNPs have to be valued in the development of antimicrobial agent. For instance, AuNPs 
functionalised with 5-fluorouracil (5-FU, an anti-leukemic drug) are used as antimicrobial 
activity against Gram-Positive such as (S. aureus) and Gram-Negative Bacteria such as 
(E. coli). Also, it investigated that, AuNPs have more effect on Gram Negative (E. coli 
and Pseudomonas aeruginosa) than Gram Positive (Staphylococcus aureus, Micrococcus 
luteus), which explained to their easier incorporation into bacteria of gram negative [23, 
24].  
 
Moreover, Lima, E., et al in 2013 illustrated that 5 nm sized AuNPs have used as an 
antimicrobial effect on E.coli and S. aureus types bacteria and reported that about 90-
95% of both bacterial colonies habitation have reduced due to AuNPs effective [24, 25]. 
In addition, the smallest NPs possess the strongest antimicrobial effect compared with  
larger size ones, due to their ability to interact easily with bacteria cells, where, bacteria 
are 50 up to 5000 times bigger than NPs [17].  
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In addition, it is noted that the average particle size of AuNPs decreased after conjugation 
with antibiotics such as ampicillin, this was suggested to be due to the combined reducing 
property of both antibiotics and borohydride during synthesis AuNPs [26]. Furthermore, 
AuNPs may be appropriate for the formulation of new types of bactericidal materials 
equivalent to the antibiotics against microbial infections. AuNPs with a small size offers 
a significant bactericidal effect due to become easier to interact with the microorganisms 
[27]. 
 
As mentioned earlier, antibacterial activity is also influenced by both concentration and 
size of metal nanoparticles. For example, 5 nm DNPs (diamond nanoparticles) were more 
effective against E. coli compared to 50 nm DNPs. TEM was used to observe the 
interactions of DNPs with bacterial cells. For instant, 5 nm DNPs accumulates on E. coli 
cells and aggregated cause affecting of the cell, also, bacterial membranes exhibit some 
defects compared to untreated control cells. However, the effect of 50 nm DNPs was 
much less obvious than 5 nm DNPs. Furthermore, larger aggregates, > 200 nm, do not 
have any effect on the bacteria cells because it cannot be penetrating inside cells [12]. 
Furthermore, the bactericidal properties of the AgNPs are size-dependent. For example, 
previous studies have confirmed that AgNPs have a diameter of ∼1–10 nm found inside 
of Gram-negative bacteria including E.coli due to their ability to interaction the bacterial 
cells [28]. 
 
In addition, the surface modifications and size of AuNPs can affect their antibacterial 
activity levels [29, 30]. AuNPs show low toxicity to biological systems compared with 
other NPs whether on the bacteria, animal, or human, as result of its unique elemental 
properties [31, 32]. 
 
AuNPs are generally used in both in vitro and in vivo investigation due to the uniqueness 
of their properties as mentioned early, also they have a high chemical stability compared 
to various nanomaterials, which have encouraged and attracted great interest in drug 
development [33, 34]. 
 
According to Zhou, Y., et al., low concentrations of citrate AuNPs have a larger inhibitory 
effect on bacterial growth in comparison to high concentrations and that maybe due to 
smaller aggregates exist at lower AuNPs concentrations and that causes further damage 
through interacting with bacterial cells.  
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It is useful to mention that, the effect of AuNPs on bacteria is dependent on their 
concentration and their affinities for cell surfaces [34, 35]. However, AgNPs have 
different effects with different concentrations on the E.coli in comparison with AuNPs, 
whereas the highest concentration has the biggest effect on the bacteria [24].  
 
In addition, functionalised AuNPs have biological and chemical activity with high 
antibacterial efficacy which reinforces their ability to target different bacterial structures 
[27, 36]. Using a stabiliser groups for NPs can be enhancing dispersion and steric 
hindrance [37], for instance, carbohydrates can act as a stabiliser and reducing agent in 
the same time which, leads to the creation of noble metal NPs, and conjugated water 
soluble NPs with potential antimicrobial applications [38]. As well, the gold(I)–PPh3 
complexes have shown noticeable biological activities: in specific, effective antimicrobial 
activities against Gram-positive bacteria [39]. 
 
It is noted that around 120 different mixed thiols–AuNPs conjugates were shown to be 
potent growth inhibitors of some types of bacteria including, E. coli, S. aureus, and 
Klebsiella pneumoniae. thiol–AuNPs conjugates AuNPs activity depended upon the 
specific combination of ligands attached to the particle surface, it is found that the AuNPs 
are more potent toward E. coli inhibition compare with several small-molecule 
antibiotics, like ampicillin (11 μM), gentamicin (1 μM), and chloramphenicol (12 μM). 
Moreover, it is shown that E. coli develops resistance against the small-molecule drug 
chloramphenicol far faster than the AuNPs [8]. 
 
In agreement with Chwalibog et al., it is investigated that, the interaction between S. 
aureus and AuNPs were trapped via biofilm and the substances which were released by 
cells and causing distortion of the cell wall [27, 40]. Also, AuNPs can bind closely to the 
surface of the microorganisms leading to visible damage to the cells membrane. It can 
lower the treatment period and reduce any side effects of drugs after coated with AuNPs 
and became highly effective against tested isolates [41]. All negative metal nanoparticles 
had cell damaging properties. For example, both AgNPs and PtNPs showed the properties 
of self-organization with the cells, where cells death was observed as a result to holes in 
the cell wall due to nanoparticles leading to leakage of cell contents. While, AuNPs did 
not create a system with microorganisms of self-organization, but it causes damage to 
fungal cells and bacteria due to interaction between the AuNPs and microorganisms [40]. 
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Taylor, E. and Webster, TJ, [42] illustrated that Nanostructures were more safely 
recommended as some microorganisms were extra resistance against traditional 
antibiotics than from NPs [17, 42]. As reported by Saha, B., et al., AuNPs conjugated 
with antibiotics had more antibacterial activity compared to the equivalent free antibiotics 
without AuNPs, and it is noted that the interaction between AuNPs and antibiotics were 
based on the adsorption of the antibiotic molecules on the surfaces of AuNPs. It is 
provided that AuNPs conjugated antibiotics were more stable compared to antibiotic free 
[26, 41].  
 
In the same way, spherical AuNPs (22–52 nm) functionalised by Cefaclor is used as an 
antibiotic drug used to treat some infections that is caused by bacteria. Cefaclor which 
contains a primary amine group which acts as both the capping agent and a reducing agent 
for the synthesis of AuNPs, leaving the β-lactam ring of Cefaclor available due to its 
activity against microbes. Antimicrobial results showed that Cefaclor reduced AuNPs 
have a strong antimicrobial activity against both Gram-negative (E. coli) bacteria and 
Gram-positive (S. aureus) compared to Cefaclor or AuNPs alone [43].  
 
Cell surfaces in Gram-negative bacteria are negatively charged as result of phosphate 
groups and carboxylate groups present in sugar acids. Cell surfaces in Gram-positive 
bacteria are also negatively charged, mainly due to the teichoic acid polymeric chains, 
that contain anionic phosphate groups in the glycerol phosphate repeat units [35, 44]. 
PAH functionalised AuNPs and were synthesised by polyelectrolyte. Poly(allylamine 
hydrochloride) (PAH) are positively charged and have high toxicity on the Gram-negative 
and Gram-positive bacteria. Charge densities of AuNPs are correlated directly to ligand 
densities. For instance, PAH-AuNPs have more positively charged surfaces and higher 
charge densities cause to stronger electrostatic interactions between cationic PAH-AuNPs 
and the surfaces of bacterial negatively charged [35].  
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6.3 Experimental Section 
6.3.1 Materials and Methods 
All chemicals, including used potassium tetrachloroaurate (KAuCl4 98%) and NaBH4 
were purchased from Sigma-Aldrich and Fisher Scientific Ltd. All solutions were 
prepared in deionised water. The experiments for antibacterial activity were carried out 
using different bacterial strains. Non-pathogenic bacteria including (E. coli NCIB 8277 
and S. aureus ATCC 6538P) were provided by the Department of Biosciences, Swansea 
University / UK. Nutrient media was utilised for evaluating bacterial growth in liquid 
broth culture. An absorbance of bacterial growth was measured by spectrophotometer at 
625 nm. 
6.3.2 Antibacterial activity 
The antibacterial activity of cationic phosphonium AuNPs against both Gram positive 
and Gram negative bacteria was confirmed in this Chapter. AuNPs were tested in four 
different dilutions and the results are summarised in following sections (see Table 6.1). 
To observe the minimum inhibitory concentration (MIC) of different cationic 
phosphonium AuNPs, MIC was defined as the lowest concentration of a chemical that 
prevents the visible growth of a bacterium, and the following procedure was carried out. 
A 96-well plate (Greiner-Dio-one) and absorbance measured using BioTek Synergy H1 
multi-mode reader spectrophotometer was used to measure the effect of AuNPs on the 
bacterial growth. Nutrient Broth Dehydrated powder was used to make the nutrient broth 
(NB) medium. All glassware and NB medium were sterilised by incubating for 24 h at 37 
°C.  
 
In the tubes (5mL) of the transparent NB media were filled and sterilised by autoclave for 
15 min at 121 °C [33, 45]. The bacterial culture was prepared via shifting a known Gram-
positive bacterial culture (S. aureus), and Gram-negative bacteria (E. coli) into different 
tubes including NB media. The positive control (test tubes having AuNPs with nutrient 
broth media without adding inoculum and a negative control (test tube having inoculum 
and nutrient broth media, free from AuNPs) incorporated in the experiment. The 
absorbance values for tubes (containing nutrient broth media, inoculum and AuNPs) were 
corrected by subtle acting discounting the corresponding absorbance values for the 
positive controls. All the experiments were confirmed in four replicates. 
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AuNPs solution were filtered through 30 µm Millipore syringe filters to remove any 
impurities before use, and were planned with four concentrations for the 4 µL (low dose) 
solution contained 0.181 µg AuNPs, 8 µL contained 0.363 µg AuNPs, 15 µL contained 
0.68 µg AuNPs, and 30 µL (high dose) contained 1.36 µg AuNPs. Four tubes of each 
dose were prepared and incubated at 37 °C for 24 h. The spectrophotometer was used to 
observe each micro-well plate which contains 200 µL from each tube [33].  
 
The micro-plate reader was provided with the values of optical density (OD) which were 
taken in absorption mode with obscured the bacterial growth for each sample, and then 
both mean and standard deviation were calculated based on four values of OD for every 
single sample. 
 
Diffusion method was used in order to calculate the inhibition zone via using Agar plates, 
both bacteria E. coli and S. aureus have developed on the nutrient Agar plate and 
maintained at 4°C overnight, and then used in the experiments [33, 46]. These two 
bacterial non-pathogens were coated over the Agar plate by using the sterile swab of 
cotton and these plates were left to dry. After that, four wells were bored by a sterile well 
cutter of 6.0 mm diameter in each agar plate. Subsequently, the suspension of AuNPs (30 
µL, 15 µL, 8 µL and 4 µL) was poured into wells named 1, 2, 3, and 4 respectively. The 
initial concentration of AuNPs is 45.34 µg/ml [33].  
 
The plates were placed to dry for 1 h in order to complete diffusion, and after that 
incubated at 37°C for 24 h. The zones of inhibition were measured. The mean surface 
area of each inhibition zone (mm) square millimetre was calculated from the mean 
diameter of each tested antibiotic. The percentage of increase in the inhibition zone areas 
for different AuNPs bacteria was calculated as (b2 − a2)/a2 × 100 where a is the inhibition 
zone without AuNPs, while b represents the inhibition zone in the presence of AuNPs 
[22]. 
6.3.3 Antimicrobial mechanism of cationic phosphonium AuNPs 
The experiments for antibacterial activity were carried out using two kinds of bacterial 
strains. Nutrient media was used in order to evaluate bacterial growth in liquid broth 
culture, and the spectrophotometer was used for measuring absorbance of bacterial 
growth at 625 nm, (the absorbance of AuNPs is zero when compared to suspended 
bacteria at 625 nm) [47]. The antibacterial effect of each dose of AuNPs was also 
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calculated statistically. Moreover, estimated value with the standard error were obtained. 
All the experiments were confirmed four times. Furthermore, all the data of experiments 
were also analysed through applying ANOVA test (p < 0.05). 
6.3.4 Synthesis of tris(2,4,6-trimethoxyphenyl)phosphoniopropylthio- 
chloride zwitterion (2C) 
In a round bottom flask with a reflux condenser a mixture of tris(2,4,6-trimethoxyphenyl)-
phosphine (1B) (3.8mmol) with 3-Chloro-1-propanethiol (15 mmol) were refluxed for 
five hours in acetonitrile (0.03 mmol) and the white precipitate (2C) was collected and 
re-crystallised from ethanol (see Reaction 1, Scheme 1).  
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6.3.5 Synthesis of (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)-
phosphonium bromide ligands zwitterion (8B) 
The syntheses of 8B is shown in Scheme 2 The compound was synthesised via reaction 
of tris(2,4,6-trimethoxyphenyl)phosphine (1B) (3.8mmol) with approximately bromo-
hexanol (15 mmol) in a round bottom flask with a reflux condenser were refluxed for five 
hours in acetonitrile (0.024 mmol), a brown solid was collected and re-crystallised from 
diethyl ether (Reaction 1, Scheme 2).  
 
The resulting salt (6B) was dissolved in hydrobromic acid (0.18 mmol, 10 ml) (48%) in 
a round bottom under reflux five hours (Reaction 2, Scheme 2). Then a mixture of -
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bromohexyl-tris(2,4,6-trimethoxyphenyl)phosphonium bromide (7B) (2 mmol) and 
potassium thioacetate (3 mmol) were stirring overnight at room temperature  in aqueous 
ethanol (1:1, 10ml) (Reaction 3, Scheme 2). The compounds looked as a brown 
precipitate 8B. TLC has used to monitor the reactions by using 20 % methanol: 80 % 
DCM (dichloromethane) as a mobile phase. The ligand 8B were achieved by DCM 
extraction of the mixture of reaction and purified by diethyl ether.  
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This Chapter is restricted to in vitro experiments. Our attention is focused on evaluating 
the results against non-pathogens of a small AuNPs with different compositions and 
surface modifications, also AuNPs were chosen to have slightly similar sizes and shapes. 
6.3.6 Synthesis gold nanoparticles  
AuNPs have synthesised with good controlled and well-characterized surface chemistries 
by using triphenylphosphoniopropylthiosulfate (4C) and (3-thioacetylpropyl)tri(p-
tolyl)phosphonium bromide (4A) compounds which have been mentioned in Chapters (2 
and 3 respectively). However, (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)- 
phosphonium bromide (8B) and tris(2,4,6-trimethoxyphenyl)-
phosphoniopropylthiochloride (2C) as protected ligands to preventing AuNPs from 
forming aggregates as will describe below. UV-Vis with DLS measurement were taken 
continuously to measure stabilities of AuNPs. The surface plasmon resonance of the 
AuNPs was recorded for nearly four months. The data were presented in Figures 6.9-6.12 
below. SPR of the particles remained stable to some extent throughout this period of time 
indicating that the AuNPs particles behaved in a quite stable manner when functionalised 
by these ligands. 
 
All these ligands have the same preparation technique. 2C and 8B were prepared in 
DMSO (0.16 mmol, 0.30 mmol respectively). The volume used for these solutions was 
30 mL. A solution of potassium tetrachloroaurate (0.12 mmol) in DMSO (10 mL) was 
also prepared. Then both, ligands and gold salt solutions were mixed and stirred. The 
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reduction was carried out by adding 5 mL of a freshly prepared aqueous solution of 
sodium borohydride (2.0 mmol) to the DMSO mixture. Liquid-liquid extractions were 
carried out by using diethyl ether in order to remove the excess of ligands in each one of 
the colloidal AuNPs solutions. 
6.4 Results and Discussion 
The AuNPs were characterised by UV-Vis spectroscopy and DLS. While, the ligands 
characterised by ATR, ESI-MS and NMR. The effect of AuNPs functionalised by 4A and 
2C on E.coli cells were found to be significantly more sensitive than AuNPs 
functionalised by 4C and 8B. 
 
However, all these compounds in this Chapter have enormous influence on S. aureus. 
AuNPs functionalised with 8B exhibited high antibacterial resistance to both Gram 
positive and Gram-negative bacteria, perhaps due to its chemical structure when 
compared to other compounds. E. coli was inhibited 13% at 0.181 µg and 24 % at 0.181 
µg (low dose), by AuNPs functionalised by 2C and 4A respectively. While, S. aureus 
was inhibited 12% at 0.36 µg (third dose), 14% at 0.68 µg (second dose) and 76% at 0.181 
µg (low dose), by AuNPs functionalised by 4C, 2C and 4A respectively, (see Figures 6.1, 
6.2). 
 
AuNPs stabilised by 4A exposed the accompanying reduction in growth. For example, at 
high concentration (1.63 µg-30 µL), the growth of S. aureus reducing to 93.71%. While 
76% was calculated, when low concentration (0.181 µg-4 µL) used. However, E. coli 
with a maximum reducing in its growth was 95.3% and was become up to 24.2% in low 
concentration (0.181 µg-4 µL), at the third concentration (0.363 µg-8 µL) was 79%. Thus, 
for complete inhibition of S. aureus, a smaller dose (0.181 µg-4 µL) is required, whereas 
the third dose (0.363 µg-8 µL) is required in case of E. coli, as Figure 6.8 shown. Based 
on these results, AuNPs functionalised by 4A exhibited highest antibacterial sensitivity 
to both kinds of bacteria.  
 
AuNPs functionalised by 2C has a slightly lower effect than 4A-AuNPs but more effect 
than 4C-AuNPs. In contrast, AuNPs functionalised with 8B had no influence on both 
types of bacteria, maybe due to increase in length of the side chain in this compound 
compared with above ones. Percentage influence of AuNPs was different according to a 
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variety of ligand stabilisers as is given in Table 6.1. Selvaraj, V., and Alagar, M, found 
that AuNPs citrate-capped offer 27 mm for the inhibition zone of E. coli [48]. In contrast, 
Nazari, ZE., et al., counted 14 mm and 13 mm for the inhibition zones for both E. coli 
and S. aureus respectively [22]. Whereas Shamaila, S., et al., revealed that the inhibition 
zones were different with a variety of AuNPs size, for instance, AuNPs with size 7–34 
nm against E. coli and S. aureus were ~31 mm and 22 mm respectively. Inhibition zones 
were about 35 mm and 25 mm in AuNPs sized 20–40 nm, respectively [33]. 
 
In this Chapter, the zone of inhibition for AuNPs stabilised by compounds 4C, 2C and 
4A against S. aureus were found to be 16, 8.5 and 23 mm respectively, in contrast, the 
inhibition zone was 22 mm and 21 mm on E. coli for AuNPs stabilised by compound 2C 
and 4A respectively. However, AuNPs were stabilised by compounds 4C and 8B did not 
have any remarkable effect on E. coli. These differences appear to be based on the basic 
distinction between the ligands coated of AuNPs which may be leading to different 
affinity of AuNPs to cells of the bacterial species used. According to Rotello, VM., et al., 
uptake and removal of NPs in cells / tissues are reliant on upon their physiochemical 
properties. For instance, cationic NPs have higher uptake and a slower rate of exocytosis 
in cells compared to their anionic NPs [9].  
 
Moreover, AuNPs functionalised with 3-mercaptopropionic acid (MPA) have the lowest 
toxicity on bacterial strains, while AuNPs functionalised with PAH have the highest cell 
death due to its strong affinity between bacteria cell and the cationic polyelectrolyte 
coating on this PAH–AuNPs. This evidence may guide future studies of ligands 
functionalised NPs [35]. Cationic AuNPs might be effective adjuvants to identified 
antibiotics, as they were shown to modify the cell surface; also, the multi-drug-resistant 
infections can be treated via surface-binding NPs [49]. Positively charged molecules have 
been chosen as ligands of AuNPs in order to increase the permeability of the outer 
membrane of bacteria [47]. 
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Figure 6.1. Percentage of inhibition of S. aureus, which treated by 4C-AuNPs, 8B-AuNPs, 2C-AuNPs, 
and 4A-AuNPs at different, concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and 
(0.181 µg-4 µL) respectively. 
 
Figure 6.2. Percentage of inhibition of E. coli, which treated by 4C -AuNPs, 8B- AuNPs, 2C-AuNPs, 
and 4A-AuNPs at different, concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and 
(0.181 µg-4 µL) respectively. 
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Figure 6.1 and 6.2 show analysis results of percent’s inhibition for all AuNPs against S. 
aureus and E. coli. The inhibition percentages were zero when 8B-AuNP tested on both 
of bacteria. While, significant increase inhibition percentages of S. aureus and E. coli 
showed when 4A-AuNP tested. 
 
According to Kirby-Bauer test for antibiotic susceptibility, the zone diameter 
interpretation (see Table 6.1) is as follows: (R) Resistant: 13 mm or less; (I) Intermediate: 
14-16 mm; and (S) Susceptible: 17 mm or more [50]. From Table 6.1, E. coli isolate is 
reading as susceptible to 4A-AuNPs and 2C-AuNPs at the high and second dose. 
However, S. aureus is reading as resistant to 2C-AuNPs and as intermediate to 4C- 
AuNPs. 
 
For 4A-AuNPs, both E. coli and S. aureus were susceptible at the high and second dose. 
In addition, E. coli resisted at different concentrations of 4C-AuNPs, whereas the growth-
inhibitory effects on S. aureus were mild. 8B-AuNPs has shown no activity toward both 
E. coli and S. aureus. 
 
In previous studies, reduction of growth inhibition effect of AuNPs on different types of 
bacteria was reported [51, 52]. In this study, it found that 2C, 4C, 4A and 8B-AuNPs with 
sizes in range from 8-17 nm and NaBH4 used as reducing agent have remarkable effect 
on the E. coli and S. aureus bacteria as mentioned above. While the effect of 15 nm citrate 
capped AuNPs on the growth of E. coli was indicated that there was no important toxic 
effect caused by AuNPs as mentioned in the literature [52]. According to the literature, 
sizes based toxicity of AuNPs are reported, it has been found that smaller particles possess 
some degree of toxicity more than the bigger particles. It was expected that smaller NPs 
can easily penetrate in the bacteria cells and affect their growth [53], and that confirms 
our results in this Chapter which showed bacteria growth were affected by small AuNPs. 
 
Furthermore, current results showed that bacterial growth curve decreased constantly 
with increasing AuNPs concentration. Also, AuNPs with the highest concentration 
showed almost slightly growth of E. coli NCIB 8277 and S. aureus ATCC 6538P. In 
addition, S. aureus and E. coli display clearly different inhibition zone according to 
variety of AuNPs with different concentration as explained in current study (see Figures 
6.3 and 6.4). 
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Table 6.1. Illustrates calculation of zone of inhibition of two types of bacteria at different concentrations, 
(1.36 µg-30 µL, 0.63 µg-15 µL, 0.363 µg-8 µL, 0.181 µg-4 µL) of 4C-AuNPs, 8B-AuNPs, 2C-AuNPs, 
and 4A-AuNPs.  
Micro 
Organism 
Organism 
Category 
Concentration 
µg/ml  
Control 
Zone of inhibition (mm). 
4C- 
AuNPs 
8B -
AuNPs- 
2C -
AuNPs 
4A- 
AuNPs 
Dose 
µl 
Au. µg 
S. aureus Gram 
Positive 30 1.36 0 16 Nil 9 23 
15 0.68 0 13 Nil 4 19 
8 0.363 0 10 Nil Nil 16 
4 0.181 0 7 Nil Nil 14 
E.coli Gram 
Negative 30 1.36 0 Nil Nil 21 22 
15 0.68 0 Nil Nil 18.5 18 
8 0.363 0 Nil Nil 9 17 
4 0.181 0 Nil Nil 5 9 
 
 
 
The toxicity of the NPs on the bacteria is believed to be caused as a result of interaction 
between NPs and bacteria cells, where dissolved ions of NPs can easily penetrate the cell 
membrane and showing their toxicity in the cytoplasm [54, 55]. 
 
Toxicity of the AuNPs was supported by the data presented in this Chapter, which 
demonstrated significant inhibition of the bacteria growth after the high concentration of 
AuNPs applied.  
 
Several MIC and zone diameter values confirmed each other and from the data presented, 
the diameters of inhibition zones (in millimetre) were calculated based on the content of 
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AuNPs producing clear zone of inhibition at different concentration after 24h at 37°C 
[22], and it appears that no antibacterial activity was observed for 8B-AuNPs at different 
concentrations against both bacteria. However, 4A-AuNPs have the higher antibacterial 
effect on E. coli and S. aureus and the inhibition zones were 22 mm and 23 mm at high 
concentration, respectively. While at lower concentration (0.181 µg/ 4µL) were 9 mm 
and 14 mm. 2C-AuNPs had a slightly smaller zone of inhibition than 4A-AuNPs and was 
21 mm on E. coli at high and 5 mm at low concentrations (0.181 µg/ 4µL), but the results 
are not signiﬁcant for the zone of inhibition in the case of S. aureus which showed only 
9 mm and 0.2 mm at high and third concentrations with no effect at lower concentration. 
The maximum inhibition zones are an extra support to confirm the data of MICs 
calculations as illustrated in Table 6.1 and Figures 6.3-6.8.  
 
 
 
 
 
Figure 6.3. An antibacterial activity of four kinds of AuNPs against S. aureus. Where A = 4C-AuNPs, B 
= 8B-AuNPs, C = 2C-AuNPs and D = 4A-AuNPs. 1, 2, 3, 4 are represent, concentrations (1.36 µg-30 µL, 
0.63 µg-15 µL, 0.363 µg-8 µL, 0.181 µg-4 µL respectively).  
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Figure 6.4. An antibacterial activity of four kinds of AuNPs against E. coli, where A = 4C-AuNPs, B = 
8B-AuNPs, C = 2C-AuNPs and D = 4A-AuNPs. 1, 2, 3, 4 are represent, concentrations (1.36 µg-30 µL, 
0.63 µg-15 µL, 0.363 µg-8 µL, 0.181 µg-4 µL respectively). 
 
 
 
Figure 6.5. An antibacterial activity of 4C-AuNPs against E. coli and S. aureus bacteria, at different, 
concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and (0.181 µg-4 µL) respectively. 
Where, (*** represents p ≤ 0.0001), (** represents p ≤ 0.001), (*represents p ≤ 0.05).  
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Figure 6.6. An antibacterial activity of 8B-AuNPs against E. coli and S. aureus bacteria, at different, 
concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and (0.181 µg-4 µL) respectively. 
 
 
Figure 6.7. An antibacterial activity of 2C-AuNPs against E. coli and S. aureus bacteria, at different, 
concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and (0.181 µg-4 µL) respectively. 
Where (*** represents p-value ≤ 0.0001), (** represents p ≤ 0.001), (*represents p ≤ 0.05). 
 
Figure 6.8. An antibacterial activity of 4A-AuNPs against E. coli and S. aureus bacteria, at different, 
concentrations (1.36 µg-30 µL), (0.63 µg-15 µL), (0.363 µg-8 µL), and (0.181 µg-4 µL) respectively. 
(*** represents p-value ≤ 0.0001), (** represents p ≤ 0.001). 
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Due to the high surface to volume ratio of NPs, allows incorporation of plentiful 
functional ligands, enabling multivalency on the surface of NP in order to enhance 
interactions to target bacteria. For example, NPs conjugated with known antibiotics in 
order to affect MDR bacteria. The antibiotic molecules can be infused with NPs via 
noncovalent or covalent bonds interactions [1, 23]. 
 
As stated with Li, X., et al., modification of the functional groups on the surface of the 
cationic monolayer-protected AuNPs (2 nm) increasing it’s effective against clinical 
isolates, such as Gram-negative (E. coli CD-2) and Gram-positive (S. aureus CD-489), 
and showed no evidence for bacterial resistance. AuNPs functionalised by different 
cationic ligands with changing in chain length, nonaromatic and aromatic characteristics 
with the hydrophobic end group offer antimicrobial efficacy. For example, the results of 
2 nm AuNPs with cationic surface properties suggested that cationic AuNPs could be 
used as antimicrobial agents [1]. 
 
Herein, the effects of functionalised AuNPs, on non-pathogenic bacteria were obvious. 
Different affected were noted based on different functional groups used. For instance, 
with changing aromatic groups from benzene in 4C-AuNP, to toluene in 4A-AuNP, and 
to trimethoxy-benzene in both 2C-AuNP and 8B-AuNP, different results collected. As 
well as, length carbon chain could offer variety effects on the bacteria. A strong 
relationship was observed between the structure of AuNPs and their bio-activities. For 
instance, from Figures 6.3-6.8, the biggest effect on E coli and S. aureus was from AuNP 
functionalised by 4A (see Figures 6.3, 6.4 and 6.8) which was harmfulness to both 
bacterial cells especially at high concentration (30 µL). The 4A contains three toluene 
groups in its structure, which might contribute to increase the bioactivity for AuNPs.  
 
The second effect was noted from 2C-AuNP, which exhibit clear influence on E coli more 
than in the case of S. aureus. It is possible that the structure of the bacteria is also a factor. 
2C-AuNP contains trimethoxy-benzene with 3 carbon chain length. While AuNP 
functionalised by 8B-AuNP, which also contains trimethoxy-benzene in its structure. 
However, 8B-AuNPs has not offer any effect on both types of bacteria maybe because it 
contains 6 carbon chain length rather than three carbon atoms like 2C-AuNP (see 
Schemes 1, 2 and Figure 6.6).  
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AuNPs functionalised by 4C has more effect on S. aureus than in the case of E. coli, 
where in the case E coli has not any obvious effect despite different concentrations used 
(see Figures 6.5 and 6.4). In contrast, in the case of the S. aureus shown slightly effect at 
high dose (30 µL) and second dose (15 µL), but no effective showed at the third (8 µL) 
and low dose (4 µL) as illustrated in Figures 6.3 and 6.5).  
 
Consequently, AuNPs with different functionalised ligands showed different effects on 
the bacteria growth, which confirm that surface chemistry of the AuNPs is a very 
important factor in terms of the effect of the AuNPs on the bacterial cells. Moreover, that 
explained why the bacteria were resisted and not affected when treated by 8B-AuNP in 
comparison with other AuNPs in this Chapter as mentioned. 
6.4.1 Characterisation of the cationic AuNP functionalised by tris(2,4,6-
trimethoxyphenyl)phosphoniopropylthiolchloride zwitterion (2C) and 8B by 
using UV-Visible and DLS studies 
Evidence of the formation of AuNPs functionalised by 2C was shown by UV-Visible 
spectroscopy technique.in Figure 6.9. Quartz cell containing DMSO served as a 
reference, bands centred at 540 nm. 
 
According to DLS results, mean diameters obtained for the AuNP functionalised by 2C 
analysed was 17.8 ± 2 nm and changed after 14 weeks to 39.2 ± 3 nm which confirm the 
UV result as shown wavelength at 540 nm and at 555 nm at time = 0 and 14 weeks 
respectively. In addition, the evidence of the formation of AuNPs functionalised by 8B 
using the reduction method in DMSO was shown by UV-Visible spectroscopy 
technique.in Figure 6.11. Using the DMSO as the blank, bands centred at 522 nm. These 
results are also in agreement DLS analysis of AuNPs. 
 
For mean diameters obtained for the 8B-AuNPs analysed were the followings: 9.2 ± 0.9 
nm (Figure 6.12) and changed to 20.4 ± 1.7 nm after 11 weeks. DLS and UV-vis show 
that all the AuNPs in this Chapter are round and spherical in shape and in a mono-
dispersional state without clear obvious aggregations. That is due to electrostatic 
repulsion and prevents aggregation of AuNPs. According to UV-Visible spectrum results, 
which showed that the SPB of AuNP functionalised by 2C is centred at 540 nm and 
convert to 555 nm after about 14 weeks, and from 522 nm to 524 nm in 8B after 11 weeks 
may be due to increase the particle size but there is no evidence for aggregation. 
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Figure 6.9. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 2C as 
protecting ligand. The different UV-visible spectra represent these Au nanoparticles dispersed in DMSO 
at time = 0, 2, 4, 6, 8, 10, 12 and 14 weeks. 
 
 
Figure 6.10. DLS for AuNP functionalised by 2C. Sizes increased as time increased 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
400 450 500 550 600 650 700 750 800 850 900
A
b
so
rb
a
n
ce
Wavelength (nm)
Time = 0
2 Weeks
4 Weeks
6 Weeks
8 Weeks
10 Weeks
12 Weeks
14 Weeks
0
5
10
15
20
25
30
0 3 0 6 0 9 0 1 2 0 1 5 0 1 8 0
N
u
m
b
er
 (
p
er
ce
n
t)
Size (d.nm)
Time=0
Time= 2 Weeks
Time= 4 Weeks
Time= 6 Weeks
Time= 8 Weeks
Time= 10 Weeks
Time=12 Weeks
Time =14 Weeks
 188 
 
 
Figure 6.11. UV-visible absorption spectra of the colloidal solutions of AuNPs functionalised using 8B 
as protecting ligand. The different UV-visible spectra represent these nanoparticles dispersed in DMSO at 
time = 0, 1, 2, 4, 7, 9 and 11 weeks. 
 
Figure 6.12. DLS of AuNPs synthesised using 8B as protecting ligand in DMSO, and corresponding 
particle size histograms. 
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It is noted that from the literature, the SPR peaks of the AuNPs with a diameter of ~15 
nm showed the wavelength at 520 nm and AuNPs with a diameter of ~30 nm exhibited 
the absorbance peak at wavelength 524 nm [56]. 
6.4.2 Characterisation of the cationic phosphonium ligands 
Several analytical techniques such as TLC, ATR-FTIR, NMR, and ESI-MS techniques 
were used in order to characterise the ligands in this Chapter before using as protecting 
ligands for AuNPs.  
6.4.3 Tris(2,4,6-trimethoxyphenyl)phosphoniopropylthiochloride zwitterion 
(2C)  
The synthesis of 2C is shown in Scheme 1. IR, NMR, ESI-MS have used for confirming 
this ligand is illustrated below. 
 
IR spectrum showed absorption bands at the regions of 800 – 829 cm-1 ( CH2), 2565 cm-
1 ( SH), 1593 cm-1 ( C-O), 1337 cm-1 (C-S-) and 3138–3065 cm-1 ( CH-Aromatic). 
NMR: 1H NMR = (CDCL3) spectrum gave signals at 3.4 (2H, t, -CH2-P),  3.3-3.7 (27H, 
s, Ph-OCH3),  2.4 (2H, m, -CH2-),  2.1 (2H, t, -CH2-SH),  1.5 (1H, s, SH), and at 6.3 
– 6.5 (6H, m, Aromatic H) ppm. ESI-MS 607.20 [M-Cl] +. The yield of 2C was 85%. 
Melting point: 120-122 °C. 
6.4.4 (6-thioacetylhexyl)-tris(2,4,6-trimethoxyphenyl)phosphonium bromide 
zwitterion (8B)  
IR spectrum for 8B showed absorption bands at 800–829 cm-1 ( CH2), 1739 cm-1 ( 
C=O), 1595 cm-1 ( C-O), 1366 cm-1 (C-S-), 1146 cm-1 ( P=O) and 3138–3065 cm-1 ( 
CH-Aromatic). NMR: 1H NMR = (CD2CL2) spectrum gave signals at at  3.5 (3H, s, CO-
CH3),  4.0 (2H, t, P- CH2CH2-CH2-), 3.3 (2H, t, -CH2-SCO),  2.5 (2H, m, CH2-CH2-
SCO),  2.0 (2H, m, CH2CH2-CH2-),  1.8 (2H, m, -CH2-), 1.4 (2H, m, -CH2-),   5.6-
6.2 (27H, s, Ph-OCH3)  and at 9.7 – 10.6 (6H, m, Aromatic H) ppm. ESI-MS 691.23 [M 
– Br]+ .The yield of 8B was 75%. Melting point: 206-208 °C. 
 
The structure of compound 2C was confirmed from its correct spectral data. Thus, IR 
spectroscopy detects the vibration characteristics of chemical functional groups of the 2C 
showed absorption band at the regions 2565 cm-1 which confirm entry of thiol group ( 
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SH) to tris(2,4,6-trimethoxyphenyl)phosphine (1B). Also, there was a peak at 1593 cm-1 
bond which corresponded to an ether group (C-O). Also (C-S-) stretching vibration has 
been assigned to a weak band in the region 621 cm-l in 2C [57, 58]. For ligand 8B, there 
were peaks at 1591 cm-1 and 1366 cm-1 for ( C-O) and (C-S) respectively. The important 
group to confirm conform 8B is a present peak at 1739 cm-1 in IR spectra to indicate to a 
carbonyl group ( C=O) [58]. 
 
1H NMR spectra provided further evidence for completed reaction for 2C which 
confirmed the existence thiol band (1H, s, SH) in 2C, which appear at δ 1.5 in CDCl3 
[59]. In addition, present twelve protons -(CH2)6 attached to the aromatic ring at chemical 
shifts from 1.4 - 4.0 ppm to produce compound 8B, due to absence this group in the start 
material tris(2,4,6-trimethoxyphenyl)phosphine (1B). Furthermore, final products 2C and 
8B were confirmed by ESI-MS, and ions corresponding to [M-Cl]+ and [M-Br]+  were 
observed at ESI-MS 607.20 m/z for 2C and 691.23 m/z for 8B, while (expected MW 2C 
and 8B are 642.5 and 770.9 g/mol respectively [60]. Based on these spectral data, 
compound 2C and 8B were assumed to be tris(2,4,6-trimethoxyphenyl)- 
phosphoniopropylthiochloride and (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)- 
phosphonium bromide zwitterion respectively. 
6.5 Conclusion 
In conclusion, novel cationic phosphonium AuNPs with different capping agents were 
synthesised using methods described in the experimental sections and thoroughly tested. 
The overall aim was to study the effect of AuNPs on the growth of two kinds of bacteria. 
It has been confirmed that our AuNPs display significant antibacterial potential for the 
both Gram negative bacteria (E. coli) and the Gram positive bacteria (S. aureus) via 
changing AuNPs surface chemistry. AuNPs with similar sizes exhibited different 
inhibitory effects at the same initial concentration and different doses. The minimum 
inhibitory content was determined as the lowest content of AuNPs. In addition, the MIC 
calculations of these AuNPs were also supportive of the results that calculated from the 
inhibition zones and confirm each other. 
 
AuNPs functionalised by different ligands display different results on the same type of 
bacteria. For example, AuNPs functionalised by 4A have the biggest effect on both kind 
of bacteria compared to other AuNPs used. As result to present tolyl groups in 4A–AuNP 
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structure, this increased its effect against the bacteria. 2C and 8B have similar chemical 
structure, where both of them have methoxy benzene groups instead toluene, but AuNPs 
functionalised by 2C was more effective than AuNPs functionalised by 8B which has 
similar chemical structure except carbon chain length which contains 6 carbon atoms in 
8B-AuNP rather than 3 in comparison with 2C structure. 4C-AuNP contains benzene 
groups in its structure showed a significate effect on the S.aureus with no effect on E.coli. 
 
Overall, from this present study, it can be concluded that certain cationic phosphonium 
AuNPs are effective toward two non-pathogenic bacterial strains causing bacterial growth 
inhibition. Moreover, based on recent findings, it proposes that, because these AuNPs are 
effective on two non-pathogenic bacteria (E. coli NCIB 8277 and S. aureus ATCC 
6538P), so they maybe offer similar results if they tested on clinical isolates in the future. 
Maybe to contain promise to reduce diseases in the future via reducing or overcome 
bacterial resistance. Could also, be used for the targeted delivery of traditional 
antibacterial substances to pathogenic bacteria as a novel antibacterial agent. 
 
AuNPs could act as an effective antibacterial agent and can be proved as an alternative 
factor in order to develop new antibacterial drugs to fight resistance problem. Also, 
AuNPs have been used to be an alternate and smart choice for drugs delivery and cancer 
therapy due to their functional nature and less side effect compared to antibiotics. 
 
The current study is a preliminary test. Quantities test growth curves are needed in order 
to be more accurate. Mechanism of interaction AuNPs with bacteria also needs more 
study in the future. An effective of theses AuNPs on other different kinds of bacteria must 
also, be taken into consideration. 
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Chapter 7: Conclusion of thesis 
7.1 Conclusions and future work 
The results presented in this thesis were conducted to assess the properties and stability 
of colloidal AuNPs manufactured for the potential use in alternative biorecognition and 
drug delivery systems. The phosphonium groups contained within the ligand have a 
variety of advantages such as ease of synthesis and biocompatibility making them ideal 
candidates for bio-applications. Phosphonium AuNPs with sizes between 5 nm -11 nm 
were obtained via the reduction of potassium tetrachloroaurate (KAuCl4) in DMSO and 
in a two-phase DCM / H2O system with presence of the protecting ligands. Some our 
phosphonium-AuNPs ligands were shown to have high affinity toward the aqueous phase. 
While other ligands that have methoxy or tolyl head group have not shown any affinity 
for the aqueous phase which led to choosing and alternative compatible solvent such as 
DMSO. UV-visible spectroscopy, DLS and TEM were used to measure the stability of 
these AuNPs for up to 6 months.  
 
In addition, from the synthesis of functionalised AuNPs, it was clear to see that the most 
versatile ligands were those containing methoxy groups with alkyl chain lengths of both 
three and six such as (3-thioacetylpropyl)tris(2,4,6-trimethoxyphenyl)phosphonium 
bromide and (6-thioacetylhexyl)tris(2,4,6-trimethoxyphenyl)phosphonium bromide 
compounds ligands produced stable AuNPs, and it was also possible to synthesis AuNPs 
by using sodium borohydride as a strong reducing agent and  ascorbic acid as a weaker 
reducing agent. Methoxy is an ideal moiety to incorporate into a ligand as it is a donator 
group and contributes electrons to the phenol group. This changes the stability of the 
AuNPs within a solution as the electronegative charge is shifted. The shorter chain ligands 
synthesised produced a more crystalline structure that was easily soluble in water in case 
ligands contain phenyl or tolyl head groups such as (3-thio-
acetylpropyl)tri(phenyl)phosphonium bromide and (3-thioacetylpropyl)tri(p-tolyl)- 
phosphonium bromide making these ligands ideal for use in biological media. 
 
The data collected with regards to the stability of AuNPs over time supported the results 
proposed in the published literature. It was clear that over the 6 months’ period, the 
stability of some of the AuNPs remained constant with no shift in the peak absorbance 
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wavelength observed using UV-Vis. As well as, it is imperative that the AuNPs remain 
stable within the body over longer time for therapeutic reasons. As a results of the pH 
stability study in this thesis, it was proposed that the optimum pH of the (3-
thioacetylpropyl)triphenylphosphonium bromide, (3-thioacetylpropyl)tri(p-tolyl)-
phosphonium bromide and (3-thioacetylpropyl)tris(2,4,6-trimethoxyphenyl)- 
phosphonium bromide showed the AuNPs produced stable within pH 9.2 and pH 5.1 with 
no sign of degradation or aggregation. The stability of the solution at this pH was 
measured using UV-Vis data which showed that the peak absorbance wavelength 
observed did not shift, suggesting a consistent size of AuNPs monodispersed within the 
solution. The stability of the AuNPs elucidated in the acidic pH study suggests that despite 
the weakly acidic nature of tumorous tissue, it would be possible for the manufactured 
nanoparticles to selectively enter the cells required and remain stable for a suitable time 
period for insure a treatment to be completed. This is due to the hydrophobic nature of 
the synthesised ligands introducing an affinity with the lipophilic cell walls. Not only do 
the hydrophobic and cationic properties of the surface coating of the AuNPs aid cell 
penetration, but it also provides a pathway for ion exchange within the biological media 
of the cell. 
 
The evidence presented for the stability of functionalised AuNPs at lower pH is 
significant as it is well documented that the pH of cancer cells is weakly acidic. In 
addition, AuNPs in present study with the similar size exhibited different inhibitory 
effects toward both Gram-negative bacteria E. coli and the Gram-positive bacteria 
Staphylococcus aureus at the same concentration. Also, study was investigated both the 
bacterial growth and the inhibition effect of the AuNP, where the effect of both size and 
surface chemistry of the AuNPs on the bacteria was clearly noted. In addition, it was 
found out that, AuNPs with different coating agents of similar final concentrations 
showed different effects on the bacteria 
 
From this present study, it can be deduced that AuNPs could act as an effective 
antibacterial agent and can be proved as an alternative factor for development of new 
antibacterial drugs with reducing resistance problem and side effects. Whilst the work 
presented was conducted in vitro, future work should include in vivo biological test via 
cellular internalisation of the phosphonium ligands coated AuNPs. This analysis could be 
achieved using a biophysical technique, such as flow cytometry technique which is 
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usually employed in the diagnosis of various health disorders where the cells are normally 
suspended in a stream of fluid and passed by an electronic detection apparatus. In order 
to prepare the samples for cytometry analysis, our cationic phosphonium AuNPs are 
planned to be internalised by incubation. Functionalised AuNPs have of a significant 
importance and expected to have a great impact in different areas in particular in the 
biological and biomedical applications. 
 
Finally, there are seven-step process that makes this research unique and different from 
many other studies is the described below:  
 
1- Synthesis novel protecting ligands have different properties toward AuNPs with fully 
characterisation. 
 
2- Synthesis of novel cationic phosphonium AuNPs dispersible in water and 
dimethylsulfoxide (DMSO) for their potential use in biomedical applications is outlined. 
 
3- Due to poor solubility of some ligands in water, DMSO as biocompatible solvent was 
used as solvent, because it is the only organic solvent approved by the U.S. Food and 
Drug Administration (FDA) for drug carrier tests. 
 
4- The functionalised AuNPs (by ligands contain phenyl, tolyl, trimethoxy head group) 
were subjected to investigate their stability over time at a pH range of 3-11.  
 
5-Synthesis well-constrained AuNPs by different reducing agent used NaBH4 (strong) 
and ascorbic acid as (weak) biocompatible reducing agent. 
 
6- Completely characterising AuNPs and studying their stability for the related period of 
time. 
 
7- Effecting the AuNPs on the bacterial growth with different concentrations used. 
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Appendix 
Appendix A2.1 
 
 
Figure A2.1 1HNMR of (4C). Following Chapter 2 
 
 
Figure A2.2 13C-NMR of (4C). Following Chapter 2 
Ph3 p (CH2)3 SSO3
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Ph3 p (CH2)3 SSO3
Benzene
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Figure A2.3 ESI-MS of (4C). Following Chapter 2 
 
 
 
Figure A2.4 ATR-FTIR of (4C). Following Chapter 2 
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Figure A2.5 ATR-FTIR of Hydroxypropyl-triphenylphosphonium bromide. Following Chapter 2 
 
 
 
Figure A2.6 ATR-FTIR of -bromopropyl-triphenylphosphonium bromide. Following Chapter 2 
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Figure A2.7 1H-NMR of (5). Following Chapter 2 
 
 
 
Figure A2.8 ATR-FTIR of (5). Following Chapter 2 
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Figure A2.9 1HNMR of (4). Following Chapter 2 
 
 
 
Figure A2.10 ESI-MS of (4). Following Chapter 2 
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Figure A2.11 ATR-FTIR of (4). Following Chapter 2 
 
 
 
Figure A2.12 ESI-MS of Hydroxypropyl-tri(p-tolyl)phenylphosphonium bromide. Following Chapter 2 
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Appendix B3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.1 1H-NMR of (4A). Following Chapter 3 
 
 
 
Figure B3.2 ESI-MS of (4A). Following Chapter 3 
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Figure B3.3 ATR-FTIR of (4A). Following Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B3.4 1H-NMR of (4B). Following Chapter 3 
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Figure B3.5 ESI-MS of (4B). Following Chapter 3 
 
 
 
Figure B3.6 ATR-FTIR of (4B). Following Chapter 3 
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Appendix C4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.1 1HNMR of (8D). Following Chapter 4 
 
 
 
Figure C4.2 ESI-MS of (8D). Following Chapter 4 
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Figure C4.3 ATR-FTIR of (8D). Following Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.4 1H-NMR of (8A). Following chapter 4 
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Figure C4.5 13C-NMR of (8A). Following Chapter 4 
 
 
 
 
Figure C4.6 ESI-MS of (8A). Following Chapter 4 
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Figure C4.7. ATR-FTIR of (8A). Following Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.8. 1H-NMR of (8B). Following Chapters 4 and 6 
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Figure C4.9 ESI-MS of (8B). Following Chapters 4 and 6 
 
 
 
 
Figure C4.10. ATR-FTIR of (8B). Following Chapters 4 and 6 
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Figure C4.11. 1H-NMR of (9D). Following Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.12. 13C NMH of (9D). Following Chapter 4 
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Figure C4.13. ESI-MS of (9D). Following Chapter 4 
 
 
 
Figure C4.14. ATR-FTIR of (9D). Following Chapter 4 
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Figure C4.15. 1H-NMR of (9A). Following Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C4.16. 13C-NMR of (9A). Following Chapter 4 
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Figure C4.17. ESI-MS of (9A). Following Chapter 4 
 
 
 
Figure C4.18. ESI-MS of -hydroxyhexyltri(P-tolyl)phosphonium bromide (6D). Following Chapter 4 
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Figure C4.19. ESI-MS of -bromohexyl-tri(P-tolyl)-phosphonium bromide (7D). Following Chapter 4 
 
 
 
 
Figure C4.20. ATR-FTIR of (9A). Following Chapter 4 
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Appendix D5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D5.1. 1H-NMR of (12D). Following Chapter 5 
 
 
 
 
 
Figure D5.2. ESI-MS of (12D). Following Chapter 5 
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Figure D5.3. ATR-FTIR of (12D). Following Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D5.4. 1H-NMR of (12A). Following Chapter 5 
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Figure D5.5. ESI-MS of (12A). Following Chapter 5 
 
 
 
 
Figure D5.6. ATR-FTIR of (12A). Following Chapter 5 
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Figure D5.7. 1HNMR of (15). Following Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D5.8. 1H-NMR of (14). Following Chapter 5 
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Figure D5.9. ESI-MS of (15). Following Chapter 5 
 
 
 
 
 
Figure D5.10. ATR-FTIR of (15). Following Chapter 5 
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Figure D5.11. 1H-NMR of (18). Following Chapter 5 
 
 
 
Figure D5.12. ESI-MS of (18). Following Chapter 5 
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Figure D5.13. ATR-FTIR of (18). Following Chapter 5 
 
 
Appendix E6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E6.1. 1H-NMR of (2C). Following Chapter 6 
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Figure E6.2. ESI-MS of (2C). Following Chapter 6 
 
 
 
 
Figure E6.3. ATR-FTIR of (2C). Following Chapter 6 
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Appendix F 
 
 
 
Figure F3.1. Illustrates the data collected through UV-Vis across the pH range produced by adding HCl 
to (5-30 µL) the AuNPs functionalised by 5-AuNP solution in (Run 2) of the acidic study. Following 
Chapter 3. 
 
 
 
Figure F3.2. Illustrates the data collected through UV-Vis across the pH range produced by adding HCl 
to (5-30 µL) the AuNPs functionalised by 5-AuNP solution in (Run 3) of the acidic study. Following 
Chapter 3. 
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Figure F3.3. Illustrates the data collected of 5-AuNPs in (Run 2) of the acidic pH experiment (pH ˂7.5) 
for comparison of DLS results with (Run 1). Following Chapter 3. 
 
 
 
Figure F3.4. Illustrates the data collected of 5-AuNP in (Run 3) of the acidic pH experiment (pH ˂7.5) 
for comparison of DLS results with (Run 1) and (Run 2). Following Chapter 3. 
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Figure F3.5. Illustrates the UV-Vis data of 5-AuNP collected for the solutions at increasing pH for (Run 
2) of the experiment. Where 1M NaOH additions were from (5-30 µL), (pH ˃7.5). Following Chapter 3. 
 
 
 
Figure F3.6. Demonstrates the UV-Vis data collected of 5-AuNP for the solutions at increasing pH for 
(Run 3) of the experiment. Where 1M NaOH additions were from (5-30 µL). Following Chapter 3. 
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Figure F3.7. Presents the data recorded of 5-AuNP for the repeat, (Run 2), at increasing pH and larger 
volumes of 1M NaOH (5-30 µL) were added to the AuNPs solution (pH ˃7.5). Following Chapter 3. 
 
 
 
 
Figure F3.8. Presents the data recorded of 5-AuNP for the repeat, (Run 3), at increasing pH (pH ˃7.5) 
and larger volumes of 1M NaOH (5-30 µL) were added to the AuNPs solution. Following Chapter 3. 
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Figure F3.9. Illustrates the data collected through UV-Vis across the pH range produced (pH ˂7.5) by 
adding 1M HCl (5-30 µL) to the 4B-AuNPs solution in (Run 2) of the acidic study. Following Chapter 3 
 
 
 
Figure F3.10. Expresses the data collected through DLS analysis of the samples in (Run 2) to give the 
diameter size and standard deviations for each pH range produced by adding 1M HCl (5-30 µL) to the 
4B-AuNPs solution. Following Chapter 3. 
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Figure F3.11. Illustrates the data collected through UV-Vis across the pH range produced (pH ˂7.5) by 
adding 1M HCl (5-30 µL) to the 4B-AuNPs solution in (Run 3) of the acidic study. Following Chapter 3 
 
 
 
Figure F3.12. Expresses the data collected through DLS analysis of the samples in (Run 3) to give the 
diameter size and standard deviations for each pH range produced by adding 1M HCl (5-30 µL) to the 
4B-AuNPs solution. Following Chapter 3. 
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Figure F3.13. Illustrates the data collected through UV-Vis across the pH range produced (pH ˃7.5) by 
adding 1M NaOH (5-30 µL) to the 4B-AuNPs solution in (Run 1) of the basic study. Following Chapter 
3. 
 
 
 
Figure F3.14. Expresses the data collected through DLS analysis of the samples in (Run 1) to give the 
diameter size and standard deviations for each pH range produced by adding 1M NaOH (5-30 µL) to the 
4B-AuNPs solution. Following Chapter 3. 
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Figure F3.15. Illustrates the data collected through UV-Vis across the pH range produced (pH ˃7.5) by 
adding 1M NaOH (5-30 µL) to the 4B-AuNPs solution in (Run 3) of the basic study. Following Chapter 
3. 
 
 
Figure F3.16. Expresses the data collected through DLS analysis of the samples in (Run 3) to give the 
diameter size and standard deviations for each pH range produced by adding 1M NaOH (5-30 µL) to the 
4B-AuNPs solution. Following Chapter 3. 
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Figure F3.17. Illustrates the data collected through UV-Vis across the pH range produced (pH ˂7.5) by 
adding HCl (5-30 µL) to the 4A-AuNPs solution in (Run 2) of the acidic study. Following Chapter 3. 
 
 
Figure F3.18. Expresses the data collected through DLS analysis of the samples in (Run 2) to give the 
diameter size and standard deviations for each pH range produced (pH ˂7.5) by adding HCl (5-30 µL) to 
the 4A-AuNPs solution. Following chapter 3. 
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Figure F3.19. Illustrates the data collected through UV-Vis across the pH range produced (pH ˂7.5) by 
adding HCl (5-30 µL) to the 4A-AuNPs solution in (Run 3) of the acidic study. Following Chapter 3. 
 
 
 
Figure F3.20. Expresses the data collected through DLS analysis of the samples in (Run 3) to give the 
diameter size and standard deviations for each pH range produced (pH ˂7.5) by adding HCl (5-30 µL) to 
the 4A-AuNPs solution. Following Chapter 3. 
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Figure F3.21. Illustrates the data collected through UV-Vis across the pH range produced (pH ˃7.5) by 
adding NaOH (5-30 µL) to the 4A-AuNPs solution in (Run 1) of the basic study. Following Chapter 3. 
 
 
 
Figure F3.22. Expresses the data collected through DLS analysis of the samples in (Run 1) to give the 
diameter size and standard deviations for each pH range produced by adding NaOH (5-30 µL) to the 4A-
AuNPs solution. Following Chapter 3. 
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Figure F3.23. Shows the data collected through UV-Vis across the pH range produced (pH ˃7.5) by 
adding NaOH (5-30 µL) to the 4A-AuNPs solution in (Run 2) of the basic study. Following Chapter 3. 
 
 
 
Figure F3.24. Expresses the data collected through DLS analysis of the samples in (Run 2) to give the 
diameter size and standard deviations for each pH range produced by adding NaOH (5-30 µL) to the 4A-
AuNPs solution. Following Chapter 3. 
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Appendix G 
 
 
Figure G4.1. UV-Vis for the stability of the 9D-AuNPs reduced by NaBH4 and dispersed in DMSO at 
time = 0, 1 and 2 months respectively. Follow Chapter 4. 
 
 
 
Figure G4.2. The effect of the time on the size disruption and standard deviation of 9D-AuNPs reduced 
by NaBH4. The size disruption was determined according to the DLS measurements. Follow Chapter 4. 
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Figure G4.3. UV-Vis for the stability of the 9A-AuNPs reduced by NaBH4 and dispersed in DMSO at 
time = 0, 2, 4, 6, and 8 weeks respectively. Follow Chapter 4. 
 
 
 
Figure G4.4. The size and standard deviation of each diameter range taken at a different time value for 
9A-AuNPs (reduced by NaBH4), according to DLS measurements. Follow Chapter 4. 
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Figure G4.5. UV-Vis for the stability of the 4-AuNPs using ascorbic acid as reducing agent, dispersed in 
aqueous solution at time = 0, 2, 4, 6, 8 and 10 weeks respectively. Different wavelength measured. 
Follow Chapter 4. 
 
 
 
Figure G4.6. The size and standard deviation of each diameter range taken at a different time value for 4-
AuNPs (using ascorbic acid as reducing agent) according to DLS study. Follow Chapter 4. 
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Figure G4.7. UV-Vis for the stability of the 8B-AuNPs dispersed using ascorbic acid as reducing agent 
in aqueous solution at different time = 0, 2, 3, 4, 5, 6, 8 and 10 weeks respectively. Follow Chapter 4. 
 
 
 
Figure G4.8. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 8B-AuNPs using ascorbic acid as reducing agent. Follow Chapter 4. 
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Appendix j 
 
 
Figure J5.1. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 12D-AuNPs using NaBH4 as reducing agent. Follow Chapter 5. 
 
 
 
Figure J5.1. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 12A-AuNPs using NaBH4 as reducing agent. Follow Chapter 5. 
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Figure J5.2. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 12A-AuNPs using ascorbic acid as reducing agent. Follow Chapter 5. 
 
 
 
Figure J5.3. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 15-AuNPs using NaBH4 as reducing agent. Follow Chapter 5. 
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Figure J5.4. The size and standard deviation of each diameter range by DLS measuring taken at a 
different time value for 18-AuNPs using NaBH4 as reducing agent. Follow Chapter 5. 
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